Author: "C. Camps" / Language: english - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"C. Camps"' showing total 286 results

Start Over Author "C. Camps" Language english

286 results on '"C. Camps"'

1. 23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC)

Author: Abad, M. Nunez, García, J.Á. García, Torres-Martínez, S., Lobo de Mena, M., Ben Hammou El Majdoubi, F., Mosqueda-Frometa, M., Herrero, C. Camps, Fariñas, S. Calabuig, and Iranzo, V.
Published: 2023
Full Text: View/download PDF

2. 17P Prognostic and predictive non-invasive biomarkers in early triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)

Author: Abad, M. Nunez, Torres-Martínez, S., Mosqueda-Frometa, M., Taberner-Bonastre, M.T., García, J.Á. García, Ben Hammou El Majdoubi, F., Lewintre, E. Jantus, Herrero, C. Camps, Iranzo, V., and Fariñas, S. Calabuig
Published: 2023
Full Text: View/download PDF

3. 2250P Exploring tumor microenvironment in lung cancer through patient-derived 3D models

Author: Juciute, N., Boada-Acosta, L.A., Torres-Martínez, S., Escorihuela, E., Maravilla, E. Munera, Mosqueda-Frometa, M., Castellote-Borrell, M., Rodriguez, A., Miranda, N., Roz, L., Navarro-Cerveró, L., Blanco, B., Guasch, J., Guijarro, R., Pastor-Martinez, E., Fariñas, S. Calabuig, Herrero, C. Camps, and Lewintre, E. Jantus
Published: 2023
Full Text: View/download PDF

4. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

Author: J. J. Reina Zoilo, D. Monge Martín, F. Caballero Martínez, A. Carrato Mena, C. Camps Herrero, M. Feijóo Saus, V. Guillem Porta, J. García-Foncillas López, R. Lopez Lopez, E. Aranda Aguilar, and E. Díaz-Rubio García
Subjects: 0301 basic medicine, Male, Cancer Research, Pediatrics, medicine.medical_specialty, Breakthrough cancer pain (BTcP), Analgesic, MEDLINE, Medical Oncology, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, medicine, Prevalence, Humans, Prevalence of BTcP, Aged, business.industry, Professional judgement, Breakthrough Pain, General Medicine, Cancer Pain, Middle Aged, Active Study, Clinical Practice, Clinical inertia, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Observational study, Female, Clinical case, business, Cancer pain
Abstract: Aims To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from clinical practice with clinical oncologists’ prior perception. Design Observational and descriptive study, using information collected by practising medical oncologists, at three moments: (a) questionnaire regarding their professional judgement of the handling of patients with BTcP in their practice, (b) cross-sectional clinical screening, to detect possible existing cases of BTcP in a representative sample of their patients, (c) retrospective self-audit of clinical case histories of patients diagnosed with BTcP to find out about how it has been handled. Participants and study period A random sample on a state level of 108 specialists in medical oncology. 540 patients who suffer some type of cancer pain on the designated study date for each specialist (July–December 2016). Results The global prevalence of BTcP in the study sample covered 91.3% of the patients who were suffering some type of cancer pain. Barely 2% of the doctors surveyed suspected figures around this mark. 40.9% of the cases had not been previously detected as BTcP by their doctors. Although 90% of the patients who had previously been diagnosed with BTcP received a specific analgesic treatment for the symptoms, 42% of those patients with known BTcP were not able to control their episodes of pain. Conclusions Clinical inertia is a serious problem in the handling of BTcP in medical oncology services, where it is the subject of a significantly low level of detection and treatment, despite the contrasting perception of specialists. pre-print 339 KB
Published: 2018

5. Cosmic-ray positron fraction measurement from 1 to 30 GeV with AMS-01

Author: Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, L. Ao, A. Arefiev, P. Azzarello, L. Baldini, M. Basile, D. Barancourt, F. Barao, G. Barbier, G. Barreira, R. Battiston, R. Becker, U. Becker, L. Bellagamba, P. Béné, J. Berdugo, P. Berges, B. Bertucci, A. Biland, S. Blasko, Boschini, M, M. Bourquin, L. Brocco, G. Bruni, M. Buénerd, J. D. Burger, W. J. Burger, X. D. Cai, C. Camps, P. Cannarsa, M. Capell, F. Cardano, D. Casadei, J. Casaus, G. Castellini, Y. H. Chang, H. F. Chen, H. S. Chen, Z. G. Chen, N. A. Chernoplekov, T. H. Chiueh, K. Cho, M. J. Choi, Y. Y. Choi, F. Cindolo, V. Commichau, A. Contin, E. Cortina Gil, M. Cristinziani, T. S. Dai, C. Delgado, S. Difalco, L. Djambazov, I. D'Antone, Z. R. Dong, P. Emonet, J. Engelberg, F. J. Eppling, T. Eronen, G. Esposito, P. Extermann, J. Favier, E. Fiandrini, P. H. Fisher, G. Flügge, N. Fouque, Y.u. Galaktionov, H. Gast, P. Giusti, Grandi, D, O. Grimm, W. Q. Gu, K. Hangarter, A. Hasan, V. Hermel, H. Hofer, W. Hungerford, M. Jongmanns, K. Karlamaa, W. Karpinski, G. Kenney, D. H. Kim, G. N. Kim, K. S. Kim, M. Y. Kim, A. Klimentov, R. Kossakowskic, A. Kouninel, V. Koutsenkol, M. Kraeberai, G. Laboriet, T. Laitinenah, G. Lamannaad, 1, E. Lanciottiz, G. Laurentij, A. Lebedevl, C. Lechanoine Lelucs, M. W. Leeo, S. C. Leeag, G. Levij, C. L. Liuy, H. T. Liui, G. Lug, Y. S. Lui, K. Lübelsmeyera, D. Luckeyl, W. Lustermannai, C. Mañaz, A. Margottij, F. Mayett, R. R. McNeild, B. Meillont, M. Menichelliad, A. Mihulk, A. Mujunenv, A. Olivaad, J. Olzema, F. Palmonarij, H. B. Parko, W. H. Parko, M. Pauluzziad, F. Paussai, E. Perrins, A. Pescij, A. Pevsnere, F. Piloae, M. Pimentax, w, V. Plyaskinac, V. Pojidaevac, M. Pohls, N. Produits, Rancoita, PG D. Rapins, F. Raupacha, D. Renai, Z. Renag, M. Ribordys, J. P. Richeuxs, E. Riihonenah, J. Ritakariv, S. Roo, U. Roeserai, C. Rossint, R. Sagdeevn, D. Santost, G. Sartorellij, C. Sbarraj, S. Schaela, A. Schultz von Dratziga, G. Schweringa, E. S. Seon, J. W. Shino, E. Shoumilovac, V. Shoutkol, T. Siedenburgl, R. Siedlinga, D. Sono, T. Songh, F. Spinellaae, M. Steuerl, G. S. Sunh, H. Suterai, X. W. Tangi, Samuel C. C. Tingl, S. M. Tingl, M. Tornikoskiv, J. Torstiah, J. Trümperq, J. Ulbrichtai, S. Urpov, E. Valtonenah, J. Vandenhirtza, E. Velikhovab, B. Verlaatai, 2, I. Vetlitskyac, F. Vezzut, J. P. Viallec, G. Viertelai, D. Vités, H. Von Guntenai, S. Waldmeier Wickiai, W. Wallraffa, B. C. Wangy, J. Z. Wangg, K. Wiikv, C. Williamsj, S. X. Wul, m, P. C. Xiah, S. Xul, J. L. Yang, L. G. Yanh, C. G. Yangi, J. Yangaf, M. Yangi, S. W. Yeu, 3, Z. Z. Xu, H. Y. Zhang, Z. P. Zhang, D. X. Zhao, Y. Zhou, G. Y. Zhu, W. Z. Zhu, H. L. Zhuang, A. Zichichi, B. Zimmermann, P. Zuccon, BOELLA, GIULIANO FILIPPO, GERVASI, MASSIMO, Bene, Pierre, Bourquin, Maurice, Cortina Gil, Eduardo, Cristinziani, Markus, Emonet, Pascal Philippe, Extermann, Pierre, Leluc, Catherine, Perrin, Eric, Pohl, Martin, Produit, Nicolas, Rapin, Divic Jean, Ribordy, Mathieu, Richeux, Jean-Pierre, Vite, Davide, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, M. AGUILAR, J. ALCARAZ, J. ALLABY, B. ALPAT, G. AMBROSI, H. ANDERHUB, L. AO, A. AREFIEV, P. AZZARELLO, L. BALDINI, M. BASILE, D. BARANCOURT, F. BARAO, G. BARBIER, G. BARREIRA, R. BATTISTON, R. BECKER, U. BECKER, L. BELLAGAMBA, P. BENE, J. BERDUGO, P. BERGES, B. BERTUCCI, A. BILAND, S. BLASKO, G. BOELLA, M. BOSCHINI, M. BOURQUIN, L. BROCCO, G. BRUNI, M. BUENERD, J.D. BURGER, W.J. BURGER, X.D. CAI, C. CAMPS, P. CANNARSA, M. CAPELL, F. CARDANO, D. CASADEI, J. CASAUS, G. CASTELLINI, Y.H. CHANG, H.F. CHEN, H.S. CHEN, Z.G. CHEN, N.A. CHERNOPLEKOV, T.H. CHIUEH, K. CHO, M.J. CHOI, Y.Y. CHOI, F. CINDOLO, V. COMMICHAU, A. CONTIN, E. CORTINA-GIL, M. CRISTINZIANI, T.S. DAI, C. DELGADO, S. DIFALCO, L. DJAMBAZOV, I. D'ANTONE, Z.R. DONG, P. EMONET, J. ENGELBERG, F.J. EPPLING, T. ERONEN, G. ESPOSITO, P. EXTERMANN, J. FAVIER, E. FIANDRINI, P.H. FISHER, G. FLUEGGE, N. FOUQUE, YU. GALAKTIONOV, H. GAST, M. GERVASI, P. GIUSTI, D. GRANDI, O. GRIMM, W.Q. GU, K. HANGARTER, A. HASAN, V. HERMEL, H. HOFER, W. HUNGERFORD, M. JONGMANNS, K. KARLAMAA, W. KARPINSKI, G. KENNEY, D.H. KIM, G.N. KIM, K.S. KIM, M.Y. KIM, A. KLIMENTOV, R. KOSSAKOWSKI, A. KOUNINE, V. KOUTSENKO, M. KRAEBER, G. LABORIE, T. LAITINEN, G. LAMANNA, E. LANCIOTTI, G. LAURENTI, A. LEBEDEV, C. LECHANOINE-LELUC, M.W.LEE, S.C. LEE, G. LEVI, C.L. LIU, H.T. LIU, G. LU, Y.S. LU, K. LUBELSMEYER, D. LUCKEY, W. LUSTERMANN, C. MANA, A. MARGOTTI, F. MAYET, R.R. MCNEIL, B. MEILLON, M. MENICHELLI, A.MIHUL, A. MUJUNEN, A. OLIVA, J. OLZEM, F. PALMONARI, H.B. PARK, W.H. PARK, M. PAULUZZI, F. PAUSS, E. PERRIN, A. PESCI, A. PEVSNER, F. PILO, M. PIMENTA, V. PLYASKIN, V. POJIDAEV, M. POHL, N. PRODUIT, P.G. RANCOITA, D. RAPIN, F. RAUPACH, D. REN, Z. REN, M. RIBORDY, J.P. RICHEAUX, E. RIIHONEN, J. RITAKARI, S. RO, U. ROESER, C. ROSSIN, R. SAGDEEV, D. SANTOS, G. SARTORELLI, C. SBARRA, S. SCHAEL, A. SCHULTZ VON DRATZIG, G. SCHWERING, E.S. SEO, J.W. SHIN, E. SHOUMILOV, V. SHOUTKO, T. SIEDENBURG, R. SIEDLING, D. SON, T. SONG, F. SPINELLA, M. STEUER, G. S. SUN, H. SUTER, X.W. TANG, SAMUEL C.C. TING, S.M. TING, M. TORNIKOSKI, J. TORSTI, J. TRUEMPER, J. ULBRICHT, S. URPO, E. VALTONEN, J. VANDENHIRTZ, E. VELIKHOV, B. VERLAAT, I. VETLITSKI, F. VEZZU, J.P. VIALLE, G. VIERTEL, D. VITE, H. VON GUNTEN, S. WALDMEIER WICKI, W. WALLRAFF, B.C. WANG, J.Z. WANG, K. WIIK, C. WILLIAMS, S.X. WU, P.C. XIA, S. XU, J.L. YAN, L.G. YAN, C.G. YANG, J. YANG, M. YANG, S.W. YE, Z.Z. XU, H.Y. ZHANG, Z.P. ZHANG, D.X. ZHAO, Y. ZHOU, G.Y.ZHU, W.Z. ZHU, H.L. ZHUANG, A. ZICHICHI, B. ZIMMERMANN, P. ZUCCON, Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, L., A, A., A, P., A, L., B, M., B, D., B, F., B, G., B, R., B, U., B, P., B, J., B, B., B, A., B, S., B, Boella, G, Boschini, M, J. D., B, W. J., B, X. D., C, C., C, P., C, M., C, F., C, D., C, J., C, G., C, Y. H., C, H. F., C, H. S., C, Z. G., C, N. A., C, T. H., C, K., C, M. J., C, Y. Y., C, V., C, A., C, E., C, T. S., D, C., D, S., D, L., D, I., D, Z. R., D, P., E, J., E, F. J., E, T., E, G., E, J., F, E., F, P. H., F, G., F, N., F, Galaktionov, Y, H., G, Gervasi, M, P., G, Grandi, D, O., G, W. Q., G, K., H, A., H, V., H, H., H, W., H, M., J, K., K, W., K, G., K, D. H., K, G. N., K, K. S., K, M. Y., K, A., K, R., K, V., K, Ac, M., K, G., L, T., L, E., L, A., L, C., L, M. W., L, S. C., L, C. L., L, H. T., L, Y. S., L, K., L, D., L, W., L, C., M, A., M, F., M, R. R., M, B., M, M., M, A., O, J., O, F., P, H. B., P, W. H., P, M., P, E., P, A., P, W, V., P, N., P, Rancoita, PG D., R, F., R, D., R, Z., R, M., R, J. P., R, E., R, J., R, S., R, U., R, C., R, R., S, D., S, G., S, C., S, S., S, A., S, E. S., S, J. W., S, E., S, V., S, T., S, F., S, M., S, G. S., S, H., S, X. W., T, Samuel C. C., T, S. M., T, M., T, J., T, J., U, S., U, E., V, J., V, B., V, I., V, F., V, J. P., V, G., V, D., V, H., V, S., W, W., W, B. C., W, J. Z., W, K., W, C., W, S. X., W, M, P. C., X, S., X, J. L., Y, L. G., Y, C. G., Y, J., Y, M., Y, S. W., Y, Z. Z., X, H. Y., Z, Z. P., Z, D. X., Z, Y., Z, G. Y., Z, W. Z., Z, H. L., Z, A., Z, B., Z, P., Z, and UCL - SST/IRMP - Institut de recherche en mathématique et physique
Subjects: Raggi cosmici, esperimento AMS, Nuclear and High Energy Physics, Astrophysics and Astronomy, Photon, Proton, Astrophysics::High Energy Astrophysical Phenomena, Cosmic ray, ddc:500.2, Astrophysics, 01 natural sciences, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Nuclear physics, FIS/05 - ASTRONOMIA E ASTROFISICA, Positron, 0103 physical sciences, 010306 general physics, Nuclear Experiment, Physics, Range (particle radiation), 010308 nuclear & particles physics, Bremsstrahlung, Order (ring theory), Cosmic Rays Positrons, AMS experiment, Physics::Accelerator Physics, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE, Energy (signal processing)
Abstract: A measurement of the cosmic ray positron fraction e+ / (e+ + e-) in the energy range of 1-30 GeV is presented. The measurement is based on data taken by the AMS-01 experiment during its 10 day Space Shuttle flight in June 1998. A proton background suppression on the order of 106 is reached by identifying converted bremsstrahlung photons emitted from positrons., Physics Letters B, 646 (4), ISSN:0370-2693, ISSN:0031-9163, ISSN:1873-2445
Published: 2007

6. A search for heavy charged and neutral leptons from Z0 decays

Author: Dimitri Bourilkov, R.J. Wu, M. MacDermott, Raffaello D'Alessandro, M.L. Chen, P.J. Li, C. Grinnell, M. A. Niaz, Leonardo Merola, A. Gordeev, C.H. Ye, R. Starosta, V. Commichau, G.Q. Hu, D. Pandoulas, T. Azemoon, P. Extermann, B. Ille, Marcella Diemoz, C. Buisson, A. Böhm, I. Leedom, H. Hofer, K. L. Tung, M. Möller, B. P. Roe, G. Von Dardel, A. Degré, T. Böhringer, G. Morand, J. Behrens, H. Anderhub, C.R. Wang, Q.Y. Yang, Z.W. Yin, U. Uwer, Fridolin Dittus, Z.Y. Lin, O. Kornadt, M. Fukushima, J.C. Sens, R. Raghavan, Harvey B Newman, J. Lettry, Claudio Luci, Elisabetta Gallo, C.F. He, Egidio Longo, S. Shevchenko, A. C. König, Laurent Vuilleumier, E. Isiksal, J.P. Martin, A. Chen, F. Ferroni, S. Beingessner, D. DiBitonto, A. Bujak, R. L. Sumner, F. Tonisch, G. H. Wang, W. Lohmann, W. Wallraff, D. Perret-Gallix, M. Guanziroli, J. Wenninger, J.P. Burq, Ph. Rosselet, M. Steuer, Zm Wang, G. Forconi, B. Stöhr, C. Zaccardelli, M. Pohl, M. M. Ilyas, R. Leiste, X.G. Li, Yu. Kamyshkov, D. Boutigny, P. K. Malhotra, H. A. Rizvi, H.J. Schreiber, L. J. Gutay, U. Roeser, R. Fabbretti, R. de Asmundis, J. Weber, L.S. Hsu, J. Salicio, Tariq Aziz, Marco Meschini, J. Fay, K. Schultze, Yu. Galaktionov, H. van der Graaf, M. Zeng, D.N. Mao, S. Reucroft, U. Becker, M. Schöntag, Mw Gruenewald, H. Haan, Ren-Yuan Zhu, Luciano Barone, R. Liu, R.C. Ball, Adrian Biland, V. Lalieu, D.S. Yan, H. Fenker, R. T. Van de Walle, G.B. Mills, K.S. Kumar, R. Weill, M. Gailloud, A.M. Cartacci, D. Kirkby, E. Thomas, H.T. Li, T. Spickermann, G. Herten, L. Urbàn, G. Landi, M. J. Glaubman, F.C. Erné, C. G. Yang, I. Scott, L. Li, G. Faber, H.F. Chen, J. Alcaraz, A. Gurtu, Aa Vorobyov, Y.J. Pei, M. Chemarin, J.Y. Liao, R.A. Khan, F. J. Eppling, L. W. Jones, A. Kunin, E. Valente, E. Jagel, Y. Zeng, P. Vikas, V. Shevchenko, T. Foreman, H.R. Dimitrov, M. Lenti, P. Arce, M. Bocciolini, K. Freudenreich, P.V.K.S. Baba, G. Sartorelli, H. L. Zhuang, D. Goujon, D. McNally, S. M. Ting, J.M. You, Mingshui Chen, A. L. Anderson, D. Duchesneau, M. Maire, E. Nagy, A. Hasan, M. Cerrada, Z. Ren, C. Chen, Vincenzo Innocente, N. Smirnov, F. Marzano, I. Vetlitsky, D. Lanske, B. Bertucci, W. J. Metzger, G. Viertel, J.M. Qian, C. Li, I. Vorobiev, Z.M. Wang, K. N. Qureshi, Y. D. Xu, P. Blömeke, P. Lebrun, X. Leytens, V. Shoutko, Crisostomo Sciacca, D. Zhang, Marco Pieri, A. Engler, Jd Burger, K. Sudhakar, C. Rippich, S. Morganti, G. Rahal-Callot, G.G.G. Massaro, Nicanor Colino, H. El Mamouni, J. G. Branson, M. Capell, J. A. Bakken, Samuel C.C. Ting, G. Fernandez, X. Lue, K.S. Yang, L. Romero, Federico Carminati, P. McBride, U. Micke, K. Lübelsmeyer, Z.Z. Xu, X. Y. Cui, J. Tòth, S. Röhner, Y. Mi, H. R. Gustafson, Y. S. Lu, S. N. Ganguli, J. Schwenke, Steven Goldfarb, F. Carbonara, M. Tonutti, J. M. Salicio, R.B. Sutton, G. Passaleva, D.H. Zhang, S. Lökös, M.C. Chen, U.K. Chaturvedi, Konrad Deiters, G. Sauvage, A. Malinin, Th. Rombach, R. Wilhelm, J. H. Field, W. Krenz, G. Schwering, An.A. Vorobyov, T. Matsuda, Alberto Aloisio, S. C. Tonwar, L. Martinez, L. Niessen, S. Patricelli, F. L. Linde, W. Böhlen, Simonetta Gentile, K. Hilgers, M. Schneegans, Jj Blaising, O. Adriani, Thomas Ferguson, T. Kramer, Kenneth Francis Read, R. Morand, Q. Ye, V. Schegelsky, G. Conforto, L. Z. Sun, V. Pojidaev, Th. Meinholz, Lucas Taylor, K. Hangarter, S.J. Fan, Sc Yeh, A. Klimentov, S.S. Gau, J.F. Li, T. Angelov, C. Maña, H. Vogt, X. W. Tang, K. Lanius, I. Sheer, G. Yang, Jian Wang, P. A. Piroué, J. Rose, C. Willmott, Mariagrazia Alviggi, D. Linnhofer, W. Friebel, M. Bourquin, L. Baksay, Speranza Falciano, G. Coignet, B. N. Jin, K. Strauch, P. Duinker, P.G. Seiler, F. Diez-Hedo, Peter Denes, V. Morgunov, Bolek Wyslouch, Qian Wang, X.L. Wang, J. Bao, Paolo Bagnaia, G. Gratta, R. Mount, V. Koutsenko, P. Schmitz, B. Borgia, L. Zehnder, J.B. Ye, C.Y. Chien, S. Banerjee, Zp Zhang, A. van Laak, W. Ruckstuhl, D. P. Stickland, H. Suter, Y.F. Wang, Y. Mir, S. Rosier-Lees, R. Malik, A. Pevsner, Barry Blumenfeld, Antonino Zichichi, J.M. Lubbers, U. Herten, Ph Fisher, H. Rykaczewski, Q. Z. Li, Y. Karyotakis, X.R. Shi, L. Antonov, I. Clare, J. Busenitz, S. Schulte, V. Kumar, J. Krizmanic, A. Marchionni, Q. An, M. Dhina, M. Micke, V. Plyaskin, T. Hebbeker, D. J. Schotanus, P. Levchenko, V.R. Krastev, E. Gonzalez, M. Röhner, N. Produit, J. Ulbricht, C. Spartiotis, S. Lanzano, Bernardo Adeva, A. A. Syed, Howard A. Stone, T.S. Dai, Q. Fan, B.C. Stringfellow, B. Spiess, V. Khoze, F. Crijns, R. Rosmalen, G. Finocchiaro, Marcel Merk, B.Z. Yang, J. Perrier, R. Bizzarri, Ian Brock, F. DeNotaristefani, L. Leistam, M. Kaur, G. Hu, B. Monteleoni, G. Chiefari, W. Kittel, P. Berges, R. Sehgal, W.G. Ma, M. Vivargent, C. Dionisi, Alain Hervé, A. Bay, A. Arefiev, Carlo Civinini, M. Maolinbay, M. Aguilar-Benitez, I. Duran, Herwig Schopper, M. White, F. Wittgenstein, L. Ludovici, E. Drago, Sau Lan Wu, T. Driever, R. Schulte, A. Kuhn, M. Harris, J.F. Zhou, S. Hancke, Y. H. Chang, George Alverson, Z.Q. Yang, G. Trowitzsch, Helmut Vogel, Kajari Mazumdar, S. Khokhar, E. Dénes, Xd Cai, F. Cesaroni, D. Ren, H. Fesefeldt, U. Vikas, A. Contin, J. Mnich, M. Hebert, Panos A Razis, J. Schütte, M. Sachwitz, F. Bruyant, R. Dolin, P. Garcia-Abia, J. M. Le Goff, K. Shmakov, Z.F. Gong, M. Wadhwa, J. A. Rubio, T. McMahon, E. Shumilov, R. Magahiz, J. D. Swain, A. Savin, D. Wright, C. Camps, P. Le Coultre, D. Schmitz, D. Antreasyan, G. Paternoster, G. Mirabelli, P. Marchesini, Robert Clare, D. Luckey, Gy L. Bencze, Y.G. Wu, Paul Lecoq, R. W. Kraemer, M. Napolitano, Piero Spillantini, H. S. Chen, S.X. Wu, Y.P. Tong, E. Tarkovsky, A. Sopczak, T.J. Wenaus, H. Akbari, Y.F. Mao, Lamberto Luminari, J. Berdugo, P. Göttlicher, J. Fehlmann, Z.L. Xue, Pierre Lecomte, M. Vollmar, Charles Timmermans, O. Rind, Hafeez R. Hoorani, M. Fabre, Georgi Sultanov, V. P. Andreev, G.J. Bobbink, B.L. Betev, G. M. Chen, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, and IHEF (IoP, FNWI)
Subjects: Physics, Nuclear and High Energy Physics, Particle physics, Sterile neutrino, 010308 nuclear & particles physics, Astrophysics::High Energy Astrophysical Phenomena, Electron–positron annihilation, High Energy Physics::Phenomenology, Dirac (software), 01 natural sciences, Lower limit, Nuclear physics, MAJORANA, grey literature, Citation analysis, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], High Energy Physics::Experiment, Neutrino, Nuclear Experiment, 010306 general physics, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment, Lepton
Abstract: We have searched for charged and neutral leptons. We exclude stable Dirac neutrinos below 42.8 GeV and stable Majorana neutrinos below 34.8 GeV. From a search for unstable neutrinos we exclude masses below 46.4 GeV (Dirac) and below 45.1 GeV (Majorana). We exclude all masses of sequential charged and neutral leptons, except if both masses are larger than 42.8 GeV (for stable Dirac neutrinos). All mass limits correspond to 95% CL.
Published: 1990

7. The Alpha Magnetic Spectrometer (AMS) on the International Space Station: Part I – results from the test flight on the space shuttle

Author: P. Extermann, H. Hofer, J.P. Richeux, Jose Maria Kenny, M. Jongmanns, H. Anderhub, P. Giusti, A. Hasan, Mauro Menichelli, G. Scolieri, Y.S. Lu, I. Lopes, S. Ro, G. Schwering, Eun-Suk Seo, L. Baldini, E. Lanciotti, F. Vezzu, Maria Ionica, S.W. Ye, V. Koutsenko, Eino Valtonen, M.Y. Kim, G. Sartorelli, D. Rapin, V. Plyaskin, Werner Lustermann, Behcet Alpat, W.Q. Gu, W.Z. Zhu, C. Delgado, E. Fiandrini, Yu. Galaktionov, D.H. Kim, J. Alcaraz, S. X. Wu, W.H. Park, Felicitas Pauss, B. Verlaat, P. Berges, K. Karlamaa, S.C.C. Ting, F. Palmonari, Zhenghao Xu, Zhuoxiang Ren, F. Velcea, Tzihong Chiueh, G. Barbier, H.B. Park, R. Kossakowski, A. Klimentov, S. Urpo, Ari Mujunen, A. Lebedev, Dong-Chul Son, G. Laurenti, K. Luebelsmeyer, E. Shoumilov, W. Hungerford, H. S. Chen, N. Produit, M. Buenerd, S. Waldmeier Wicki, M. Basile, E. Riihonen, A. Mihul, Timo Laitinen, J. Yang, V. Postolache, V. Pojidaev, M. Steuer, P.C. Xia, G.S. Sun, Jian Wang, M. Ribordy, K. Hangarter, H. L. Zhuang, M. Pauluzzi, Stefan Schael, H. Suter, Guohuai Zhu, G. Boella, X.W. Tang, M. Kraber, A. Pevsner, M. A. Huang, Mao-Zhi Yang, Tao Song, J.L. Yan, N.A. Chernoplekov, J. Vandenhirtz, Z.G. Chen, C. Camps, Ciaran Williams, D. Ren, D. Luckey, I. Vetlitsky, Samuel C.C. Ting, N. Dinu, Zhidong Zhang, Anselmo Margotti, E. Cortina-Gil, M. Bourquin, A. Papi, Adrian Biland, R. Ionica, L. Djambazov, Paolo Zuccon, A. Contin, I. D'Antone, M.W. Lee, Jungwook Shin, F. Barao, G. Castellini, J. P. Da Cunha, Gui Nyun Kim, N. Fouque, P. Levtchenko, Massimo Gervasi, Kyung-Suk Cho, J. D. Burger, F. Mayet, M. Pohl, P. Yeh, G. Lu, C. Maña, C. Lechanoine-Leluc, A. Schultz von Dratzig, C. Rossin, Hengchang Liu, A. Mourao, S. Blasko, G. Laborie, C. Sbarra, Peter H. Fisher, L.G. Yan, V. Hermel, J.D. Deus, X. D. Cai, M.J. Choi, O. Grimm, J. Casaus, M. Capell, Philipp Azzarello, R. Siedling, J. Berdugo, Yun Wang, A. Arefiev, Roald Z. Sagdeev, J. Engelberg, H. von Gunten, C.L. Liu, L. Bellagamba, Changgen Yang, D. Casadei, U. Roser, R. R. McNeil, B. Meillon, Giuseppe Levi, Y.L. Chuang, K. Wiik, P. Bene, Federico Cindolo, J. J. Torsti, Antonino Zichichi, L. Brocco, J. Ritakari, Y. H. Chang, G. Kenney, P. Cannarsa, Y.Y. Choi, D. Barancourt, J. Favier, Waclaw Karpinski, E. Babucci, U. Becker, Dawei Zhao, R. Becker, Z.R. Dong, E. Perrin, K.S. Kim, Claudia Cecchi, F. J. Eppling, M. Aguilar, V. Shoutko, S. Bizzaglia, G. Esposito, M. Pimenta, G. Fluegge, D. Grandi, B. Bertucci, D. Santos, G. Ambrosi, T. S. Dai, A. Pesci, B.C. Wang, D. Vité, G. Lamanna, G. Viertel, J. P. Vialle, H.F. Chen, G.P. Barreira, W. J. Burger, Frank Raupach, Roberto Battiston, L. Ao, J. Ulbricht, Hao Zhang, S.C. Lee, J. Trümper, P. Emonet, M. J. Boschini, V. Commichau, E. P. Velikhov, B. Zimmermann, Merja Tornikoski, Markus Cristinziani, T. Eronen, P. G. Rancoita, W. Wallraff, G. Bruni, Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, Ao, L, Arefiev, A, Azzarello, P, Babucci, E, Baldini, L, Basile, M, Berdugo, J, Berges, P, Bertucci, B, Biland, A, Bizzaglia, S, Blasko, S, Boella, G, Boschini, M, Bourquin, M, Brocco, L, Bruni, G, Buenerd, M, Burger, J, Burger, W, Cai, X, Camps, C, Cannarsa, P, Capell, M, Casadei, D, Casaus, J, Castellini, G, Cecchi, C, Chang, Y, Chen, H, Chen, Z, Chernoplekov, N, Chiueh, T, Cho, K, Choi, M, Choi, Y, Chuang, Y, Cindolo, F, Commichau, V, Contin, A, Cortina-Gil, E, Cristinziani, M, da Cunha, J, Dai, T, Delgado, C, Deus, J, Dinu, N, Djambazov, L, D'Antone, I, Dong, Z, Emonet, P, Engelberg, J, Eppling, F, Eronen, T, Esposito, G, Extermann, P, Favier, J, Fiandrini, E, Fisher, P, Fluegge, G, Fouque, N, Galaktionov, Y, Gervasi, M, Giusti, P, Grandi, D, Grimms, O, Gu, W, Hangarter, K, Hasan, A, Hermel, V, Hofer, H, Huang, M, Hungerford, W, Ionica, M, Ionica, R, Jongmanns, M, Karlamaa, K, Karpinski, W, Kenney, G, Kenny, J, Kim, D, Kim, G, Kim, K, Kim, M, Klimentov, A, Kossakowski, R, Koutsenko, V, Kraeber, M, Laborie, G, Laitinen, T, Lamanna, G, Lanciotti, E, Laurenti, G, Lebedev, A, Lechanoine-Leluc, C, Lee, M, Lee, S, Levi, G, Levtchenko, P, Liu, C, Liu, H, Lopes, I, Lu, G, Lu, Y, Lubelsmeyer, K, Luckey, D, Lustermann, W, Mana, C, Margotti, A, Mayet, F, Mcneil, R, Meillon, B, Menichelli, M, Mihul, A, Mourao, A, Mujunen, A, Palmonari, F, Papi, A, Park, H, Park, W, Pauluzzi, M, Pauss, F, Perrin, E, Pesci, A, Pevsner, A, Pimenta, M, Plyaskin, V, Pojidaev, V, Pohl, M, Postolache, V, Produit, N, Rancoita, P, Rapin, D, Raupach, F, Ren, D, Ren, Z, Ribordy, M, Richeux, J, Riihonen, E, Ritakari, J, Ro, S, Roeser, U, Rossin, C, Sagdeev, R, Santos, D, Sartorelli, G, Sbarra, C, Schael, S, von Dratzig, A, Schwering, G, Scolieri, G, Seo, E, Shin, J, Shoutko, V, Shoumilov, E, Siedling, R, Son, D, Song, T, Steuer, M, Sun, G, Suter, H, Tang, X, Ting, S, Tornikoski, M, Torsti, J, Trumper, J, Ulbricht, J, Urpo, S, Valtonen, E, Vandenhirtz, J, Velcea, F, Velikhov, E, Verlaat, B, Vetlitsky, I, Vezzu, F, V, Jp, Viertel, G, Vite, D, Von Gunten, H, Wicki, S, Wallraff, W, Wang, B, Wang, J, Wang, Y, Wiik, K, Williams, C, Wu, S, Xia, P, Yan, J, Yan, L, Yang, C, Yang, J, Yang, M, Ye, S, Yeh, P, Xu, Z, Zhang, H, Zhang, Z, Zhao, D, Zhu, G, Zhu, W, Zhuang, H, Zichichi, A, Zimmermann, B, Zuccon, P, Ambrosi, Giovanni, Azzarello, Philipp, Bene, Pierre, Bourquin, Maurice, Cortina Gil, Eduardo, Cristinziani, Markus, Emonet, Pascal Philippe, Extermann, Pierre, Leluc, Catherine, Perrin, Eric, Pohl, Martin, Produit, Nicolas, Rapin, Divic Jean, Ribordy, Mathieu, Richeux, Jean-Pierre, Vite, Davide, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, CIEMAT, E-28040, Madrid, Spain, and UCL - SST/IRMP - Institut de recherche en mathématique et physique
Subjects: Physics, 010308 nuclear & particles physics, FIS/06 - FISICA PER IL SISTEMA TERRA E PER IL MEZZO CIRCUMTERRESTRE, General Physics and Astronomy, chemistry.chemical_element, Electron, ddc:500.2, 01 natural sciences, Spectral line, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Nuclear physics, FIS/05 - ASTRONOMIA E ASTROFISICA, Positron, Earth's magnetic field, FIS/01 - FISICA SPERIMENTALE, chemistry, 13. Climate action, Antiproton, 0103 physical sciences, Alpha Magnetic Spectrometer, Nucleon, 010303 astronomy & astrophysics, AMS, Cosmic Rays, Antimatter, Helium, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE
Abstract: The Alpha Magnetic Spectrometer (AMS) was flown on the space shuttle Discovery during flight STS-91 (June 1998) in a 51.7 deg orbit at altitudes between 320 and 390 km. A search for antihelium nuclei in the rigidity range 1–140 GV was performed. No antihelium nuclei were detected at any rigidity. An upper limit on the flux ratio of antihelium to helium of < 1.1×10^−6 was obtained. The high energy proton, electron, positron, helium, antiproton and deuterium spectra were accurately measured. For each particle and nuclei two distinct spectra were observed: a higher energy spectrum and a substantial second spectrum. Positrons in the second spectrum were found to be much more abundant than electrons. Tracing particles from the second spectra shows that most of them travel for an extended period of time in the geomagnetic field, and that the positive particles (p and e+) and negative ones (e−) originate from two complementary geographic regions. The second helium spectrum flux over the energy range 0.1–1.2 GeV/nucleon was measured to be (6.3 ± 0.9) × 10^−3(m^2 s sr)^−1. Over 90 percent of the helium flux was determined to be 3He at the 90% confidence level
Published: 2002

8. Apoyo psicológico y psicooncología

Author: P.T. Sánchez Hernández, J.M. Iranzo Miguélez, and C. Camps Herrero
Subjects: Medicine(all), Cartas al director, Text mining, business.industry, Apoyo emocional, General Medicine, Apoyo psicológico, Family Practice, Psychology, business, Psicooncología, Humanities
Published: 2002

9. Cosmic protons

Author: J. Alcaraz, B. Alpat, G. Ambrosi, H. Anderhub, L. Ao, A. Arefiev, P. Azzarello, E. Babucci, L. Baldini, M. Basile, D. Barancourt, F. Barao, G. Barbier, G. Barreira, R. Battiston, R. Becker, U. Becker, L. Bellagamba, P. Béné, J. Berdugo, P. Berges, B. Bertucci, A. Biland, S. Bizzaglia, S. Blasko, G. Boella, M. Boschini, M. Bourquin, L. Brocco, G. Bruni, M. Buenerd, J.D. Burger, W.J. Burger, X.D. Cai, C. Camps, P. Cannarsa, M. Capell, D. Casadei, J. Casaus, G. Castellini, C. Cecchi, Y.H. Chang, H.F. Chen, H.S. Chen, Z.G. Chen, N.A. Chernoplekov, T.H. Chiueh, Y.L. Chuang, F. Cindolo, V. Commichau, A. Contin, P. Crespo, M. Cristinziani, J.P. da Cunha, T.S. Dai, J.D. Deus, N. Dinu, L. Djambazov, I. D'Antone, Z.R. Dong, P. Emonet, J. Engelberg, F.J. Eppling, T. Eronen, G. Esposito, P. Extermann, J. Favier, E. Fiandrini, P.H. Fisher, G. Fluegge, N. Fouque, Yu. Galaktionov, M. Gervasi, P. Giusti, D. Grandi, O. Grimm, W.Q. Gu, K. Hangarter, A. Hasan, V. Hermel, H. Hofer, M.A. Huang, W. Hungerford, M. Ionica, R. Ionica, M. Jongmanns, K. Karlamaa, W. Karpinski, G. Kenney, J. Kenny, W. Kim, A. Klimentov, R. Kossakowski, V. Koutsenko, M. Kraeber, G. Laborie, T. Laitinen, G. Lamanna, G. Laurenti, A. Lebedev, S.C. Lee, G. Levi, P. Levtchenko, C.L. Liu, H.T. Liu, I. Lopes, G. Lu, Y.S. Lu, K. Lübelsmeyer, D. Luckey, W. Lustermann, C. Maña, A. Margotti, F. Mayet, R.R. McNeil, B. Meillon, M. Menichelli, A. Mihul, A. Mourao, A. Mujunen, F. Palmonari, A. Papi, I.H. Park, M. Pauluzzi, F. Pauss, E. Perrin, A. Pesci, A. Pevsner, M. Pimenta, V. Plyaskin, V. Pojidaev, M. Pohl, V. Postolache, N. Produit, P.G. Rancoita, D. Rapin, F. Raupach, D. Ren, Z. Ren, M. Ribordy, J.P. Richeux, E. Riihonen, J. Ritakari, U. Roeser, C. Roissin, R. Sagdeev, G. Sartorelli, A. Schultz von Dratzig, G. Schwering, G. Scolieri, E.S. Seo, V. Shoutko, E. Shoumilov, R. Siedling, D. Son, T. Song, M. Steuer, G.S. Sun, H. Suter, X.W. Tang, Samuel C.C. Ting, S.M. Ting, M. Tornikoski, J. Torsti, J. Trümper, J. Ulbricht, S. Urpo, I. Usoskin, E. Valtonen, J. Vandenhirtz, F. Velcea, E. Velikhov, B. Verlaat, I. Vetlitsky, F. Vezzu, J.P. Vialle, G. Viertel, D. Vité, H. Von Gunten, S. Waldmeier Wicki, W. Wallraff, B.C. Wang, J.Z. Wang, Y.H. Wang, K. Wiik, C. Williams, S.X. Wu, P.C. Xia, J.L. Yan, L.G. Yan, C.G. Yang, M. Yang, S.W. Ye, P. Yeh, Z.Z. Xu, H.Y. Zhang, Z.P. Zhang, D.X. Zhao, G.Y. Zhu, W.Z. Zhu, H.L. Zhuang, A. Zichichi, B. Zimmermann, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, Alcaraz, J, Alpat, B, Ambrosi, G, Anderhub, H, Ao, L, Arefiev, A, Azzarello, P, Babucci, E, Baldini, L, Basile, M, Barancourt, D, Barao, F, Barbier, G, Barreira, G, Battiston, R, Becker, R, Becker, U, Bellagamba, L, Béné, P, Berdugo, J, Berges, P, Bertucci, B, Biland, A, Bizzaglia, S, Blasko, S, Boella, G, Boschini, M, Bourquin, M, Brocco, L, Bruni, G, Buenerd, M, Burger, J, Burger, W, Cai, X, Camps, C, Cannarsa, P, Capell, M, Casadei, D, Casaus, J, Castellini, G, Cecchi, C, Chang, Y, Chen, H, Chen, Z, Chernoplekov, N, Chiueh, T, Chuang, Y, Cindolo, F, Commichau, V, Contin, A, Crespo, P, Cristinziani, M, Cunha, J, Dai, T, Deus, J, Dinu, N, Djambazov, L, D'Antone, I, Dong, Z, Emonet, P, Engelberg, J, Eppling, F, Eronen, T, Esposito, G, Extermann, P, Favier, J, Fiandrini, E, Fisher, P, Fluegge, G, Fouque, N, Galaktionov, Y, Gervasi, M, Giusti, P, Grandi, D, Grimm, O, Gu, W, Hangarter, K, Hasan, A, Hermel, V, Hofer, H, Huang, M, Hungerford, W, Ionica, M, Ionica, R, Jongmanns, M, Karlamaa, K, Karpinski, W, Kenney, G, Kenny, J, Kim, W, Klimentov, A, Kossakowski, R, Koutsenko, V, Kraeber, M, Laborie, G, Laitinen, T, Lamanna, G, Laurenti, G, Lebedev, A, Lee, S, Levi, G, Levtchenko, P, Liu, C, Liu, H, Lopes, I, Lu, G, Lu, Y, Lübelsmeyer, K, Luckey, D, Lustermann, W, Maña, C, Margotti, A, Mayet, F, Mcneil, R, Meillon, B, Menichelli, M, Mihul, A, Mourao, A, Mujunen, A, Palmonari, F, Papi, A, Park, I, Pauluzzi, M, Pauss, F, Perrin, E, Pesci, A, Pevsner, A, Pimenta, M, Plyaskin, V, Pojidaev, V, Pohl, M, Postolache, V, Produit, N, Rancoita, P, Rapin, D, Raupach, F, Ren, D, Ren, Z, Ribordy, M, Richeux, J, Riihonen, E, Ritakari, J, Roeser, U, Roissin, C, Sagdeev, R, Sartorelli, G, Dratzig, A, Schwering, G, Scolieri, G, Seo, E, Shoutko, V, Shoumilov, E, Siedling, R, Son, D, Song, T, Steuer, M, Sun, G, Suter, H, Tang, X, Ting, S, Tornikoski, M, Torsti, J, Trümper, J, Ulbricht, J, Urpo, S, Usoskin, I, Valtonen, E, Vandenhirtz, J, Velcea, F, Velikhov, E, Verlaat, B, Vetlitsky, I, Vezzu, F, Vialle, J, Viertel, G, Vité, D, Gunten, H, Wicki, S, Wallraff, W, Wang, B, Wang, J, Wang, Y, Wiik, K, Williams, C, Wu, S, Xia, P, Yan, J, Yan, L, Yang, C, Yang, M, Ye, S, Yeh, P, Xu, Z, Zhang, H, Zhang, Z, Zhao, D, Zhu, G, Zhu, W, Zhuang, H, Zichichi, A, Zimmermann, B, Ambrosi, Giovanni, Azzarello, Philipp, Bene, Pierre, Bourquin, Maurice, Cristinziani, Markus, Emonet, Pascal Philippe, Extermann, Pierre, Perrin, Eric, Pohl, Martin, Produit, Nicolas, Rapin, Divic Jean, Ribordy, Mathieu, Richeux, Jean-Pierre, and Vite, Davide
Subjects: [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Nuclear and High Energy Physics, FIS/05 - ASTRONOMIA E ASTROFISICA, Cosmic rays: protons, FIS/01 - FISICA SPERIMENTALE, 010308 nuclear & particles physics, 0103 physical sciences, ddc:500.2, Nuclear Experiment, 010303 astronomy & astrophysics, 01 natural sciences, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE
Abstract: The primary proton spectrum in the kinetic energy range 0.2 to 200 GeV was measured by the Alpha Magnetic Spectrometer (AMS) during space shuttle flight STS–91 at an altitude of 380 km. The complete data set combining three shuttle attitudes and including all known systematic effects is presented.
Published: 2001

10. Search for antihelium in cosmic rays

Author: Z.R. Dong, S. Bizzaglia, G. Ambrosi, J. Casaus, M. Pimenta, T. S. Dai, Samuel C.C. Ting, L. Djambazov, B.C. Wang, G. Molinari, A. Klimentov, B. Bertucci, S. X. Wu, R. Pilastrini, G. Lamanna, L.G. Yan, R. Siedling, J. Favier, Philipp Azzarello, J. J. Torsti, Antonino Zichichi, A. Hasan, Mauro Menichelli, L. Ao, Inkyu Park, J.P. Vialle, M. Steuer, P.C. Xia, Peter H. Fisher, Ilya Usoskin, P. G. Rancoita, Jing Wang, F. Palmonari, J. Isbert, M. Ribordy, G. Boella, H. von Gunten, P. Crespo, W. J. Burger, N. Fouque, R. Ionica, Federico Cindolo, J.P. Richeux, R. Cavalletti, D.X. Zhao, U. Roeser, N.A. Chernoplekov, C. G. Yang, Nicolas Produit, M. Buenerd, A. Cotta-Ramusino, R. Flaminio, J. P. Da Cunha, Anselmo Margotti, D. Rapin, V. Plyaskin, W. Kim, Roberto Battiston, G.Y. Zhu, W.Z. Zhu, G. Fluegge, G. Bruni, G. Viertel, P. Levtchenko, E. Fiandrini, G. Laurenti, K. Luebelsmeyer, S. Waldmeier Wicki, S.C. Lee, Yu. Galaktionov, F. Massera, D. Vité, J. Ulbricht, A. Chiarini, Hao Zhang, H. S. Chen, C. Rossin, G. Pancaldi, Felicitas Pauss, S. Recupero, Ciaran Williams, R. Kossakowski, W. Karpinski, J. Alcaraz, F. Barao, P. Yeh, E. Emonet, L.K. Ding, H.T. Liu, E. P. Velikhov, G. Torromeo, M. Basile, G.S. Sun, A. Pevsner, J.L. Yan, X. D. Cai, L. Baldini, F. Mezzanotte, C.L. Liu, L. Bellagamba, S. Blasko, K. Hangarter, J. Berdugo, Adrian Biland, G. Barbier, J. Vandenhirtz, V. Hermel, A. Arefiev, E. Prati, Jose Maria Kenny, R. R. McNeil, T.G. Guzik, B. Meillon, W.K. Gu, G. Kenney, I. D'Antone, J.P. Wefel, Markus Cristinziani, T. Eronen, R. Becker, Y.L. Chuang, P. Bene, B. Alpat, D. Luckey, E. Riihonen, A. Mihul, M. Jongmanns, C.C. Feng, D. Casadei, W. Wallraff, J. Krieger, H.L. Zhuang, G. Castellini, Massimo Gervasi, Zhuoxiang Ren, G. Schwering, W. Hungerford, A. Papi, Timo Laitinen, D. Santos, F. Tenbusch, B. Verlaat, P. Berges, Raffaele Mezzenga, S. Urpo, Ari Mujunen, G. Laborie, V. Shoutko, M. Pauluzzi, Y. S. Lu, G.P. Barreira, Yun Wang, V. Commichau, J. Truemper, A. Pesci, D. Ren, M. Capell, V. Koutsenko, Eino Valtonen, F. Vezzu, P. Cannarsa, C. Camps, T.P. Li, M. Ionica, H. Postema, A. Contin, M. Yang, E. Babucci, U. Becker, A. Lebedev, Dong-Chul Son, P. Giusti, I. Lopes, E. Perrin, F. J. Eppling, D. Alvisi, G. Lu, F. Raupach, C. Maña, P. Extermann, S. M. Ting, H. Hofer, G. Esposito, I. Vetlitsky, G. Sartorelli, M. Lolli, G. Maehlum, E.A. Werner, Fabio Finelli, Z.G. Chen, Werner Lustermann, Giuseppe Levi, X. W. Tang, Tao Song, M. Bourquin, V. Pojidaev, E. Shoumilov, H. Suter, J. D. Burger, Roald Z. Sagdeev, A. Mourao, J. Ritakari, Y. H. Chang, D. Barancourt, N. Dinu, H. Anderhub, Tzihong Chiueh, M. A. Huang, Jorge Dias de Deus, F. Mayet, A. Schultz von Dratzig, Alcaraz, J, Alvisi, D, Alpat, B, Ambrosi, G, Anderhub, H, Ao, L, Arefiev, A, Azzarello, P, Babucci, E, Baldini, L, Basile, M, Barancourt, D, Barao, F, Barbier, G, Barreira, G, Battiston, R, Becker, R, Becker, U, Bellagamba, L, Béné, P, Berdugo, J, Berges, P, Bertucci, B, Biland, A, Bizzaglia, S, Blasko, S, Boella, G, Bourquin, M, Bruni, G, Buenerd, M, Burger, J, Burger, W, Cai, X, Cavalletti, R, Camps, C, Cannarsa, P, Capell, M, Casadei, D, Casaus, J, Castellini, G, Chang, Y, Chen, H, Chen, Z, Chernoplekov, N, Chiarini, A, Chiueh, T, Chuang, Y, Cindolo, F, Commichau, V, Contin, A, Cotta Ramusino, A, Crespo, P, Cristinziani, M, Dacunha, J, Dai, T, Deus, J, Ding, L, Dinu, N, Djambazov, L, D'Antone, I, Dong, Z, Emonet, P, Eppling, F, Eronen, T, Esposito, G, Extermann, P, Favier, J, Feng, C, Fiandrini, E, Finelli, F, Fisher, P, Flaminio, R, Fluegge, G, Fouque, N, Galaktionov, Y, Gervasi, M, Giusti, P, Gu, W, Guzik, T, Hangarter, K, Hasan, A, Hermel, V, Hofer, H, Huang, M, Hungerford, W, Ionica, M, Ionica, R, Isbert, J, Jongmanns, M, Karpinski, W, Kenney, G, Kenny, J, Kim, W, Klimentov, A, Krieger, J, Kossakowski, R, Koutsenko, V, Laborie, G, Laitinen, T, Lamanna, G, Laurenti, G, Lebedev, A, Lee, S, Levi, G, Levtchenko, P, Li, T, Liu, C, Liu, H, Lolli, M, Lopes, I, Lu, G, Lu, Y, Lübelsmeyer, K, Luckey, D, Lustermann, W, Maehlum, G, Maña, C, Margotti, A, Massera, F, Mayet, F, Mcneil, R, Meillon, B, Menichelli, M, Mezzanotte, F, Mezzenga, R, Mihul, A, Molinari, G, Mourao, A, Mujunen, A, Palmonari, F, Pancaldi, G, Papi, A, Park, I, Pauluzzi, M, Pauss, F, Perrin, E, Pesci, A, Pevsner, A, Pilastrini, R, Pimenta, M, Plyaskin, V, Pojidaev, V, Postema, H, Prati, E, Produit, N, Rancoita, P, Rapin, D, Raupach, F, Recupero, S, Ren, D, Ren, Z, Ribordy, M, Richeux, J, Riihonen, E, Ritakari, J, Roeser, U, Roissin, C, Sagdeev, R, Santos, D, Sartorelli, G, Schultzvondratzig, A, Schwering, G, Shoutko, V, Shoumilov, E, Siedling, R, Son, D, Song, T, Steuer, M, Sun, G, Suter, H, Tang, X, Ting, S, Tenbusch, F, Torromeo, G, Torsti, J, Trümper, J, Ulbricht, J, Urpo, S, Usoskin, I, Valtonen, E, Vandenhirtz, J, Velikhov, E, Verlaat, B, Vetlitsky, I, Vezzu, F, Vialle, J, Viertel, G, Vité, D, Vongunten, H, Waldmeierwicki, S, Wallraff, W, Wang, B, Wang, J, Wang, Y, Wefel, J, Werner, E, Williams, C, Wu, S, Xia, P, Yan, J, Yan, L, Yang, C, Yang, M, Yeh, P, Zhang, H, Zhao, D, Zhu, G, Zhu, W, Zhuang, H, Zichichi, A, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), and AMS
Subjects: Astrophysics and Astronomy, Nuclear and High Energy Physics, FOS: Physical sciences, chemistry.chemical_element, Space Shuttle, Cosmic ray, Astrophysics, 7. Clean energy, 01 natural sciences, High Energy Physics - Experiment, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], High Energy Physics - Experiment (hep-ex), FIS/05 - ASTRONOMIA E ASTROFISICA, Rigidity (electromagnetism), 0103 physical sciences, Alpha Magnetic Spectrometer, 010306 general physics, Helium, Physics, 010308 nuclear & particles physics, Astrophysics (astro-ph), Astronomy, Flux ratio, FIS/01 - FISICA SPERIMENTALE, chemistry, Cosmic rays: anti-helium, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE
Abstract: The Alpha Magnetic Spectrometer (AMS) was flown on the space shuttle Discovery during flight STS-91 in a 51.7 degree orbit at altitudes between 320 and 390 km. A total of 2.86 * 10^6 helium nuclei were observed in the rigidity range 1 to 140 GV. No antihelium nuclei were detected at any rigidity. An upper limit on the flux ratio of antihelium to helium of < 1.1 * 10^-6 is obtained., 18 pages, Latex, 9 .eps figures
Published: 2000

11. Leptons in near earth orbit

Author: L. Djambazov, P. Giusti, G. Scolieri, I. Lopes, Dawei Zhao, P. G. Rancoita, E. Babucci, U. Becker, F. Vezzu, E. Perrin, F. J. Eppling, G. Barbier, S. M. Ting, S.C. Lee, R. Ionica, F. Palmonari, H. von Gunten, G. Esposito, Z.R. Dong, Federico Cindolo, Changgen Yang, H. T. Liu, Diego Casadei, Yu. Galaktionov, D. Vité, A. Lebedev, U. Roeser, G. Castellini, Dong-Chul Son, Z. L. Ren, J. Alcaraz, Guohuai Zhu, Yun Wang, S. Bizzaglia, A. Arefiev, P. Extermann, H. Hofer, W. Wallraff, Ilya Usoskin, Jing Wang, P. Levtchenko, P. Emonet, T. S. Dai, H. Anderhub, Waclaw Karpinski, E. Fiandrini, R. Becker, P. Cannarsa, R. R. McNeil, D. Rapin, C. Roissin, B.C. Wang, M. Pimenta, E. P. Velikhov, B. Zimmermann, V. Plyaskin, Roald Z. Sagdeev, B. Meillon, H. S. Chen, L. Baldini, J. Casaus, A. Hasan, E. Riihonen, Mauro Menichelli, K. Karlamaa, A. Mihul, Giovanna Bruni, G. Kenney, N. Produit, D. Grandi, M. Ribordy, S. Urpo, W. J. Burger, Merja Tornikoski, Markus Cristinziani, G. Schwering, A. Pesci, I. Vetlitsky, L.G. Yan, I. D'Antone, Y. H. Chang, Tengfei Song, W.Q. Gu, B. Bertucci, D. Barancourt, N. Dinu, V. Commichau, G. Laborie, P. Crespo, Mao-Zhi Yang, J. J. Torsti, M. Jongmanns, Antonino Zichichi, Adrian Biland, V. Postolache, Peter H. Fisher, T. Eronen, C. Camps, J. Berdugo, N. Fouque, J. P. Da Cunha, Massimo Gervasi, J. Vandenhirtz, H. F. Chen, F. Barao, S. Blasko, Zhenyu Zhang, H.L. Zhuang, G. Viertel, E. Shoumilov, Jose Maria Kenny, W. Hungerford, F. Velcea, Y.L. Chuang, O. Grimm, J.L. Yan, K. Wiik, P. Bene, H. Suter, J.P. Richeux, Tzihong Chiueh, V. Hermel, M. Buenerd, Timo Laitinen, M. Capell, A. Papi, Eun-Suk Seo, M. Pauluzzi, R. Siedling, G. Fluegge, W.Z. Zhu, Giovanni Ambrosi, L. Ao, M. Bourquin, D. Ren, G. Lu, C. Maña, V. Koutsenko, Eino Valtonen, Felicitas Pauss, R. Kossakowski, A. Klimentov, G.S. Sun, A. Contin, Samuel C.C. Ting, M. A. Huang, M. J. Boschini, M. Basile, K. Hangarter, Roberto Battiston, A. Pevsner, D. Luckey, F. Mayet, Ciaran Williams, J. Ulbricht, A. Schultz von Dratzig, P. Yeh, G. Laurenti, Claudia Cecchi, S. Waldmeier Wicki, Hao Zhang, Z.G. Chen, S. X. Wu, J. Ritakari, X. D. Cai, J. Trümper, V. Shoutko, Inkyu Park, M. Steuer, P.C. Xia, S.W. Ye, C.L. Liu, L. Bellagamba, G. Lamanna, J. Engelberg, Xiao-Dong Tang, J. P. Vialle, K. Lübelsmeyer, G.P. Barreira, M. Ionica, P. Azzarello, Z. Z. Xu, V. Pojidaev, B. Verlaat, G. Sartorelli, P. Berges, Giuseppe Levi, Lu Yuzhang, Ari Mujunen, Werner Lustermann, Behcet Alpat, J. D. Burger, Frank Raupach, A. Mourao, J.D. Deus, L. Brocco, G. Boella, N.A. Chernoplekov, Anselmo Margotti, W. Kim, M. Kraeber, J. Favier, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, Alcaraz, J, Alpat, B, Ambrosi, G, Anderhub, H, Ao, L, Arefiev, A, Azzarello, P, Babucci, E, Baldini, L, Basile, M, Barancourt, D, Barao, F, Barbier, G, Barreira, G, Battiston, R, Becker, R, Becker, U, Bellagamba, L, Béné, P, Berdugo, J, Berges, P, Bertucci, B, Biland, A, Bizzaglia, S, Blasko, S, Boella, G, Boschini, M, Bourquin, M, Brocco, L, Bruni, G, Buenerd, M, Burger, J, Burger, W, Cai, X, Camps, C, Cannarsa, P, Capell, M, Casadei, D, Casaus, J, Castellini, G, Cecchi, C, Chang, Y, Chen, H, Chen, Z, Chernoplekov, N, Chiueh, T, Chuang, Y, Cindolo, F, Commichau, V, Contin, A, Crespo, P, Cristinziani, M, Cunha, J, Dai, T, Deus, J, Dinu, N, Djambazov, L, D'Antone, I, Dong, Z, Emonet, P, Engelberg, J, Eppling, F, Eronen, T, Esposito, G, Extermann, P, Favier, J, Fiandrini, E, Fisher, P, Fluegge, G, Fouque, N, Galaktionov, Y, Gervasi, M, Giusti, P, Grandi, D, Grimm, O, Gu, W, Hangarter, K, Hasan, A, Hermel, V, Hofer, H, Huang, M, Hungerford, W, Ionica, M, Ionica, R, Jongmanns, M, Karlamaa, K, Karpinski, W, Kenney, G, Kenny, J, Kim, W, Klimentov, A, Kossakowski, R, Koutsenko, V, Kraeber, M, Laborie, G, Laitinen, T, Lamanna, G, Laurenti, G, Lebedev, A, Lee, S, Levi, G, Levtchenko, P, Liu, C, Liu, H, Lopes, I, Lu, G, Lu, Y, Lübelsmeyer, K, Luckey, D, Lustermann, W, Maña, C, Margotti, A, Mayet, F, Mcneil, R, Meillon, B, Menichelli, M, Mihul, A, Mourao, A, Mujunen, A, Palmonari, F, Papi, A, Park, I, Pauluzzi, M, Pauss, F, Perrin, E, Pesci, A, Pevsner, A, Pimenta, M, Plyaskin, V, Pojidaev, V, Postolache, V, Produit, N, Rancoita, P, Rapin, D, Raupach, F, Ren, D, Ren, Z, Ribordy, M, Richeux, J, Riihonen, E, Ritakari, J, Roeser, U, Roissin, C, Sagdeev, R, Sartorelli, G, Dratzig, A, Schwering, G, Scolieri, G, Seo, E, Shoutko, V, Shoumilov, E, Siedling, R, Son, D, Song, T, Steuer, M, Sun, G, Suter, H, Tang, X, Ting, S, Tornikoski, M, Torsti, J, Trümper, J, Ulbricht, J, Urpo, S, Usoskin, I, Valtonen, E, Vandenhirtz, J, Velcea, F, Velikhov, E, Verlaat, B, Vetlitsky, I, Vezzu, F, Vialle, J, Viertel, G, Vité, D, Gunten, H, Wicki, S, Wallraff, W, Wang, B, Wang, J, Wang, Y, Wiik, K, Williams, C, Wu, S, Xia, P, Yan, J, Yan, L, Yang, C, Yang, M, Ye, S, Yeh, P, Xu, Z, Zhang, H, Zhang, Z, Zhao, D, Zhu, G, Zhu, W, Zhuang, H, Zichichi, A, and Zimmermann, B
Subjects: Nuclear and High Energy Physics, Cosmic Rays, AMS, Cosmic ray, Electron, Astrophysics, Kinetic energy, 01 natural sciences, Spectral line, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Nuclear physics, FIS/05 - ASTRONOMIA E ASTROFISICA, AMS-01, 0103 physical sciences, Alpha Magnetic Spectrometer, AMS, 010306 general physics, 010303 astronomy & astrophysics, Physics, Earth's orbit, Cosmic rays: leptons, Cosmic Rays, cosmic rays, AMS-01, FIS/01 - FISICA SPERIMENTALE, Earth's magnetic field, 13. Climate action, High Energy Physics::Experiment, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE, Lepton
Abstract: The lepton spectra in the kinetic energy ranges 0.2 to 40 GeV for e − and 0.2 to 3 GeV for e + were measured by the Alpha Magnetic Spectrometer (AMS) during space shuttle flight STS–91 at altitudes near 380 km. From the origin of the leptons two distinct spectra were observed: a higher energy spectrum and a substantial second spectrum with positrons much more abundant than electrons. Tracing leptons from the second spectra shows that most of these leptons travel for an extended period of time in the geomagnetic field and that the e + and e − originate from two complementary geographic regions.
Published: 2000

12. Protons in near earth orbit

Author: J. Alcaraz, D. Alvisi, B. Alpat, G. Ambrosi, H. Anderhub, L. Ao, A. Arefiev, P. Azzarello, E. Babucci, L. Baldini, M. Basile, D. Barancourt, F. Barao, G. Barbier, G. Barreira, R. Battiston, R. Becker, U. Becker, L. Bellagamba, P. Béné, J. Berdugo, P. Berges, B. Bertucci, A. Biland, S. Bizzaglia, S. Blasko, G. Boella, M. Boschini, M. Bourquin, G. Bruni, M. Buenerd, J.D. Burger, W.J. Burger, X.D. Cai, R. Cavalletti, C. Camps, P. Cannarsa, M. Capell, D. Casadei, J. Casaus, G. Castellini, Y.H. Chang, H.F. Chen, H.S. Chen, Z.G. Chen, N.A. Chernoplekov, A. Chiarini, T.H. Chiueh, Y.L. Chuang, F. Cindolo, V. Commichau, A. Contin, A. Cotta–Ramusino, P. Crespo, M. Cristinziani, J.P. da Cunha, T.S. Dai, J.D. Deus, N. Dinu, L. Djambazov, I. D'Antone, Z.R. Dong, P. Emonet, J. Engelberg, F.J. Eppling, T. Eronen, G. Esposito, P. Extermann, J. Favier, C.C. Feng, E. Fiandrini, F. Finelli, P.H. Fisher, R. Flaminio, G. Fluegge, N. Fouque, Yu. Galaktionov, M. Gervasi, P. Giusti, D. Grandi, W.Q. Gu, K. Hangarter, A. Hasan, V. Hermel, H. Hofer, M.A. Huang, W. Hungerford, M. Ionica, R. Ionica, M. Jongmanns, K. Karlamaa, W. Karpinski, G. Kenney, J. Kenny, W. Kim, A. Klimentov, R. Kossakowski, V. Koutsenko, G. Laborie, T. Laitinen, G. Lamanna, G. Laurenti, A. Lebedev, S.C. Lee, G. Levi, P. Levtchenko, C.L. Liu, H.T. Liu, M. Lolli, I. Lopes, G. Lu, Y.S. Lu, K. Lübelsmeyer, D. Luckey, W. Lustermann, C. Maña, A. Margotti, F. Massera, F. Mayet, R.R. McNeil, B. Meillon, M. Menichelli, F. Mezzanotte, R. Mezzenga, A. Mihul, G. Molinari, A. Mourao, A. Mujunen, F. Palmonari, G. Pancaldi, A. Papi, I.H. Park, M. Pauluzzi, F. Pauss, E. Perrin, A. Pesci, A. Pevsner, R. Pilastrini, M. Pimenta, V. Plyaskin, V. Pojidaev, H. Postema, V. Postolache, E. Prati, N. Produit, P.G. Rancoita, D. Rapin, F. Raupach, S. Recupero, D. Ren, Z. Ren, M. Ribordy, J.P. Richeux, E. Riihonen, J. Ritakari, U. Roeser, C. Roissin, R. Sagdeev, D. Santos, G. Sartorelli, A. Schultz von Dratzig, G. Schwering, E.S. Seo, V. Shoutko, E. Shoumilov, R. Siedling, D. Son, T. Song, M. Steuer, G.S. Sun, H. Suter, X.W. Tang, Samuel C.C. Ting, S.M. Ting, M. Tornikoski, G. Torromeo, J. Torsti, J. Trümper, J. Ulbricht, S. Urpo, I. Usoskin, E. Valtonen, J. Vandenhirtz, F. Velcea, E. Velikhov, B. Verlaat, I. Vetlitsky, F. Vezzu, J.P. Vialle, G. Viertel, D. Vité, H. Von Gunten, S. Waldmeier Wicki, W. Wallraff, B.C. Wang, J.Z. Wang, Y.H. Wang, K. Wiik, C. Williams, S.X. Wu, P.C. Xia, J.L. Yan, L.G. Yan, C.G. Yang, M. Yang, S.W. Ye, P. Yeh, Z.Z. Xu, H.Y. Zhang, Z.P. Zhang, D.X. Zhao, G.Y. Zhu, W.Z. Zhu, H.L. Zhuang, A. Zichichi, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, Alcaraz, J, Alvisi, D, Alpat, B, Ambrosi, G, Anderhub, H, Ao, L, Arefiev, A, Azzarello, P, Babucci, E, Baldini, L, Basile, M, Barancourt, D, Barao, F, Barbier, G, Barreira, G, Battiston, R, Becker, R, Becker, U, Bellagamba, L, Béné, P, Berdugo, J, Berges, P, Bertucci, B, Biland, A, Bizzaglia, S, Blasko, S, Boella, G, Boschini, M, Bourquin, M, Bruni, G, Buenerd, M, Burger, J, Burger, W, Cai, X, Cavalletti, R, Camps, C, Cannarsa, P, Capell, M, Casadei, D, Casaus, J, Castellini, G, Chang, Y, Chen, H, Chen, Z, Chernoplekov, N, Chiarini, A, Chiueh, T, Chuang, Y, Cindolo, F, Commichau, V, Contin, A, Cotta–ramusino, A, Crespo, P, Cristinziani, M, Cunha, J, Dai, T, Deus, J, Dinu, N, Djambazov, L, D'Antone, I, Dong, Z, Emonet, P, Engelberg, J, Eppling, F, Eronen, T, Esposito, G, Extermann, P, Favier, J, Feng, C, Fiandrini, E, Finelli, F, Fisher, P, Flaminio, R, Fluegge, G, Fouque, N, Galaktionov, Y, Gervasi, M, Giusti, P, Grandi, D, Gu, W, Hangarter, K, Hasan, A, Hermel, V, Hofer, H, Huang, M, Hungerford, W, Ionica, M, Ionica, R, Jongmanns, M, Karlamaa, K, Karpinski, W, Kenney, G, Kenny, J, Kim, W, Klimentov, A, Kossakowski, R, Koutsenko, V, Laborie, G, Laitinen, T, Lamanna, G, Laurenti, G, Lebedev, A, Lee, S, Levi, G, Levtchenko, P, Liu, C, Liu, H, Lolli, M, Lopes, I, Lu, G, Lu, Y, Lübelsmeyer, K, Luckey, D, Lustermann, W, Maña, C, Margotti, A, Massera, F, Mayet, F, Mcneil, R, Meillon, B, Menichelli, M, Mezzanotte, F, Mezzenga, R, Mihul, A, Molinari, G, Mourao, A, Mujunen, A, Palmonari, F, Pancaldi, G, Papi, A, Park, I, Pauluzzi, M, Pauss, F, Perrin, E, Pesci, A, Pevsner, A, Pilastrini, R, Pimenta, M, Plyaskin, V, Pojidaev, V, Postema, H, Postolache, V, Prati, E, Produit, N, Rancoita, P, Rapin, D, Raupach, F, Recupero, S, Ren, D, Ren, Z, Ribordy, M, Richeux, J, Riihonen, E, Ritakari, J, Roeser, U, Roissin, C, Sagdeev, R, Santos, D, Sartorelli, G, Dratzig, A, Schwering, G, Seo, E, Shoutko, V, Shoumilov, E, Siedling, R, Son, D, Song, T, Steuer, M, Sun, G, Suter, H, Tang, X, Ting, S, Tornikoski, M, Torromeo, G, Torsti, J, Trümper, J, Ulbricht, J, Urpo, S, Usoskin, I, Valtonen, E, Vandenhirtz, J, Velcea, F, Velikhov, E, Verlaat, B, Vetlitsky, I, Vezzu, F, Vialle, J, Viertel, G, Vité, D, Gunten, H, Wicki, S, Wallraff, W, Wang, B, Wang, J, Wang, Y, Wiik, K, Williams, C, Wu, S, Xia, P, Yan, J, Yan, L, Yang, C, Yang, M, Ye, S, Yeh, P, Xu, Z, Zhang, H, Zhang, Z, Zhao, D, Zhu, G, Zhu, W, Zhuang, H, and Zichichi, A
Subjects: Nuclear and High Energy Physics, Astrophysics and Astronomy, Proton, FOS: Physical sciences, Flux, Space Shuttle, Astrophysics, Kinetic energy, 7. Clean energy, 01 natural sciences, High Energy Physics - Experiment, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], High Energy Physics - Experiment (hep-ex), FIS/05 - ASTRONOMIA E ASTROFISICA, 0103 physical sciences, Alpha Magnetic Spectrometer, Cosmic rays, AMS, AMS, Nuclear Experiment, 010303 astronomy & astrophysics, Cosmic rays, Physics, Range (particle radiation), Earth's orbit, 010308 nuclear & particles physics, Astrophysics (astro-ph), Earth's magnetic field, FIS/01 - FISICA SPERIMENTALE, 13. Climate action, Physics::Space Physics, cosmic rays: protons, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE, Particle Physics - Experiment
Abstract: The proton spectrum in the kinetic energy range 0.1 to 200 GeV was measured by the Alpha Magnetic Spectrometer (AMS) during space shuttle flight STS-91 at an altitude of 380 km. Above the geomagnetic cutoff the observed spectrum is parameterized by a power law. Below the geomagnetic cutoff a substantial second spectrum was observed concentrated at equatorial latitudes with a flux ~ 70 m^-2 sec^-1 sr^-1. Most of these second spectrum protons follow a complicated trajectory and originate from a restricted geographic region., 19 pages, Latex, 7 .eps figures
Published: 2000

13. The L3 silicon microvertex detector

Author: Roberto Castello, Alain Hervé, A. Gabbanini, P. Extermann, P. Lecomte, A. Bay, J. S. Kapustinsky, E. Babucci, J. Xu, M. Lebeau, G. Passaleva, E. Fiandrini, R. Leiste, S. R. Hou, G. Landi, A. Chen, Maurizio Biasini, J.P. Richeux, Willis Lin, B. Schöneich, S. Easo, Gian Mario Bilei, H. Kirst, L. Baksay, S. Pensotti, J. Kornis, H. Tuchscherer, M. Pauluzzi, T. Hofer, J. Ding, G. Terza, P. Ladron, F. Tonisch, Attilio Santocchia, M. L. Brooks, Roberto Battiston, O. Adriani, G. J. Bobbink, G.B. Mills, P. Schmitz, C. Camps, P. Duinker, Joel Goldstein, K. Hangarter, G. F. Susinno, R. Massetti, D. DiBitonto, G. Castellini, A. Marin, W. Baur, Gy L. Bencze, R. Siedling, W. J. Burger, M. Hofer, Claude Hauviller, S. Waldmeier, T. N. Thompson, R. Weill, D. Kim, E. Lejeune, G. Zilizi, D. M. Lee, Andrea Baschirotto, E. Perrin, K. Subham, Giovanni Ambrosi, S. P. Ahlen, L. Djambazov, M. Sachwitz, A. Gougas, T. Paul, A. Adam, Wolfgang Lohmann, H. Vogt, B. Bertucci, J. Alcaraz, W. W. Kinnison, S. C. Yeh, Maria Isabel Josa, N. Produit, V. R. Krastev, J. Tóth, S. Wang, M. Acciarri, G. Viertel, B. Zhou, P. G. Rancoita, H. Nowak, G. Trowitzsch, V. Commichau, M. Okle, M. Bosetti, T. E. Coan, B. Checcuccl, M. Rattaggi, M. Caria, M. Tesi, J. Boissevain, L. Servoli, and J. Busenitz
Subjects: Physics, Nuclear and High Energy Physics, Silicon, Physics::Instrumentation and Detectors, business.industry, Detector, Readout electronics, chemistry.chemical_element, Monitoring system, Displacement (vector), Nuclear physics, Optics, Data acquisition, chemistry, Radiation monitoring, High Energy Physics::Experiment, Detectors and Experimental Techniques, business, Instrumentation
Abstract: The design and construction of the silicon strip microvertex detector (SMD) of the L3 experiment at LEP are described. We present the sensors, readout electronics, data acquisition system, mechanical assembly and support, displacement monitoring systems and radiation monitoring system of the recently installed double-sided, double-layered SMD. This detector utilizes novel and sophisticated techniques for its readout.
Published: 1994

14. Performance On Test Beam of the L3 Double-sided Silicon Microstrip Detector

Author: P. Schmitz, C. Camps, J. Wegmann, Roberto Battiston, W. J. Burger, W. W. Kinnison, S. C. Yeh, K. Hangarter, Jozsef Toth, G.J. Bobbink, Gy L. Bencze, J. Busenitz, E. Fiandrini, B. Checcucci, P. Extermann, G. M. Bilei, S. P. Ahlen, M. Caria, O. Adriani, M. Rattaggi, A. Chen, Wt Lin, L. Servoli, J.S. Kapustinski, Achim Rosch, D. M. Lee, A. Marin, Claude Hauviller, S. Waldmeier, R. Leiste, T. Paul, D. DiBitonto, M. Bosetti, T. E. Coan, S. Easo, Alain Hervé, G. Landi, M. Sachwitz, Maurizio Biasini, V. Commichau, G. Castellini, Pierre Lecomte, A. Bay, B. Schöneich, G. Hu, Dai-Sik Kim, Attilio Santocchia, S. Pensotti, G. Terzi, B. Zhou, M. Pauluzzi, P. G. Rancoita, A. Gougas, Giovanni Ambrosi, M. Lebeau, G. Trowitzsch, F. Tonisch, H. Nowak, E. Babucci, M. L. Brooks, A. Adam, I. Josa, E. Perrin, P. Duinker, R. Weill, R. Massetti, G. Viertel, G. Passaleva, G.B. Mills, Andrea Baschirotto, Wolfgang Lohmann, H. Vogt, B. Bertucci, V. R. Krastev, and G. F. Susinno
Subjects: Physics, Nuclear and High Energy Physics, Silicon, business.industry, Amplifier, Detector, chemistry.chemical_element, Noise (electronics), Particle detector, Semiconductor detector, chemistry, Optoelectronics, business, Instrumentation, Ohmic contact, Beam (structure)
Abstract: Two modules of the L3 Silicon Microvertex Detector (SMD) have been tested on beam. The active area of the modules consists of double sided silicon microstrip detectors; the implantation pitch is 25 μm and 50 μm in the junction and ohmic side, respectively. The detectors are read out by a VLSI radiation hard amplifier (SVX-H). The position resolution, with a readout pitch of 50 μm and 200 μm for the two sides, is determined to be 7.0 μm and 14.3 μm. A signal to noise ratio ⩾ 16 and a detection efficiency ⩾ 99% are measured for both sides.
Published: 1994

15. Search for a low mass neutral Higgs boson in Z0 decay

Author: G. Landi, M. Merk, P. Vikas, Alain Hervé, R. Rosmalen, M. Fabre, A. Bay, A. A. Syed, K. Sudhakar, Georgi Sultanov, R. A. Khan, Carlo Civinini, T. Driever, M. Maolinbay, Tariq Aziz, V. P. Andreev, G.J. Bobbink, X.G. Li, M. Aguilar-Benitez, I. Duran, B.C. Stringfellow, P. Schmitz, Alexei Klimentov, J.M. Qian, Egidio Longo, J.C. Sens, M. Yzerman, F. Crijns, T. Kramer, M. Chemarin, Herwig Schopper, Valery Schegelsky, Antonino Zichichi, Ph Fisher, H. Rykaczewski, C. Camps, K. Freudenreich, F. Ferroni, Y. Zeng, Igor Vorobiev, M. White, G. M. Chen, J. J. Blaising, M. M. Ilyas, Y. Karyotakis, H.T. Li, G. Finocchiaro, Y. H. Chang, G. Fernandez, B. L. Betev, George Alverson, Panos A Razis, R. Fabbretti, H. R. Gustafson, Vineet Kumar, P. Blömeke, H. Haan, J. Behrens, P. J. Li, P. Lebrun, Fridolin Dittus, Mariagrazia Alviggi, Dimitri Bourilkov, Marco Meschini, R.J. Wu, A. Sopczak, J. Perrier, L. Baksay, Yu. Galaktionov, Crisostomo Sciacca, François Chollet, Marco Pieri, C. Rippich, D. Pandoulas, T. McMahon, B. Monteleoni, Petr Levchenko, S. Röhner, D. Kirkby, BT Bouwens, J. Alcaraz, R. Malik, T. Spickermann, L.S. Hsu, G. Morand, W. Wallraff, Guofan Hu, J.M. Lubbers, M. Bourquin, F. Wittgenstein, K. Strauch, G. Gratta, L. Urbàn, Zhuoxiang Ren, M. Wadhwa, D. J. Schotanus, Bernard Ille, R. Magahiz, J. M. You, A. Arefiev, Aa Vorobyov, E. Jagel, W. Kittel, N. Produit, Wen-Gan Ma, L. Ludovici, E. Drago, An.A. Vorobyov, T. Matsuda, A. Chen, O. Adriani, J. Salicio, Lucas Taylor, I. Vetlitsky, A. Gordeev, M. Micke, Jozsef Toth, J. Lettry, Claudio Luci, Konrad Deiters, C.Y. Chien, M. Lenti, A. L. Anderson, Cheng Chen, B. Stöhr, J. D. Swain, K. N. Qureshi, O. Rind, P. McBride, L. Niessen, Sau Lan Wu, Jean Fay, M. Dhina, D. Boutigny, D.W. Schmitz, G.G.G. Massaro, Z. Y. Lin, Elisabetta Gallo, U. Roeser, Alberto Aloisio, Y.J. Pei, M. Harris, G. A. Yang, R.C. Ball, Z.L. Xue, Adrian Biland, Wolfgang Lohmann, H. Vogt, B. Bertucci, M.L. Chen, G. Sauvage, Ying Wu, V. Plyaskin, E. Nagy, C-Q. Li, C. Zaccardelli, Nicanor Colino, Yanwen Liu, Chenliang Wang, Federico Carminati, Th. Meinholz, X. Lue, U. K. Chaturvedi, A. Böhm, Hafeez R. Hoorani, Y. S. Lu, Marcella Diemoz, G. Coignet, J. F. Zhou, Y. Mi, G. Schwering, Robert Clare, J. G. Branson, X. W. Tang, Z.Q. Yang, P. A. Piroué, D.N. Mao, Yu. Kamyshkov, K.D. Shmakov, S. J. Fan, S. Reucroft, Harvey B Newman, D. DiBitonto, Luciano Romero, Bolek Wyslouch, Qian Wang, Helmut Vogel, S. C. Yeh, M. Möller, R. Leiste, H. Fenker, E. Dénes, R. Sehgal, M. Schneegans, Jérôme Rose, J. H. Field, K. Hilgers, Ph. Rosselet, G. Trowitzsch, S. C. Tonwar, Zhen Zhang, F. Marzano, B. N. Jin, S. Rosier-Lees, W. Krenz, M. MacDermott, R. Raghavan, A. C. König, G. Mirabelli, H. F. Chen, Thomas Hebbeker, Paul Lecoq, R. W. Kraemer, L. Z. Sun, Z. W. Yin, Qiang Li, W. Böhlen, Mw Gruenewald, G. Von Dardel, S. Schulte, Frank Filthaut, M. Sachwitz, S. N. Ganguli, C. F. He, P. Le Coultre, K. Lübelsmeyer, Piero Spillantini, Y.P. Tong, M. A. Niaz, Laurent Vuilleumier, Ren-Yuan Zhu, Luciano Barone, M. Napolitano, T. Ferguson, E. Isiksal, M. Guanziroli, C. G. Yang, W. Ruckstuhl, K. Hangarter, A. Degré, X. L. Wang, S. X. Wu, L. Zehnder, M. Vivargent, Christine Buisson, G. Herten, Q.Y. Yang, T. Böhringer, W. Friebel, G. Faber, U. Herten, A. Gurtu, D. P. Stickland, P. Marchesini, A. Pevsner, Ming Zeng, R. L. Sumner, G. H. Wang, A. Engler, J. P. Martin, V. Commichau, H. J. Schreiber, J.B. Ye, S. Banerjee, Z. M. Wang, C. J.W.P. Timmermans, P. Extermann, Giovanni Paternoster, G. Chiefari, S. Shevchenko, Raffaello D'Alessandro, C. Grinnell, H. S. Chen, A. Kuhn, M. Röhner, M. Bocciolini, Lamberto Luminari, K. S. Kumar, Y. Mir, C. H. Ye, Barry Blumenfeld, R. Starosta, A.M. Cartacci, D. Luckey, H.R. Dimitrov, Gy L. Bencze, I. Leedom, B. Z. Yang, A. Hasan, S. Beingessner, H. Hofer, Kajari Mazumdar, M. Capell, J. A. Bakken, J. Wenninger, J. Fehlmann, S. Patricelli, Reinhard W. Schulte, F. C. Erné, K. L. Tung, E. Thomas, Pierre Lecomte, Y. D. Xu, M. Steuer, Y.F. Mao, V. Shevchenko, J. M. Salicio, V. Pojidaev, U. Micke, D. Perret-Gallix, H. S. Fesefeldt, Leonardo Merola, R. T. Van de Walle, G. Sartorelli, Nikita Smirnov, J. Mnich, G. Forconi, J. Weber, D. Linnhofer, Zm Wang, J.H. Wang, Zhongyukun Xu, P. K. Malhotra, S. Khokhar, R. Mount, H. A. Rizvi, A. Kunin, J. D. Burger, G. Rahal-Callot, E. Shumilov, C. Maña, P.G. Seiler, Q. Ye, I. Scott, F. Diez-Hedo, T. Azemoon, T. Foreman, C. Spartiotis, P. Duinker, J. Berdugo, M. Hebert, Peter Denes, M. Gailloud, G.B. Mills, Samuel C.C. Ting, R. Wilhelm, E. Valente, R. Bizzarri, W. J. Metzger, Paolo Bagnaia, M.C. Chen, R. Weill, T.J. Wenaus, S. Hancke, M. Schöntag, V. Shoutko, Steven Goldfarb, D. McNally, J. Bao, R. Morand, R.B. Sutton, G. Passaleva, Manjit Kaur, F. Carbonara, Marcos Cerrada, X. Leytens, G. Viertel, K. Schultze, E. Tarkovsky, H. van der Graaf, Xd Cai, L. Martinez, H. Akbari, Howard A. Stone, F. L. Linde, S. Morganti, T.S. Dai, Ian Brock, J. Schwenke, F. DeNotaristefani, F. Tonisch, X. Y. Cui, Q. Fan, R. Dolin, Daqiang Zhang, D. Zhang, U. Uwer, D. Lanske, B. Borgia, J. Ulbricht, A. van Laak, M. Fukushima, X.R. Shi, L. Leistam, J. M. Le Goff, I. Clare, B. P. Roe, J. Busenitz, Z.F. Gong, P. Göttlicher, F. Cesaroni, J. Y. Liao, J. Schütte, M. Tonutti, M. Vollmar, S. Lanzano, F. Bruyant, L. J. Gutay, U. Becker, D. Wright, Mingshui Chen, I. Sheer, J.A. Rubio, F. J. Eppling, L. W. Jones, H. El Mamouni, V. Morgunov, D. S. Yan, S. M. Ting, A. Bujak, Oliver Kornadt, M. Pohl, P. Berges, D. Ren, B. Spiess, U. Vikas, M. Maire, L. Li, D. Duchesneau, A. Contin, Alexander Malinin, Alexander Savin, V. Lalieu, V. Koutsenko, J.F. Li, J.P. Burq, H. Suter, Y.F. Wang, Valentin V. Khoze, L. Antonov, J. Krizmanic, A. Marchionni, V.R. Krastev, E. Gonzalez, Bernardo Adeva, T. Angelov, K. Lanius, G. Hu, Carlos Willmott, Speranza Falciano, D. Antreasyan, Qi An, S. Lökös, K.S. Yang, Th. Rombach, Simonetta Gentile, Kenneth Francis Read, G. Conforto, D. Hauschildt, R. Liu, S. S. Gau, P.V.K.S. Baba, H. L. Zhuang, M. J. Glaubman, P. Arce, D. Goujon, Vincenzo Innocente, H. Anderhub, R. de Asmundis, C. Dionisi, Pablo Garcia-Abia, IHEF (IoP, FNWI), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), and L3
Subjects: Physics, Nuclear and High Energy Physics, Particle physics, 010308 nuclear & particles physics, High Energy Physics::Phenomenology, Elementary particle, 01 natural sciences, Standard Model, Nuclear physics, Particle decay, Pair production, 0103 physical sciences, Higgs boson, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], High Energy Physics::Experiment, Invariant mass, 010306 general physics, Particle Physics - Experiment, Lepton, Boson
Abstract: We have searched for the neutral Higgs boson produced in the decays of the Z 0 through the process Z 0 → H 0 l + l − in the mass range M H 0 0 → hadrons we exclude a minimal standard model Higgs boson in the mass range 0 M H 0
Published: 1990

16. Test of QED in e+e−→γγ at LEP

Author: C-Q. Li, Guofan Hu, M. Guanziroli, Sc Yeh, R. Bizzarri, S. Hancke, G. Fernandez, L. Baksay, L. Leistam, L.S. Hsu, Z. W. Yin, S. N. Ganguli, E. Shumilov, S. Röhner, M. Schöntag, W. Böhlen, F. Wittgenstein, V. Shoutko, C.Y. Chien, S. Beingessner, P. Berges, M. Maire, R. Liu, L. Ludovici, E. Drago, Yu. Galaktionov, M. Fabre, R.J. Wu, J.M. Lubbers, L. Niessen, Jozsef Toth, J. Lettry, Claudio Luci, D. Pandoulas, J. Alcaraz, Tariq Aziz, V. Shevchenko, O. Rind, J. M. Salicio, M. Bourquin, Hafeez R. Hoorani, Georgi Sultanov, Fl Linde, S. S. Gau, S. X. Wu, R. A. Khan, K. Strauch, X.R. Shi, Z.Y. Lin, B. P. Roe, P.V.K.S. Baba, H. L. Zhuang, X. Lue, T. Driever, V. P. Andreev, L. Li, G.J. Bobbink, D. Duchesneau, M. Chemarin, Alexander Malinin, Elisabetta Gallo, U. Micke, M. Harris, P.G. Seiler, J. Busenitz, G. M. Chen, F. Diez-Hedo, T. Spickermann, U. K. Chaturvedi, R. Malik, Chenliang Wang, Y. S. Lu, J.M. Qian, Y. J. Pei, D. Linnhofer, M. Tonutti, R.B. Sutton, Kajari Mazumdar, S. Khokhar, T.R. McMahon, Joachim Mnich, L. Urbàn, S. Rosier-Lees, T. Riemann, J.G. Branson, F. de Notaristefani, B. Stringfellow, Z.Z. Xu, P. Le Coultre, T. Foreman, K. Hangarter, T. Böhringer, Jérôme Rose, J.F. Li, L. J. Gutay, P. Duinker, R. Starosta, D. Luckey, Gy L. Bencze, G. Herten, Peter Denes, Reinhard W. Schulte, F. C. Erné, H. Suter, Y.F. Wang, W. Friebel, G. Faber, G. Schwering, Paolo Bagnaia, U. Becker, A. Bujak, Oliver Kornadt, M. Pohl, Bernard Ille, Crisostomo Sciacca, S. Reucroft, M. Steuer, J. H. Field, G. Trowitzsch, Marco Pieri, C. Rippich, C. Dionisi, A. Leike, G. Forconi, R. Magahiz, J. Weber, Marco Meschini, Valentin V. Khoze, M. J. Glaubman, Cheng Chen, D. Antreasyan, Pablo Garcia-Abia, L. Antonov, B. Stöhr, Qi An, S. Lökös, D.N. Mao, Xd Cai, K.S. Yang, F. J. Eppling, L. W. Jones, D. S. Yan, B. Spiess, Mingshui Chen, J. Berdugo, S. M. Ting, Alain Hervé, H. R. Gustafson, Ren-Yuan Zhu, Luciano Barone, C. Souyri, R. Leiste, J. Bao, I. Sheer, G. Landi, J. Krizmanic, A. Marchionni, C. Zaccardelli, J. D. Swain, Zhuoxiang Ren, M. Wadhwa, D. J. Schotanus, J. M. You, X. L. Wang, B. N. Jin, H. Nowak, An.A. Vorobyov, H.F. Chen, V. Lalieu, J.M. Thenard, A.M. Cartacci, H.R. Dimitrov, T. Matsuda, Th. Rombach, Simonetta Gentile, V.R. Krastev, E. Gonzalez, Kenneth Francis Read, Q.Y. Yang, N. Produit, A. Kuhn, Bernardo Adeva, V. Koutsenko, V. Morgunov, A. Bay, Carlo Civinini, H. El Mamouni, O. Adriani, M. Maolinbay, X.G. Li, M. Aguilar-Benitez, I. Duran, G.B. Mills, Samuel C.C. Ting, A. Gurtu, G. A. Yang, Dimitri Bourilkov, V. Commichau, H. J. Schreiber, M. Bocciolini, A. Hasan, G. Conforto, L. Z. Sun, T. Angelov, B. Monteleoni, Y. D. Xu, C. Spartiotis, M. Merk, Raffaello D'Alessandro, C. Grinnell, Lucas Taylor, A. A. Syed, K. Lanius, E. Jagel, Federico Carminati, B. L. Betev, J. D. Burger, G. Hu, Wolfgang Lohmann, H. Vogt, P. Arce, M. Gailloud, M. G. Alviggi, P. Vikas, R. Rosmalen, Herwig Schopper, J. Behrens, M. White, J. A. Bakken, Wolfgang Lange, G. Rahal-Callot, D. Goujon, D. Ren, P. J. Li, T. Kramer, L. Zehnder, W. Wallraff, Leonardo Merola, Steven Goldfarb, Fridolin Dittus, B. Bertucci, G. Passaleva, R. Morand, Y. H. Chang, J.P. Burq, George Alverson, Z. L. Xue, S. Patricelli, W. Kittel, Carlos Willmott, Yu. Kamyshkov, J. J. Blaising, Q. Ye, Luciano Romero, Bolek Wyslouch, Nicanor Colino, A. Böhm, T. Azemoon, Howard A. Stone, E. Dénes, R. Sehgal, T.S. Dai, Speranza Falciano, F. Tonisch, Mw Gruenewald, Q. Fan, J.B. Ye, F. Crijns, H. van der Graaf, G. Coignet, S. Banerjee, G.H. Wang, U. Vikas, G. Morand, K. Schultze, Vincenzo Innocente, Y. Mi, E. Tarkovsky, K. Sudhakar, D. Zhang, Bz Yang, A. Contin, U. Uwer, Egidio Longo, Marcos Cerrada, H. T. Li, A. Chen, J. Salicio, Zp Zhang, C. G. Yang, J.C. Sens, Sebastian Nowak, C. F. He, B. Borgia, D. Lanske, J. Ulbricht, A. van Laak, Alexander Savin, K. S. Kumar, H. Haan, G. Finocchiaro, Lamberto Luminari, Igor Vorobiev, V. Plyaskin, Giorgio Gratta, S. L. Wu, Panos A Razis, Vineet Kumar, E. Nagy, Konrad Deiters, P. Schmitz, A. Pevsner, I. Clare, S. C. Tonwar, W.G. Ma, J. Fehlmann, P. Blömeke, A. Arefiev, P. Göttlicher, W. Ruckstuhl, I. Vetlitsky, Barry Blumenfeld, M. M. Ilyas, Patricia McBride, Alexei Klimentov, Alberto Aloisio, A. Gordeev, M. Micke, D. P. Stickland, C. Camps, Valery Schegelsky, Antonino Zichichi, Aa Vorobyov, P. Lebrun, Thomas Ferguson, R.C. Ball, Adrian Biland, M. Vivargent, Christine Buisson, Pierre Lecomte, Z. M. Wang, G. Sartorelli, H. Anderhub, Y. Mir, C. H. Ye, Ph Fisher, Yanwen Liu, H. Rykaczewski, R. Fabbretti, K.D. Shmakov, S. J. Fan, K. Freudenreich, M. Schneegans, Z.Q. Yang, Y. Karyotakis, Andre Sopczak, K. N. Qureshi, Th. Meinholz, G. Sauvage, F. Marzano, W. Krenz, D. DiBitonto, A. Engler, M. MacDermott, Jean Fay, M. Capell, M. Dhina, D. Boutigny, R. Raghavan, D. Perret-Gallix, H. S. Fesefeldt, X. W. Tang, W.-D. Nowak, A. C. König, Y.P. Tong, Laurent Vuilleumier, E. Isiksal, P. A. Piroué, Harvey B Newman, I. C. Brock, M. A. Niaz, G. Mirabelli, E. Thomas, J.H. Wang, P. K. Malhotra, H. A. Rizvi, K. Hilgers, A. Kunin, K. Lübelsmeyer, Piero Spillantini, R. L. Sumner, Qiang Li, M. Hebert, J. Wenninger, M. Sachwitz, F. Ferroni, V. Pojidaev, G. Fanker, S. Schulte, R. Wilhelm, Nikita Smirnov, W. J. Metzger, Y. Zeng, Richard Mount, Zm Wang, F. Carbonara, U. Herten, C. J.W.P. Timmermans, P. Extermann, L. Martinez, R. de Asmundis, I. Leedom, H. Hofer, K. L. Tung, C. Maña, M. Lenti, A. L. Anderson, Ying Wu, J. F. Zhou, Qun Wang, F. Cesaroni, J. Y. Liao, J. Schütte, F. Bruyant, M.L. Chen, R. Dolin, M. Fukushima, Marcella Diemoz, J. M. Le Goff, P.M. Levchenko, Z.F. Gong, G. Von Dardel, D. Kirkby, J. A. Rubio, A. Degré, P. Marchesini, Ming Zeng, M. Röhner, Y.F. Mao, R. T. Van de Walle, E. Valente, R. Weill, D. McNally, X. Leytens, G. Viertel, Hans J. Vogel, S. Morganti, J. Schwenke, X. Y. Cui, J. Perrier, M. Möller, G. Chiefari, S. Shevchenko, M. Vollmar, S. Lanzano, D. Wright, J.P. Martin, T.J. Wenaus, Manjit Kaur, H. Akbari, Daqiang Zhang, G. Paternoster, D.W. Schmitz, G.G.G. Massaro, Robert Clare, Ph. Rosselet, Thomas Hebbeker, Paul Lecoq, R. W. Kraemer, M. Napolitano, and H. S. Chen
Subjects: Physics, Nuclear and High Energy Physics, Particle physics, Annihilation, 010308 nuclear & particles physics, Branching fraction, Electron–positron annihilation, Elementary particle, 7. Clean energy, 01 natural sciences, Massless particle, Nuclear physics, Particle decay, 0103 physical sciences, Center of mass, 010306 general physics, Boson
Abstract: We have measured the cross-section of the reaction e + e − → γγ at center of mass energies around the Z 0 mass. The results are in good agreement with QED predictions. For the QED cutoff parameters the limit of Λ + > 103 GeV and Λ − 118 GeV are found. For the decays Z 0 → γ ,Z 0 → π 0 γ , Z 0 → γγγ we find upper limits of 2.9 × 10 −4 ,2.9×10 −4 ,4.1×10 −4 and 1.2×10 −4 , respectively. All limits are at 95% CL.
Published: 1990

17. Search for the neutral Higgs bosons of the minimal supersymmetric standard model from Z0 decays

Author: P. Blömeke, J.Y. Liao, R.A. Khan, P. Vikas, R.J. Wu, Raffaello D'Alessandro, X. Lue, C. Grinnell, A. Gordeev, D. Lanske, Leonardo Merola, L. Antonov, Z.M. Wang, J.M. Lubbers, Y. S. Lu, Ph Fisher, H. Rykaczewski, K. Sudhakar, J. M. Salicio, C.H. Ye, R. Starosta, D. Pandoulas, Q. Z. Li, Y. Karyotakis, R. Morand, D. Perret-Gallix, B. P. Roe, K.S. Yang, D. Linnhofer, T. Azemoon, Y.P. Tong, F. Cesaroni, S. Schulte, V. Kumar, J. Krizmanic, A. Marchionni, R. Wilhelm, J. H. Field, L. J. Gutay, U. Uwer, R. Mount, U. Becker, Q. An, E. Tarkovsky, J.A. Rubio, M. Dhina, M. Micke, T. Hebbeker, M. Möller, R. Leiste, J. Schütte, E. Thomas, T.J. Wenaus, X.G. Li, P. Levchenko, V.R. Krastev, E. Gonzalez, W. Böhlen, M.L. Chen, A. Bujak, M. Pohl, R. Malik, M. Zeng, H. Akbari, M. Sachwitz, F. J. Eppling, L. W. Jones, Marcella Diemoz, G. Von Dardel, A. Degré, J.C. Sens, T. Böhringer, R. Raghavan, R. T. Van de Walle, I. Scott, S. M. Ting, J.M. You, U. Micke, B. Wysłlouch, Yu. Kamyshkov, C.F. He, C.R. Wang, Y.F. Mao, Z.W. Yin, V. Shoutko, S. Lanzano, Bernardo Adeva, J. Tòth, E. Valente, D. Ren, V. Lalieu, F. Bruyant, D. McNally, G. Paternoster, J. Rose, S. Shevchenko, A. C. König, Laurent Vuilleumier, E. Isiksal, G. Viertel, T. Angelov, C. Maña, Qian Wang, J. Lettry, Claudio Luci, S. Hancke, S. Morganti, L. Romero, P. Marchesini, X. Y. Cui, V. Khoze, Robert Clare, G. Herten, L. Urbàn, B. Monteleoni, F. Wittgenstein, R. Dolin, Lamberto Luminari, Elisabetta Gallo, Y.G. Wu, G. Faber, Mw Gruenewald, Ren-Yuan Zhu, Luciano Barone, R. L. Sumner, K. Lanius, G. H. Wang, Paul Lecoq, R. W. Kraemer, B. Stöhr, J. Salicio, M. Napolitano, L. Li, W. Ruckstuhl, W. Kittel, L. Baksay, D. Duchesneau, Y. H. Chang, M. Fukushima, P. Göttlicher, V. Plyaskin, P. Garcia-Abia, E. Jagel, C. Zaccardelli, J. Fehlmann, C. Camps, U.K. Chaturvedi, D. P. Stickland, A. Pevsner, L. Ludovici, J. Wenninger, George Alverson, C. G. Yang, Z.Q. Yang, F.C. Erné, A. Gurtu, Egidio Longo, H. Anderhub, D. J. Schotanus, Barry Blumenfeld, G. Gratta, H. S. Chen, S.X. Wu, Y. Mir, S. Rosier-Lees, A.M. Cartacci, Mingshui Chen, J.F. Li, J. M. Le Goff, K. Shmakov, Z.F. Gong, Yu. Galaktionov, D.N. Mao, H.R. Dimitrov, P. Le Coultre, S. Reucroft, E. Drago, C.Y. Chien, Konrad Deiters, J. Alcaraz, P. K. Malhotra, H. A. Rizvi, A. Zichichi, Y. Zeng, K. S. Kumar, Zm Wang, Speranza Falciano, Pierre Lecomte, M. Röhner, M. Maire, E. Nagy, N. Produit, H. van der Graaf, M. Schöntag, J. A. Bakken, H. Suter, Y.F. Wang, Federico Carminati, J. D. Burger, K. N. Qureshi, W. Krenz, G. Rahal-Callot, C. Li, I. Vorobiev, G. Trowitzsch, D.S. Yan, M. Bocciolini, H. Fenker, Alberto Aloisio, Sau Lan Wu, A. Hasan, M. Cerrada, K. Hilgers, M. Chemarin, Charles Timmermans, M. M. Ilyas, J. Ulbricht, C. Spartiotis, M.C. Chen, Helmut Vogel, O. Kornadt, T. Driever, R. Schulte, J. G. Branson, Y. Liu, L. Niessen, Y. D. Xu, Samuel C.C. Ting, A. Savin, D. Wright, R. Fabbretti, M. Tonutti, W. Wallraff, D. Boutigny, U. Roeser, M. Gailloud, H.F. Chen, R. Liu, J. Behrens, S. Patricelli, G. Sartorelli, W. J. Metzger, G.G.G. Massaro, F. Carbonara, D. Luckey, Gy L. Bencze, R. Rosmalen, R. Bizzarri, A. A. Syed, Ian Brock, F. DeNotaristefani, Sc Yeh, A. Klimentov, Kajari Mazumdar, L. Martinez, A. Kuhn, S. Khokhar, S. N. Ganguli, J. Schwenke, F. Tonisch, Fridolin Dittus, M. MacDermott, B.C. Stringfellow, J.M. Qian, Q. Ye, V. Schegelsky, K. Freudenreich, Jj Blaising, T. Kramer, V. Pojidaev, Th. Meinholz, S.S. Gau, P.V.K.S. Baba, H. Fesefeldt, Howard A. Stone, Steven Goldfarb, L. Leistam, A. Malinin, T.S. Dai, G. Morand, Q. Fan, R.B. Sutton, G. Passaleva, H. El Mamouni, R. de Asmundis, Dimitri Bourilkov, P.J. Li, F. L. Linde, H. Vogt, G. Hu, V. Commichau, U. Vikas, M. Bourquin, E. Dénes, K. Strauch, X. W. Tang, Xd Cai, I. Sheer, A. Contin, W. Friebel, J.P. Burq, M. A. Niaz, G.Q. Hu, H. R. Gustafson, B. Spiess, M. Harris, F. Crijns, J.F. Zhou, D. Schmitz, Jian Wang, P. A. Piroué, A. Sopczak, J. Berdugo, H. L. Zhuang, A. Kunin, X.L. Wang, G. Finocchiaro, P. Extermann, K. Lübelsmeyer, Z.Z. Xu, D.H. Zhang, P. Berges, M. Madhwa, B. Borgia, A. van Laak, B. Ille, A. Böhm, I. Leedom, C. Dionisi, V. Koutsenko, G. Sauvage, H. Hofer, K. L. Tung, An.A. Vorobyov, T. Matsuda, Marcel Merk, D. Antreasyan, M. Guanziroli, G. Mirabelli, G. Yang, B.Z. Yang, Mariagrazia Alviggi, H.T. Li, C. Willmott, M. J. Glaubman, G. Schwering, S. Röhner, S. Lökös, C. Buisson, U. Herten, Alain Hervé, I. Vetlitsky, J. Perrier, G. Coignet, O. Adriani, Lucas Taylor, K. Hangarter, S.J. Fan, P. Duinker, Y.J. Pei, Th. Rombach, J. Fay, X.R. Shi, Z.L. Xue, B. N. Jin, I. Clare, J. Busenitz, Piero Spillantini, R. Weill, A. Bay, Simonetta Gentile, Q.Y. Yang, M. Schneegans, V. Morgunov, A. Arefiev, Harvey B Newman, Z.Y. Lin, P. Arce, R.C. Ball, D. Goujon, Adrian Biland, D. DiBitonto, Kenneth Francis Read, Carlo Civinini, J. Bao, W. Lohmann, Ph. Rosselet, T. Spickermann, Vincenzo Innocente, G. Fernandez, M. Lenti, M. Maolinbay, G. Conforto, L. Z. Sun, M. Steuer, G. Forconi, M. Kaur, J. Weber, A. L. Anderson, X. Leytens, H. Haan, I. Duran, M. Aguilar-Benitez, M. Vollmar, Herwig Schopper, P. Lebrun, G.B. Mills, A. Engler, J. Mnich, P. Schmitz, Aa Vorobyov, M. Capell, M. White, T. McMahon, L. Zehnder, O. Rind, J.B. Ye, S. Banerjee, J.P. Martin, M. Hebert, Panos A Razis, R. Sehgal, A. Chen, F. Ferroni, S. Beingessner, N. Smirnov, F. Marzano, Zp Zhang, Tariq Aziz, G. Chiefari, E. Shumilov, H.J. Schreiber, Hafeez R. Hoorani, K. Schultze, M. Fabre, R. Magahiz, W.G. Ma, M. Vivargent, Crisostomo Sciacca, J. D. Swain, Marco Pieri, Georgi Sultanov, C. Rippich, P. McBride, V. P. Andreev, G.J. Bobbink, B.L. Betev, G. M. Chen, P.G. Seiler, F. Diez-Hedo, Peter Denes, Paolo Bagnaia, L.S. Hsu, Marco Meschini, D. Kirkby, V. Shevchenko, T. Foreman, C. Chen, B. Bertucci, D. Zhang, Nicanor Colino, Y. Mi, S. C. Tonwar, Thomas Ferguson, G. Landi, and IHEF (IoP, FNWI)
Subjects: Quark, Physics, Nuclear and High Energy Physics, Particle physics, High Energy Physics::Lattice, Electron–positron annihilation, High Energy Physics::Phenomenology, Elementary particle, Supersymmetry, Nuclear physics, Higgs boson, High Energy Physics::Experiment, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment, Lepton, Minimal Supersymmetric Standard Model, Boson
Abstract: We present the results from a search for the light neutral scalar Higgs boson h° and the pseudoscalar Higgs boson A° of the minimal super-symmetric standard model. The analysis is based on a data sample corresponding to 71 000 hadronic Z° decays recorded with the L3 detector at LEP. No evidence for the existence of the neutral Higgs bosons h° and A° has been found. The region of h° and A° masses up to 41.5 GeV is excluded at 95% confidence level.
Published: 1990

18. Measurement of g$_A$ and g$_V$ the neutral current coupling constants to leptons

Author: R. Weill, L. Baksay, Y. Mi, R. Liu, Boleslaw Wyslouch, C.Y. Chien, E. Valente, K. Luebelsmeyer, A. Boehm, U. Micke, S. S. Gau, P.V.K.S. Baba, S. C. Tonwar, R. Mount, G. Viertel, P. J. Li, M. Guanziroli, A. L. Anderson, A. Arefev, E. Shumilov, J. Zoll, V. Shoutko, Thomas Ferguson, S. Morganti, Fridolin Dittus, John Krizmanic, Tariq Aziz, M. Tonutti, L.S. Hsu, Federico Carminati, Yu. Galaktionov, M. Vollmar, R. Leiste, J. Schwenke, X. Y. Cui, E. Dénes, G. Herten, Ying Wu, J. F. Zhou, P. Marchesini, J. Berdugo, J. Alcaraz, S.Y. Zhang, Ming Zeng, Jj Blaising, T. Kramer, T. Angelov, W. Friebel, G. Faber, Corinne Goy, D. Kaplan, U. Uwer, Y.F. Mao, A. Chen, R. T. Van de Walle, C-Q. Li, J. Salicio, G. Hu, P. Schmitz, Y. Peng, H. Haan, D. Harting, S. Patricelli, Cheng Chen, F.G. Hartjes, A. Kuhn, M. Roehner, F. de Notaristefani, D. Guesewell, X. L. Wang, S. Schulte, J. Busenitz, E. Nagy, C. Pols, L. Urbàn, Yu. Kamyshkov, Alexei Klimentov, M. Fabre, Carlos Willmott, Q. Ye, Jozsef Toth, Mw Gruenewald, Egidio Longo, I. Vetlitsky, S. Beingessner, W. Ruckstuhl, C. Camps, J. A. Bakken, Speranza Falciano, P. Bloemeke, D. P. Stickland, J. Lettry, Claudio Luci, Z. M. Wang, W. Boehlen, P. Schmitt, Crisostomo Sciacca, Dimitri Bourilkov, Zhuoxiang Ren, Marco Pieri, D. J. Schotanus, H. T. Li, C. Rippich, K. Freudenreich, R. Morand, Z. L. Xue, F. Cesaroni, X. Lue, U. K. Chaturvedi, Y. Mir, C. H. Ye, J. Onvlee, R.C. Ball, Adrian Biland, C. G. Yang, Elisabetta Gallo, J.M. Thenard, A.M. Cartacci, H.R. Dimitrov, Zhen Zhang, C. Dionisi, J. M. You, M.L. Chen, U. Becker, M. Gettner, J. Mnich, Alain Hervé, Raffaello D'Alessandro, C. Grinnell, K.D. Shmakov, S. J. Fan, N. Produit, Qi An, Y. S. Lu, Howard A. Stone, J. Y. Liao, T.S. Dai, J. D. Burger, G. Rahal-Callot, Leonardo Merola, W. Walk, G. Mirabelli, B. P. Roe, Chenliang Wang, Sandra Consuegra Rodríguez, Wen-Gan Ma, R. Bizzarri, S. Hancke, Ian Brock, M. M. Ilyas, A. Bay, D. Campana, a C. Koenig, A. Engler, Konrad Deiters, K.S. Yang, Th. Rombach, T. Azemoon, G. A. Yang, D.N. Mao, Simonetta Gentile, M. Capell, C. Souyri, B. Monteleoni, F. J. Eppling, L. W. Jones, C. Maña, V. Plyaskin, Marcella Diemoz, Piero Spillantini, D. S. Yan, W. Kittel, G. Von Dardel, Alberto Aloisio, A. Grimes, S. M. Ting, Carlo Civinini, J.M. Qian, M. Maolinbay, B. Stoehr, H. S. Fesefeldt, Jérôme Rose, R. A. Khan, G. Sauvage, Marcos Cerrada, K. Schultze, E. Tarkovsky, R. Wilhelm, Philip Kaaret, B. Borgia, F. Marzano, Kenneth Francis Read, G. Coignet, W. Krenz, P. Duinker, R. Fabbretti, X.G. Li, L. Leistam, S. Reucroft, D. Lanske, Th. Meinholz, M. Aguilar-Benitez, I. Duran, P. F. Klok, Sc Yeh, G. Fernandez, D. Pandoulas, G. Conforto, Oliver Kornadt, M. Pohl, Herwig Schopper, D. Antreasyan, H. Fenker, W. Wallraff, B. Auroy, Guofan Hu, H. F. Chen, Vincenzo Innocente, X. W. Tang, M. White, I. Sheer, P. A. Piroué, M. Gailloud, J. Bao, T. Spickermann, S. Kwan, M. MacDermott, V. P. Andreev, Harvey B Newman, C. Jakobs, F. Wittgenstein, M. Bourquin, K. Strauch, F. Bruyant, K. Hilgers, A. Heavey, G. Landi, J. G. Branson, Bernard Ille, X.R. Shi, L. Ludovici, E. Drago, L. Niessen, Sau Lan Wu, F. Ferroni, R. Magahiz, B. N. Jin, I. Clare, G.J. Bobbink, Steven Goldfarb, Y. Zeng, T. Driever, Z. W. Yin, M. Chemarin, M. Vivargent, M. Sachwitz, An.A. Vorobyov, T. Matsuda, R L. Sumner, S. N. Ganguli, P. Berges, A. Degré, M. Maire, J. D. Swain, Giovanni Paternoster, Ren-Yuan Zhu, Luciano Barone, M. Harris, R.B. Sutton, P. Vikas, P. McBride, D.H. Zhang, O. Adriani, G. Chiefari, U. Herten, L. Zehnder, M. Schneegans, P. Extermann, G. M. Chen, M. G. Alviggi, I. Leedom, B. Z. Yang, H. Hofer, L. Antonov, J. H. Field, S. Shevchenko, K. L. Tung, Yueh-Feng Liu, S. Banerjee, P. Goettlicher, F.C. Erné, Q.Y. Yang, K. Sudhakar, A. Gurtu, Helmut Vogel, B. Spiess, Lamberto Luminari, M. Schoentag, V. Lalieu, P. Lebrun, A. A. Syed, K. Lanius, J. Fehlmann, A. Marchionni, T. Riemann, V. Commichau, H. J. Schreiber, Pierre Lecomte, V. Koutsenko, M. Bocciolini, Charles Timmermans, V.R. Krastev, E. Jagel, P. Le Coultre, E. Gonzalez, F. Crijns, K. Hangarter, S. X. Wu, Y. H. Chang, J.P. Burq, George Alverson, Bernardo Adeva, R. Starosta, D. Luckey, Gy L. Bencze, Vineet Kumar, W.-D. Nowak, L. Li, Ph. Rosselet, D. Boutigny, Kajari Mazumdar, Reinhard W. Schulte, G. Schwering, Alexander Malinin, Marcel Merk, M. Steuer, X. D. Cai, G. Forconi, J.F. Li, L. Montanet, J. Schuette, J. Perrier, R.J. Wu, K N. Qureshi, J. Weber, H. Suter, Y.F. Wang, E. Perrin, B. L. Betev, D. Perret-Gallix, Valentin V. Khoze, G.B. Mills, G. Morand, J.C. Sens, R. Dolin, R. Raghavan, Y.P. Tong, Laurent Vuilleumier, E. Isiksal, M. Fukushima, G. H. Wang, S C C. Ting, J. Wenninger, V. Pojidaev, Nikita Smirnov, J. M. Le Goff, Z.F. Gong, J. A. Rubio, H. Anderhub, T.J. Wenaus, H. Akbari, T. Boehringer, M. J. Glaubman, Y. Karyotakis, C. Zabounidis, D. Goujon, D.W. Schmitz, Robert Clare, Thomas Hebbeker, Paul Lecoq, R. W. Kraemer, A. Sopczak, X. Leytens, M. Napolitano, H. S. Chen, S. Lanzano, D. Wright, J.P. Martin, Igor Vorobiev, M. Hebert, Panos A Razis, A. Gordeev, M. Micke, Z.Q. Yang, Mingshui Chen, V. Morgunov, D. Ren, A. Contin, Alexander Savin, Luciano Romero, Qian Wang, V. Shevchenko, C. F. He, P.G. Seiler, Giorgio Gratta, A. Pevsner, Peter Denes, Barry Blumenfeld, Paolo Bagnaia, Marco Meschini, E. Thomas, J.H. Wang, D. Kirkby, Zhongyukun Xu, A. Kunin, H. van der Graaf, T. Foreman, Y.J. Pei, Wolfgang Lohmann, H. Vogt, B. Bertucci, D. Zhang, J. Ulbricht, W. J. Metzger, Nicanor Colino, G.G.G. Massaro, F. Carbonara, L. Martinez, F. L. Linde, Valery Schegelsky, Antonino Zichichi, J.M. Lubbers, H. Rykaczewski, D. Linnhoefer, S. Rosier-Lees, S. Loekoes, Jean Fay, M. Dhina, Z. Y. Lin, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), L3, and IHEF (IoP, FNWI)
Subjects: Coupling constant, Physics, Nuclear and High Energy Physics, Neutral current, 010308 nuclear & particles physics, media_common.quotation_subject, Electron–positron annihilation, Analytical chemistry, Elementary particle, 01 natural sciences, Asymmetry, Nuclear physics, Particle scattering, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], 010306 general physics, Pseudovector, Particle Physics - Experiment, media_common, Lepton
Abstract: We have measured both the rates and the forward-backward asymmetry of l+l− from Z0→l+l− (where l=μ, τ) with the L3 detector. We obtained Γll=88±4±3 MeV and the vector neutral current coupling constant, gv=0.00±0.07 and the axial vector neutral current coupling constant, gA=−0.515±0.015.
Published: 1990

19. Mass limits for excited electrons and muons from Z0 decay

Author: C.R. Wang, M. Fabre, L. Antonov, Georgi Sultanov, R. A. Khan, S. Schulte, T. Driever, A. Arefiev, J. Krizmanic, A. Marchionni, V. P. Andreev, R. W. Kraemer, V.R. Krastev, W. Ruckstuhl, D. P. Stickland, Aa Vorobyov, Y. Mir, C. H. Ye, E. Gonzalez, M. Chemarin, P. Marchesini, F. Marzano, S. Lanzano, Bernardo Adeva, W. Krenz, J.M. Thenard, A.M. Cartacci, H.R. Dimitrov, P.H. Fisher, M. J. Glaubman, M. Möller, G. Landi, H. El Mamouni, C. Zabounidis, G. Rahal-Callot, R.J. Wu, A. Sopczak, P. Vikas, S. X. Wu, C-Q. Li, P. Arce, D. Goujon, J.M. Lubbers, D. Pandoulas, T. McMahon, R. Bizzarri, S. Hancke, Ian Brock, F. DeNotaristefani, L. Leistam, M. Gruenewald, K. Schultze, S. Khokar, R. Rosmalen, P. Berges, E. G. Thomas, M. Maire, Ming Zeng, Vincenzo Innocente, E. Tarkovsky, D. Lanske, T. Spickermann, S. Kwan, K. Sudhakar, Ph. Rosselet, M. Steuer, G. Forconi, J. Weber, E. Perrin, T.J. Wenaus, L. Li, Hafeez R. Hoorani, Qi An, S. Lökös, Raffaello D'Alessandro, C. Grinnell, Sc Yeh, G. Fernandez, L. Urbàn, J.F. Li, Tariq Aziz, H. Suter, Y.F. Wang, C. Dionisi, Pablo Garcia-Abia, Alain Hervé, V. Plyaskin, H. Anderhub, K.S. Yang, Th. Rombach, S. Rosier-Lees, T. Riemann, M. Röhner, L.S. Hsu, G.B. Mills, Y. Mi, Valentin V. Khoze, Bernard Ille, A. C. König, Samuel C.C. Ting, H. Akbari, P. Le Coultre, T. Kramer, J. J. Blaising, J.C. Sens, D.N. Mao, Jozsef Toth, Steven Goldfarb, J. Lettry, Claudio Luci, X.L. Wang, M. Bourquin, C. Souyri, R. Magahiz, X. Lue, U. K. Chaturvedi, Y. S. Lu, Sebastian Nowak, B. Borgia, Leonardo Merola, W. Walk, K. Hangarter, R.B. Sutton, A. Bay, R. Starosta, Simonetta Gentile, Y.F. Mao, Elisabetta Gallo, K. Strauch, M. Gailloud, D. Luckey, Gy L. Bencze, F. Cesaroni, J. D. Swain, H. Haan, A. van Laak, K. N. Qureshi, G. Chiefari, S. Shevchenko, Carlo Civinini, M. Maolinbay, H.F. Chen, Reinhard W. Schulte, Jérôme Rose, Federico Carminati, J. Y. Liao, R. de Asmundis, Suresh C Tonwar, Luciano Romero, Qian Wang, P. McBride, T. Azemoon, G. Trowitzsch, Lawrence W. Jones, X.G. Li, W.-D. Nowak, C. Timmermans, G. Schwering, M. Aguilar-Benitez, I. Duran, Herwig Schopper, M. White, S. Reucroft, A. Leike, H. Fenker, Kenneth Francis Read, I. Vetlitsky, R.C. Ball, Adrian Biland, G. Herten, G. Conforto, C. F. He, X.R. Shi, I. Clare, J. Schütte, L. Montanet, K.D. Shmakov, S. J. Fan, W. Friebel, G. Faber, A. Bujak, D.W. Schmitz, G.G.G. Massaro, Oliver Kornadt, Marcos Cerrada, M. Pohl, W. Wallraff, P. Göttlicher, E. Valente, Crisostomo Sciacca, Marco Pieri, C. Rippich, Ren-Yuan Zhu, Guofan Hu, Corinne Goy, Dimitri Bourilkov, E. Dénes, B. P. Roe, Robert Clare, A. Pevsner, A. Böhm, Luciano Barone, D. McNally, Thomas Ferguson, D.J. Schotanus, G. Coignet, A. Engler, Barry Blumenfeld, Jd Burger, R. Malik, M. Capell, R. Liu, B. N. Jin, J. A. Bakken, H. Nowak, Valery Schegelsky, Antonino Zichichi, D. Perret-Gallix, H. S. Fesefeldt, Q.Y. Yang, Thomas Hebbeker, Paul Lecoq, X. Leytens, M. Napolitano, Laszlo Gutay, J. G. Branson, S. Beingessner, G. Viertel, H. Rykaczewski, B. L. Betev, R. Leiste, S. S. Gau, P.V.K.S. Baba, S. Patricelli, F. Bruyant, V. Morgunov, Q. Ye, A. Gurtu, Lamberto Luminari, J. Mnich, Y. Karyotakis, S. Morganti, W.G. Ma, Z. W. Yin, S. N. Ganguli, V. Commichau, H. J. Schreiber, H. S. Chen, J. Schwenke, J. Fehlmann, X. Y. Cui, L. Zehnder, D. Kaplan, G. Sauvage, A. Degré, T. Foreman, P. Duinker, G. Morand, Jean Fay, S. Banerjee, Giovanni Paternoster, M. Dhina, D. Boutigny, M. Bocciolini, E. Nagy, M. Vivargent, B.Z. Yang, Christine Buisson, C. Spartiotis, J. Bao, Pierre Lecomte, G. Sartorelli, F. Crijns, Zhuoxiang Ren, A. Hasan, Harvey B Newman, R. Raghavan, M.L. Chen, Z. M. Wang, Konrad Deiters, R. Dolin, M. Gettner, J.H. Wang, J. M. You, Alberto Aloisio, A. Ricker, Y.P. Tong, P. K. Malhotra, H. A. Rizvi, N. Produit, K. Hilgers, Laurent Vuilleumier, A. Heavey, Qiang Li, L. Baksay, A. Malinin, A. Grimes, A. Kunin, H. van der Graaf, C. Maña, Marcella Diemoz, T. Angelov, E. Isiksal, P.G. Seiler, R. Morand, Z. L. Xue, M. Vollmar, B. Spiess, Petr Levchenko, F. Diez-Hedo, M. Sachwitz, S. Röhner, F. Wittgenstein, J. Behrens, P. J. Li, Th. Meinholz, G. Von Dardel, G. A. Yang, K. Lanius, V.G. Shevchenko, G. Gratta, W. Kittel, Howard A. Stone, T.S. Dai, D. Wright, C.Y. Chien, U. Herten, D. Antreasyan, Peter Denes, X. W. Tang, I. Sheer, P. Lebrun, F. Tonisch, P. A. Piroué, R. Wilhelm, Fridolin Dittus, T. Böhringer, A. A. Syed, S. Linnhofer, G. Mirabelli, G. Hu, Q. Fan, R. L. Sumner, Wolfgang Lange, G. H. Wang, V. Lalieu, L. Ludovici, E. Drago, F. Carbonara, Paolo Bagnaia, B.C. Stringfellow, S.Y. Zhang, U. Becker, J. Wenninger, K. Lübelsmeyer, Piero Spillantini, L. Niessen, Sau Lan Wu, Z.Y. Lin, L. Martinez, Marco Meschini, D. Kirkby, V. Pojidaev, F. L. Linde, A. Kuhn, M. Harris, M. Fukushima, Y.J. Pei, Wolfgang Lohmann, H. Vogt, B. Bertucci, D. Zhang, J. Ulbricht, Nicanor Colino, Nikita Smirnov, Zm Wang, F. J. Eppling, D. S. Yan, V. Koutsenko, D. H. Zhang, G. Finocchiaro, U. Uwer, A. Chen, J. Salicio, Carlos Willmott, J. Perrier, S. M. Ting, Speranza Falciano, J.P. Burq, E. Jagel, H. T. Li, Yanwen Liu, Egidio Longo, M. Merk, G. J. Bobbink, J. M. Le Goff, M. M. Ilyas, B. Wyso̵uch, F. Ferroni, Y. Zeng, Z.F. Gong, R. Fabbretti, J. A. Rubio, P. Schmitz, Alexei Klimentov, C. Camps, K. Freudenreich, R. Weill, W. J. Metzger, J. M. Salicio, Yu. Galaktionov, U. Micke, J. Alcaraz, Cheng Chen, R. Mount, B. Stöhr, C. Zaccardelli, Helmut Vogel, J. Berdugo, Y. H. Chang, George Alverson, B. Monteleoni, R. T. Van de Walle, Vineet Kumar, A. L. Anderson, Kajari Mazumdar, Ying Wu, J. F. Zhou, M. Schneegans, M. MacDermott, Mingshui Chen, M. A. Niaz, Xd Cai, P. Extermann, I. Leedom, H. Hofer, K. L. Tung, Z.Z. Xu, D. Ren, U. Vikas, A. Contin, Alexander Savin, M. Guanziroli, J. P. Martin, E. Shumilov, J. Zoll, J. H. Field, M. Schöntag, W. Böhlen, V. Shoutko, J.M. Qian, Philip Kaaret, M. Tonutti, An.A. Vorobyov, Igor Vorobiev, T. Matsuda, M. Hebert, O. Adriani, M. G. Alviggi, Zhiqing Zhang, F. C. Erné, Yu. Kamyshkov, C. G. Yang, K. S. Kumar, Panos A Razis, P. Blömeke, A. Gordeev, M. Micke, Z.Q. Yang, IHEF (IoP, FNWI), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), and L3
Subjects: Physics, Nuclear and High Energy Physics, Particle physics, Muon, 010308 nuclear & particles physics, Electron–positron annihilation, Detector, 01 natural sciences, Nuclear physics, Excited state, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Limit (mathematics), 010306 general physics, Particle Physics - Experiment
Abstract: We searched for excited electrons and muons from Z 0 decay in the channels ee→eeγ, ee→eeγγ, ee→(e)eγ, ee→μμγ, ee→μμγγ. using the L3 detector at LEP. The lower mass limit for e ∗ is 45.0 GeV and for μ ∗ 45.3 GeV. The upper limits of ll ∗ Z 0 and ll ∗ γ couplings at 95% CL have been determined up to m l∗ close to the Z 0 mass.
Published: 1990

20. A test of QCD based on 4-jet events from Z$^0$ decays

Author: B. Adeva, O. Adriani, M. Aguilar-Benitez, H. Akbari, J. Alcaraz, A. Aloisio, G. Alverson, M.G. Alviggi, Q. An, H. Anderhub, A.L. Anderson, V.P. Andreev, T. Angelov, L. Antonov, D. Antreasyan, P. Arce, A. Arefiev, T. Azemoon, T. Aziz, P.V.K.S. Baba, P. Bagnaia, J.A. Bakken, L. Baksay, R.C. Ball, S. Banerjee, J. Bao, L. Barone, A. Bay, U. Becker, J. Behrens, S. Beingessner, Gy.L. Bencze, J. Berdugo, P. Berges, B. Bertucci, B.L. Betev, A. Biland, R. Bizzarri, J.J. Blaising, P. Blömeke, B. Blumenfeld, G.J. Bobbink, M. Bocciolini, W. Böhlen, A. Böhm, T. Böhringer, B. Borgia, D. Bourilkov, M. Bourquin, D. Boutigny, J.G. Branson, I.C. Brock, F. Bruyant, C. Buisson, A. Bujak, J.D. Burger, J.P. Burg, J. Busenitz, X.D. Cai, C. Camps, M. Capell, F. Carbonara, F. Carminati, A.M. Cartacci, M. Cerrada, F. Cesaroni, Y.H. Chang, U.K. Chaturvedi, M. Chemarin, A. Chen, C. Chen, G.M. Chen, H.F. Chen, H.S. Chen, M. Chen, M.L. Chen, G. Chiefari, C.Y. Chien, C. Civinini, I. Clare, R. Clare, G. Coignet, N. Colino, V. Commichau, G. Conforto, A. Contin, F. Crijns, X.Y. Cui, T.S. Dai, R. D'Alessandro, R. de Asmundis, A. Degré, K. Deiters, E. Dénes, P. Denes, F. DeNotaristefani, M. Dhina, D. DiBitonto, M. Diemoz, F. Diez-Hedo, H.R. Dimitrov, C. Dionisi, F. Dittus, R. Dolin, E. Drago, T. Driever, D. Duchesneau, P. Duinker, I. Duran, H. El Mamouni, A. Engler, F.J. Eppling, F.C. Erné, P. Extermann, R. Fabbretti, G. Faber, S. Falciano, Q. Fan, S.J. Fan, M. Fabre, J. Fay, J. Fehlmann, H. Fenker, T. Ferguson, G. Fernandez, F. Ferroni, H. Fesefeldt, J. Field, G. Finocchiaro, P.H. Fisher, G. Forconi, T. Foreman, K. Freudenreich, W. Friebel, M. Fukushima, M. Gailloud, Yu. Galaktionov, E. Gallo, S.N. Ganguli, P. Garcia-Abia, S.S. Gau, S. Gentile, M. Gettner, M. Glaubman, S. Goldfarb, Z.F. Gong, E. Gonzalez, A. Gordeev, P. Göttlicher, D. Goujon, C. Goy, G. Gratta, A. Grimes, C. Grinnell, M. Gruenewald, M. Guanziroli, A. Gurtu, L.J. Gutay, H. Haan, S. Hancke, K. Hangarter, M. Harris, A. Hasan, C.F. He, A. Heavey, T. Hebbeker, M. Hebert, G. Herten, U. Herten, A. Hervé, K. Hilgers, H. Hofer, H. Hoorani, L.S. Hsu, G. Hu, G.Q. Hu, B. Ille, M.M. Ilyas, V. Innocente, E. Isiksal, E. Jagel, B.N. Jin, L.W. Jones, P. Kaaret, R.A. Khan, Yu. Kamyshkov, D. Kaplan, Y. Karyotakis, M. Kaur, S. Khokhar, V. Khoze, D. Kirkby, W. Kittel, A. Klimentov, A.C. König, O. Kornadt, V. Koutsenko, R.W. Kraemer, T. Kramer, V.R. Krastev, W. Krenz, J. Krizmanic, A. Kuhn, K.S. Kumar, V. Kumar, A. Kunin, S. Kwan, A. van Laak, V. Lalieu, G. Landi, K. Lanius, W. Lange, D. Lanske, S. Lanzano, P. Lebrun, P. Lecomte, P. Lecoq, P. Le Coultre, I. Leedom, J.M. Le Goff, A. Leike, L. Leistam, R. Leiste, J. Lettry, P.M. Levchenko, X. Leytens, C. Li, H.T. Li, J.F. Li, L. Li, P.J. Li, Q. Li, X.G. Li, J.Y. Liao, Z.Y. Lin, F.L. Linde, D. Linnhofer, R. Liu, Y. Liu, W. Lohmann, S. Lökös, E. Longo, Y.S. Lu, J.M. Lubbers, K. Lübelsmeyer, C. Luci, D. Luckey, L. Ludovici, X. Lue, L. Luminari, W.G. Ma, M. MacDermott, R. Magahiz, M. Maire, P.K. Malhotra, R. Malik, A. Malinin, C. Maña, D.N. Mao, Y.F. Mao, M. Maolinbay, P. Marchesini, A. Marchionni, J.P. Martin, L. Martinez, F. Marzano, G.G.G. Massaro, T. Matsuda, K. Mazumdar, P. McBride, T. McMahon, D. McNally, Th. Meinholz, M. Merk, L. Merola, M. Meschini, W.J. Metzger, Y. Mi, M. Micke, U. Micke, G.B. Mills, Y. Mir, G. Mirabelli, J. Mnich, M. Möller, L. Montanet, B. Monteleoni, G. Morand, R. Morand, S. Morganti, V. Morgunov, R. Mount, E. Nagy, M. Napolitano, H. Newman, M.A. Niaz, L. Niessen, W.D. Nowak, H. Nowak, S. Nowak, D. Pandoulas, G. Paternoster, S. Patricelli, Y.J. Pei, D. Perret-Gallix, J. Perrier, A. Pevsner, M. Pieri, P.A. Piroué, V. Plyaskin, M. Pohl, V. Pojidaev, N. Produit, J.M. Qian, K.N. Qureshi, R. Raghavan, G. Rahal-Callot, P. Razis, K. Read, D. Ren, Z. Ren, S. Reucroft, A. Ricker, T. Riemann, C. Rippich, H.A. Rizvi, B.P. Roe, M. Röhner, S. Röhner, Th. Rombach, L. Romero, J. Rose, S. Rosier-Lees, R. Rosmalen, Ph. Rosselet, J.A. Rubio, W. Ruckstuhl, H. Rykaczewski, M. Sachwitz, J. Salicio, J.M. Salicio, G. Sartorelli, G. Sauvage, A. Savin, V. Schegelsky, D. Schmitz, P. Schmitz, M. Schneegans, M. Schöntag, H. Schopper, D.J. Schotanus, H.J. Schreiber, R. Schulte, S. Schulte, K. Schultze, J. Schütte, J. Schwenke, G. Schwering, C. Sciacca, R. Sehgal, P.G. Seiler, J.C. Sens, I. Sheer, V. Shevchenko, S. Shevchenko, X.R. Shi, K. Shmakov, V. Shoutko, E. Shumilov, N. Smirnov, A. Sopczak, C. Souyri, C. Spartiotis, T. Spickermann, B. Spiess, P. Spillantini, R. Starosta, M. Steuer, D.P. Stickland, B. Stöhr, H. Stone, K. Strauch, B.C. Stringfellow, K. Sudhakar, G. Sultanov, R.L. Sumner, H. Suter, R.B. Sutton, J.D. Swain, A.A. Syed, X.W. Tang, E. Tarkovsky, J.M. Thenard, E. Thomas, C. Timmermans, Samuel C.C. Ting, S.M. Ting, Y.P. Tong, F. Tonisch, M. Tonutti, S.C. Tonwar, J. Tòth, G. Trowitzsch, K.L. Tung, J. Ulbricht, L. Urbán, U. Uwer, E. Valente, R.T. Van de Walle, H. van der Graaf, I. Vetlitsky, G. Viertel, P. Vikas, U. Vikas, M. Vivargent, H. Vogel, H. Vogt, M. Vollmar, G. Von Dardel, I. Vorobiev, A.A. Vorobyov, An.A. Vorobyov, L. Vuilleumier, M. Wadhwa, W. Walk, W. Wallraff, C.R. Wang, G.H. Wang, J.H. Wang, Q.F. Wang, X.L. Wang, Y.F. Wang, Z. Wang, Z.M. Wang, J. Weber, R. Weill, T.J. Wenaus, J. Wenninger, M. White, R. Wilhelm, C. Willmott, F. Wittgenstein, D. Wright, R.J. Wu, S.L. Wu, S.X. Wu, Y.G. Wu, B. Wysłouch, Z.Z. Xu, Z.L. Xue, D.S. Yan, B.Z. Yang, C.G. Yang, G. Yang, K.S. Yang, Q.Y. Yang, Z.Q. Yang, Q. Ye, C.H. Ye, S.C. Yeh, Z.W. Yin, J.M. You, C. Zabounidis, C. Zaccardelli, L. Zehnder, M. Zeng, Y. Zeng, D. Zhang, D.H. Zhang, S.Y. Zhang, Z.P. Zhang, J.F. Zhou, R.Y. Zhu, A. Zichichi, J. Zoll, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), and L3
Subjects: Nuclear and High Energy Physics, 010308 nuclear & particles physics, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], 010306 general physics, 01 natural sciences, Particle Physics - Experiment
Published: 1990

21. A precision measurement of the number of neutrino species

Author: L.S. Hsu, Konrad Deiters, Yu. Galaktionov, Alberto Aloisio, A. Grimes, Valery Schegelsky, Antonino Zichichi, Ph Fisher, H. Rykaczewski, M. Fabre, Th. Meinholz, J. Alcaraz, Helmut Vogel, Federico Carminati, Jozsef Toth, A. Heavey, A. A. Syed, J. Lettry, Claudio Luci, Wolfgang Lange, B.C. Stringfellow, Qiang Li, Y. Karyotakis, R.C. Ball, Adrian Biland, Georgi Sultanov, F. Crijns, X. W. Tang, I. Sheer, P. A. Piroué, Elisabetta Gallo, M. J. Glaubman, M. Möller, Lamberto Luminari, G. Finocchiaro, Marcel Merk, H. F. Chen, R. A. Khan, Kajari Mazumdar, J. Perrier, R. Malik, K.D. Shmakov, G. Chiefari, L. Urbàn, S. Shevchenko, Chenliang Wang, S. Khokhar, T.R. McMahon, M. Wadhwa, D. J. Schotanus, J. M. You, N. Produit, G. A. Yang, Jean Fay, M. Sachwitz, M. Dhina, D. Boutigny, H. El Mamouni, Cheng Chen, Ren-Yuan Zhu, Tariq Aziz, B. Stöhr, C. Zaccardelli, S. Reucroft, Luciano Barone, J. Fehlmann, Z. Y. Lin, V. P. Andreev, A. Engler, A. Leike, C. Zabounidis, S. C. Yeh, H. Fenker, S. Patricelli, Xd Cai, Pierre Lecomte, G.J. Bobbink, J.Y. Liao, E. Thomas, J.H. Wang, D.N. Mao, C. Souyri, S.J. Fan, M. Capell, C. Dionisi, Yu. Kamyshkov, F.C. Erné, Q.Y. Yang, B. L. Betev, Zhongyukun Xu, P. K. Malhotra, H. A. Rizvi, A. Gurtu, A. Kunin, H. van der Graaf, Q. Ye, P. Arce, D. Goujon, G. Sartorelli, M.L. Chen, G. Landi, U. Herten, R. Dolin, D. Perret-Gallix, H. S. Fesefeldt, F. Ferroni, V. Commichau, H. J. Schreiber, Pablo Garcia-Abia, Charles Timmermans, Raffaello D'Alessandro, C. Grinnell, Mw Gruenewald, Crisostomo Sciacca, D. Pandoulas, Marco Pieri, D. Antreasyan, G. M. Chen, Y. Zeng, M. Bocciolini, C. Rippich, Vincenzo Innocente, Alain Hervé, W. J. Metzger, P. Vikas, G. Morand, Qi An, M. Fukushima, Leonardo Merola, W. Walk, M. Gettner, S. Beingessner, T. Spickermann, S. Kwan, A. Hasan, G.G.G. Massaro, M. Gailloud, S. Lökös, C. G. Yang, T. Azemoon, X. Leytens, B. N. Jin, K.S. Yang, H. Nowak, F. Carbonara, R.J. Wu, A. Sopczak, J. Behrens, L. Martinez, J. Mnich, Bernard Ille, A. Bay, J.C. Sens, Th. Rombach, R. L. Summer, R. Raghavan, R. Magahiz, T. Kramer, C. Maña, Marcella Diemoz, L. Baksay, F. L. Linde, P. Lebrun, Fridolin Dittus, J. J. Blaising, K. Sudhakar, J. M. Le Goff, A. C. König, Y.P. Tong, L. Zehnder, Laurent Vuilleumier, P. Schmitz, E. Isiksal, K. S. Kumar, Simonetta Gentile, J. D. Swain, H. Anderhub, Marcos Cerrada, Z.F. Gong, P. Duinker, S. Banerjee, P. McBride, Alexei Klimentov, Carlo Civinini, M. Maolinbay, G. Gratta, C. Camps, H. Haan, Dimitri Bourilkov, Boleslaw Wyslouch, Luciano Romero, Qian Wang, S.Y. Zhang, C.Y. Chien, J. A. Rubio, K. Freudenreich, Y. Mi, G. H. Wang, J. Bao, F. Cesaroni, Kenneth Francis Read, I. Vetlitsky, U. Uwer, G. Conforto, J. Wenninger, X.G. Li, M. Aguilar-Benitez, I. Duran, J.M. Lubbers, A. Böhm, J.M. Qian, Philip Kaaret, G. Von Dardel, A. Chen, C. F. He, C-Q. Li, V. Pojidaev, G. Coignet, J. Salicio, S. C. Tonwar, Nikita Smirnov, L. J. Gutay, A. Pevsner, U. Becker, Zm Wang, R. Liu, Herwig Schopper, M. White, Barry Blumenfeld, R. de Asmundis, T. Böhringer, E. Valente, Thomas Ferguson, G. Sauvage, X. Lue, U. K. Chaturvedi, J. Schütte, S. S. Gau, P.V.K.S. Baba, Zhen Zhang, Speranza Falciano, F. J. Eppling, L. W. Jones, D. S. Yan, Y. S. Lu, R. Bizzarri, S. Hancke, K. N. Qureshi, Harvey B Newman, E. Dénes, R. Sehgal, An.A. Vorobyov, T. Matsuda, G. Mirabelli, Marco Meschini, Ian Brock, M. Chermarin, D. McNally, D. Kirkby, K. Hilgers, S. M. Ting, Jérôme Rose, S. X. Wu, F. DeNotaristefani, Egidio Longo, R. Wilhelm, Yanwen Liu, Y. H. Chang, W.-D. Nowak, George Alverson, W. Ruckstuhl, J. H. Field, G. Trowitzsch, D. P. Stickland, F. Bruyant, L. Leistam, O. Adriani, M. G. Alviggi, G. Viertel, G. Schwering, Vineet Kumar, T. Foreman, K. Lübelsmeyer, Piero Spillantini, Hafeez R. Hoorani, L. Montanet, Y. Mir, C. H. Ye, Y.J. Pei, M. M. Ilyas, G. Fernandez, D.W. Schmitz, Wolfgang Lohmann, H. Vogt, D. DiBitonto, Ph. Rosselet, B. Bertucci, D. Zhang, R. Rosmalen, S. Morganti, T. Angelov, M. Steuer, R. Fabbretti, J. Ulbricht, Nicanor Colino, X. L. Wang, E. Nagy, M. Vivargent, Christine Buisson, G. Forconi, J. Schwenke, J. Weber, W. Wallraff, M. MacDermott, Robert Clare, Guofan Hu, Thomas Hebbeker, X. Y. Cui, K. Lanius, M. A. Niaz, G. Hu, V. Shevchenko, Z. M. Wang, Paul Lecoq, R. W. Kraemer, M. Bourquin, M. Napolitano, P. Berges, P. Extermann, S. Rosier-Lees, T. Riemann, Z. Ren, P. Marchesini, I. Leedom, B. Z. Yang, J. G. Branson, K. Strauch, P.G. Seiler, G.B. Mills, A. Arefiev, H. Hofer, K. L. Tung, B. Monteleoni, Petr Levchenko, S. Röhner, F. Diez-Hedo, Peter Denes, Z. W. Yin, S. N. Ganguli, M. Maire, Ming Zeng, H. S. Chen, Aa Vorobyov, L. Li, R. Weill, P. Le Coultre, A. Degré, Giovanni Paternoster, Paolo Bagnaia, W. Kittel, D. Duchesneau, Carlos Willmott, K. Hangarter, F. Wittgenstein, L. Ludovici, E. Drago, M. Röhner, Alexander Malinin, B. Spiess, L. Niessen, Sau Lan Wu, T. Driever, H. T. Li, P.J. Li, V. Lalieu, F. Marzano, Y.F. Mao, W. Krenz, A. L. Anderson, V. Koutsenko, J.M. Thenard, A.M. Cartacci, H.R. Dimitrov, M. Harris, J.P. Burq, T.J. Wenaus, E. Jagel, Manjit Kaur, Ying Wu, J. F. Zhou, Samuel C.C. Ting, J.F. Li, R. T. Van de Walle, J. D. Burger, Steven Goldfarb, R. Starosta, H. Akbari, D. Luckey, Gy L. Bencze, B. P. Roe, G. Rahal-Callot, Reinhard W. Schulte, R.B. Sutton, D.H. Zhang, M. Schneegans, A. Bujak, Oliver Kornadt, M. Pohl, H. Suter, K. Schultze, E. Tarkovsky, J. M. Salicio, Y.F. Wang, D. Lanske, M. Vollmar, U. Micke, D. Linnhofer, R. Mount, S. Lanzano, D. Wright, Valentin V. Khoze, J. Berdugo, L. Antonov, J. Krizmanic, A. Marchionni, V.R. Krastev, E. Gonzalez, Bernardo Adeva, M. Guanziroli, J. P. Martin, E. Shumilov, J. Zoll, M. Schöntag, W. Böhlen, V. Shoutko, M. Tonutti, Mingshui Chen, V. Morgunov, D. Ren, U. Vikas, A. Contin, Alexander Savin, Igor Vorobiev, M. Hebert, Panos A Razis, P. Blömeke, A. Gordeev, M. Micke, Z.Q. Yang, Sebastian Nowak, B. Borgia, A. van Laak, X.R. Shi, I. Clare, J. Busenitz, P. Göttlicher, R. Leiste, D. Kaplan, C. Spartiotis, R. Morand, Z. L. Xue, Howard A. Stone, T.S. Dai, F. Tonisch, Q. Fan, G. Herten, W. Friebel, G. Faber, Corinne Goy, A. Kuhn, J. A. Bakken, V. Plyaskin, Wen-Gan Ma, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, and IHEF (IoP, FNWI)
Subjects: Nuclear and High Energy Physics, Particle physics, problem formulation, Electron–positron annihilation, Scalar (mathematics), Hadron, problem modeling, 01 natural sciences, problem understanding, Standard Model, Nuclear physics, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], information retrieval, Nuclear Experiment, 010306 general physics, Physics, Range (particle radiation), maxims of conversation, 010308 nuclear & particles physics, High Energy Physics::Phenomenology, problem expression, High Energy Physics::Experiment, competitive intelligence, Center of mass, Neutrino, pragmatics, Particle Physics - Experiment
Abstract: If simplified, every information retrieval problem can be solved when the information need implied by its expression has been identified. We are interested in the criteria used in realising a good information retrieval problem expression. We have listed these criteria through some principles and maxims which first characterized the communication between two persons are applied. We choose to use the gricean maxims because they are the most favoured for this type of situation. Secondly, we have tried to identify some others principles that can be used to realise a good information retrieval problem expression. The principles by Grice can not resolve all forms of error associated with this particular form of communication. In our work, we defined three other principles namely: adhesion principle, reformulation principle, memorization principle. We give some examples of situations where the principles we have formulated are not applicable and the consequences. We present the possible applications of our new model: MIRABEL, which can help in the description of information retrieval problem from. It also compels its user to use essential good expression principle implicitly.
Published: 1990

22. Search for excited neutrinos from Z$^0$ decays

Author: Dimitri Bourilkov, E. Nagy, E. Valente, M. Guanziroli, Tariq Aziz, R. Raghavan, R. Weill, D. McNally, Y.P. Tong, M. Schneegans, D. M. Lee, Laurent Vuilleumier, F. Cesaroni, J. P. Martin, X. Leytens, G. Viertel, G. Sauvage, J. Y. Liao, E. Isiksal, S. Morganti, W. Kittel, E. Shumilov, Ren-Yuan Zhu, Luciano Barone, J. Schütte, Crisostomo Sciacca, François Chollet, Marco Pieri, G. H. Wang, J. Schwenke, G. Herten, W. Friebel, G. Faber, M. Schöntag, X. Y. Cui, M. Möller, V. Shoutko, A. Kuhn, Harvey B Newman, K. Hilgers, C. Rippich, J. Wenninger, J. A. Bakken, U. Micke, F. Bruyant, M. J. Glaubman, V. Pojidaev, D. Linnhofer, H. F. Chen, V. Plyaskin, Nikita Smirnov, R. Mount, M. Tonutti, Zm Wang, T. Angelov, M. Fabre, S. Beingessner, D. Pandoulas, T. McMahon, Wen-Gan Ma, H. El Mamouni, B. P. Roe, G. Chiefari, K. Lanius, Qiang Li, J. Berdugo, G. Hu, F. C. Erné, Q.Y. Yang, A. Gurtu, Igor Vorobiev, Konrad Deiters, Georgi Sultanov, V. Commichau, H. J. Schreiber, J. Mnich, M.L. Chen, Sc Yeh, S. Shevchenko, Helmut Vogel, Alberto Aloisio, M. Sachwitz, L. Li, L. Urbàn, R. A. Khan, Carlos Willmott, R.C. Ball, Adrian Biland, Panos A Razis, L. J. Gutay, G. Landi, D. Duchesneau, T. Driever, P. Arce, T. Foreman, G. Fernandez, Speranza Falciano, T. Spickermann, A. Bujak, Oliver Kornadt, P. Blömeke, M. Bocciolini, P. Duinker, Alexander Malinin, M. Merk, U. Becker, Raffaello D'Alessandro, C. Grinnell, K.D. Shmakov, S. J. Fan, A. A. Syed, D. Goujon, M. Pohl, A. Gordeev, M. Micke, B. L. Betev, Th. Meinholz, P. Vikas, Bernard Ille, A. C. König, Kajari Mazumdar, S. Khokhar, Marcella Diemoz, G. Von Dardel, D.N. Mao, Yu. Kamyshkov, A. Hasan, R. Rosmalen, X. W. Tang, Leonardo Merola, Y. D. Xu, J. Bao, V. P. Andreev, M. Chemarin, J.F. Li, H. T. Li, Qi An, S. Lökös, K.S. Yang, Th. Rombach, Z.Q. Yang, B. Spiess, G. M. Chen, K. Sudhakar, F. J. Eppling, L. W. Jones, D. S. Yan, S. M. Ting, U. Herten, F. Plasil, T. Azemoon, H. Suter, Y.F. Wang, V. Lalieu, A. Degré, E. Dénes, R. Sehgal, Simonetta Gentile, Mingshui Chen, Mw Gruenewald, G. B. Mills, G. Morand, B.C. Stringfellow, M. Yzerman, V. Koutsenko, P. A. Piroué, T. Böhringer, P. Marchesini, Alexei Klimentov, C. Camps, Vincenzo Innocente, C. G. Yang, Xd Cai, Valentin V. Khoze, R. Dolin, I. Sheer, Marcos Cerrada, R. Magahiz, Ming Zeng, J. D. Swain, J.P. Burq, Kenneth Francis Read, S. Rosier-Lees, D. H. Zhang, E. Jagel, A. Engler, L. Antonov, G. Conforto, V. Morgunov, G. Finocchiaro, M. Bourquin, K. Strauch, P. Le Coultre, K. S. Kumar, L.S. Hsu, M. Röhner, Yu. Galaktionov, M. Fukushima, C. Maña, J. Perrier, U. Roeser, D. Hauschildt, B. N. Jin, K. Freudenreich, D. Ren, W. Wallraff, Guofan Hu, R. L. Summer, J. Salicio, J. Alcaraz, L. Baksay, Marco Meschini, K. Hangarter, R. Malik, Jozsef Toth, U. Vikas, J.M. Qian, M. Capell, J. Krizmanic, D. Perret-Gallix, H. S. Fesefeldt, H. O. Cohn, J. Lettry, Claudio Luci, A. Contin, K. N. Qureshi, Alexander Savin, Yanwen Liu, L. Z. Sun, Y.F. Mao, A. Marchionni, R. Starosta, Elisabetta Gallo, V.R. Krastev, R. Liu, G. Gratta, D. Luckey, Gy L. Bencze, A. Böhm, Cheng Chen, B. Stöhr, J. M. Le Goff, E. Gonzalez, Reinhard W. Schulte, D. Kirkby, H. R. Gustafson, S. S. Gau, P.V.K.S. Baba, Z. W. Yin, C.Y. Chien, T.J. Wenaus, C. Zaccardelli, W. W. Kinnison, Chenliang Wang, G. S. Sanders, Z.F. Gong, S. N. Ganguli, Zhuoxiang Ren, G. Coignet, J. A. Rubio, M. Wadhwa, R.J. Wu, A. Sopczak, H. L. Zhuang, S. Lanzano, Bernardo Adeva, Giovanni Paternoster, Wolfgang Stoeffl, I. Scott, Federico Carminati, S. Reucroft, Manjit Kaur, C. Timmermans, G. Schwering, J. M. You, H. Anderhub, P. McBride, An.A. Vorobyov, T. Matsuda, N. Produit, H. Fenker, A.M. Cartacci, C-Q. Li, J.M. Lubbers, L. Zehnder, H.R. Dimitrov, H. Akbari, D. Antreasyan, Zhen Zhang, G. A. Yang, O. Adriani, Lucas Taylor, R. Bizzarri, S. Hancke, Ian Brock, F. DeNotaristefani, J.C. Sens, J. D. Burger, G. Mirabelli, G. Rahal-Callot, W. J. Metzger, L. Leistam, X. L. Wang, S. Patricelli, M.C. Chen, J.B. Ye, O. Rind, K. Schultze, E. Tarkovsky, S. Banerjee, T. Kramer, P. Berges, D. Lanske, Hafeez R. Hoorani, K. Lübelsmeyer, Piero Spillantini, M. Maire, J. J. Blaising, Q. Ye, S. Schulte, W. Ruckstuhl, D. P. Stickland, Y. Mir, C. H. Ye, Y.J. Pei, Lamberto Luminari, M. Vivargent, Christine Buisson, R. de Asmundis, W. Böhlen, H. Haan, Wolfgang Lohmann, H. Vogt, Mariagrazia Alviggi, B. Bertucci, J. Fehlmann, Z. M. Wang, I. Vetlitsky, Pierre Lecomte, G. Sartorelli, Nicanor Colino, Y. H. Chang, George Alverson, C. Dionisi, R. T. Van de Walle, Vineet Kumar, V. Shevchenko, Pablo Garcia-Abia, Alain Hervé, B. Borgia, A. Bay, P.G. Seiler, F. Ferroni, Y. Zeng, F. Diez-Hedo, J. Ulbricht, A. van Laak, Peter Denes, Paolo Bagnaia, Carlo Civinini, Y. Mi, M. Maolinbay, S. C. Tonwar, X.R. Shi, I. Clare, Frank Filthaut, Thomas Ferguson, X.G. Li, J. Busenitz, P. Göttlicher, D.J. Schotanus, M. Aguilar-Benitez, I. Duran, Herwig Schopper, R. Leiste, M. White, Petr Levchenko, S. Röhner, C. Spartiotis, F. Wittgenstein, M. Gailloud, R. Morand, Z. L. Xue, L. Ludovici, E. Drago, L. Niessen, Sau Lan Wu, Howard A. Stone, T.S. Dai, F. Tonisch, Q. Fan, D. Zhang, M. Harris, J.G. Branson, O. Fackler, E. Thomas, J.H. Wang, Zhongyukun Xu, P. K. Malhotra, H. A. Rizvi, A. Kunin, H. van der Graaf, M. Hebert, R. Wilhelm, F. Carbonara, L. Martinez, F. L. Linde, Luciano Romero, Bolek Wyslouch, Qian Wang, J. Behrens, P. J. Li, P. Lebrun, Fridolin Dittus, BT Bouwens, U. Uwer, A. Chen, X. Lue, U. K. Chaturvedi, Y. S. Lu, Jérôme Rose, J. H. Field, G. Trowitzsch, C. F. He, A. Pevsner, Barry Blumenfeld, Valery Schegelsky, Antonino Zichichi, Ph Fisher, H. Rykaczewski, Y. Karyotakis, A. Arefiev, Aa Vorobyov, Jean Fay, M. Dhina, D. Boutigny, F. Crijns, Z. Y. Lin, F. Marzano, W. Krenz, Samuel C.C. Ting, Steven Goldfarb, R.B. Sutton, G. Passaleva, M. MacDermott, M. A. Niaz, S. X. Wu, D. DiBitonto, M. Steuer, G. Forconi, J. Weber, P. Extermann, I. Leedom, B. Z. Yang, H. Hofer, K. L. Tung, Egidio Longo, G. J. Bobbink, M. M. Ilyas, R. Fabbretti, M. Lenti, A. L. Anderson, Ying Wu, J. F. Zhou, M. Vollmar, D. Wright, D.W. Schmitz, G.G.G. Massaro, Robert Clare, Ph. Rosselet, Thomas Hebbeker, Paul Lecoq, R. W. Kraemer, M. Napolitano, H. S. Chen, B. Monteleoni, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, and IHEF (IoP, FNWI)
Subjects: Physics, Nuclear and High Energy Physics, Antiparticle, Particle physics, Annihilation, 010308 nuclear & particles physics, Elementary particle, 01 natural sciences, 7. Clean energy, Massless particle, Particle decay, Excited state, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], High Energy Physics::Experiment, Neutrino, 010306 general physics, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment, Lepton
Abstract: We have searched for the excited electron neutrino produced from Z 0 decays in the channel e + e − →νν ∗ using the L3 detector at LEP. The decays ν ∗ →eW and ν ∗ →νγ have been investigated. We have determined an upper limit on the Zνν ∗ coupling as a function of m ν ∗ up to the Z 0 mass.
Published: 1990

23. A determination of electroweak parameters from $Z^{0}$ decays into charged leptons

Author: Samuel C.C. Ting, A. A. Syed, Luciano Romero, Bolek Wyslouch, Steven Goldfarb, G. Passaleva, B.C. Stringfellow, C. F. He, H. van der Graaf, F. Crijns, D. DiBitonto, A. Pevsner, F. Ferroni, T. Kramer, G. Landi, A. Engler, M. Gruenewald, G. Finocchiaro, Barry Blumenfeld, J. J. Blaising, L. Antonov, M. MacDermott, Zhen Zhang, H. Anderhub, Y. Zeng, M. Merk, M. A. Niaz, R. de Asmundis, M. J. Glaubman, G. Mirabelli, P. Vikas, J. Perrier, H. El Mamouni, H. Haan, Mariagrazia Alviggi, C. J.W.P. Timmermans, X. Lue, R. Rosmalen, P. Extermann, K. Lübelsmeyer, Piero Spillantini, Valery Schegelsky, I. Leedom, B. Z. Yang, U. K. Chaturvedi, C. Rippich, Antonino Zichichi, P. Arce, D. Goujon, Vincenzo Innocente, R. Liu, R. Leiste, Ph Fisher, Y. S. Lu, J. Krizmanic, A. Marchionni, V.R. Krastev, H. Hofer, K. L. Tung, C. Buisson, Raffaello D'Alessandro, Igor Vorobiev, H. Rykaczewski, Qiang Li, M. Sachwitz, S. X. Wu, Y. Karyotakis, U. Roeser, R. Weill, M. Möller, M. Hebert, J. Alcaraz, Panos A Razis, E. Gonzalez, I. Vetlitsky, K. Sudhakar, C. Grinnell, Jérôme Rose, S. Lanzano, Bernardo Adeva, U. Herten, P.V.K.S. Baba, Ph. Rosselet, Y. Mi, P. Blömeke, A.M. Cartacci, J. H. Field, G. Trowitzsch, Leonardo Merola, Z.F. Gong, Jean Fay, M. Dhina, R. W. Kraemer, C-Q. Li, H. L. Zhuang, M. Steuer, R.C. Ball, G. Forconi, M. Lenti, D. Pandoulas, T. McMahon, Yanwen Liu, A. Gordeev, M. Micke, D. Boutigny, R.B. Sutton, J. Weber, T. Spickermann, A. L. Anderson, Z. Y. Lin, R. Bizzarri, S. Hancke, Helmut Vogel, J. M. Salicio, Adrian Biland, U. Micke, Ying Wu, J. F. Zhou, Ian Brock, Ren-Yuan Zhu, Luciano Barone, L. Leistam, O.F. Wang, D. Linnhofer, E. Valente, T. Azemoon, C. Spartiotis, L. Urbàn, G. Chiefari, S. Shevchenko, H.R. Dimitrov, Z.Q. Yang, Bernard Ille, R. Magahiz, E. Thomas, J.H. Wang, Zhongyukun Xu, P. K. Malhotra, H. A. Rizvi, A. Kunin, K.D. Shmakov, S. S. Gau, S. C. Tonwar, L.S. Hsu, R. Mount, Q. Fan, Q.Y. Yang, J. D. Swain, P. McBride, G.B. Mills, A. Arefiev, Qi An, P. Berges, Mingshui Chen, Marcos Cerrada, R. Malik, Kajari Mazumdar, Egidio Longo, J.C. Sens, S. Khokhar, Aa Vorobyov, C. Maña, Thomas Ferguson, A. Gurtu, Jozsef Toth, V. Commichau, H. J. Schreiber, J. Lettry, Claudio Luci, M. Maire, L. Li, S. Lökös, D. Duchesneau, J. Berdugo, R. Morand, K.S. Yang, Z. L. Xue, Th. Rombach, M. Capell, B. N. Jin, A. Böhm, J. D. Burger, D.N. Mao, V. Morgunov, G. Rahal-Callot, Dimitri Bourilkov, D. McNally, Alexander Malinin, R. Wilhelm, W. J. Metzger, G. Paternoster, Simonetta Gentile, B. Monteleoni, Yu. Galaktionov, D. Ren, L. J. Gutay, M. M. Ilyas, R. Fabbretti, Yu. Kamyshkov, H. S. Chen, F. Carbonara, Elisabetta Gallo, M. Bocciolini, Howard A. Stone, T.S. Dai, A. Hasan, F. Tonisch, Chenliang Wang, Kenneth Francis Read, Y. D. Xu, Zhuoxiang Ren, D. Perret-Gallix, H. S. Fesefeldt, G. Conforto, G. Coignet, M. Wadhwa, D. J. Schotanus, Lamberto Luminari, J. M. You, W. Kittel, J.F. Li, Xd Cai, F. Cesaroni, J. Y. Liao, U. Becker, M. Gailloud, G. Schwering, F. Marzano, W. Krenz, U. Vikas, E. Nagy, A. Contin, N. Produit, R. Raghavan, G. Sauvage, D.W. Schmitz, G.G.G. Massaro, Robert Clare, A. C. König, Y.P. Tong, E. Isiksal, Alexander Savin, K. Schultze, L. Martinez, F. L. Linde, E. Tarkovsky, S. Reucroft, H.S. Chen, P. Schmitz, Alexei Klimentov, C. Camps, V. Shevchenko, J. Fehlmann, H. Fenker, B. Borgia, M.C. Chen, T. Angelov, X. Leytens, G. Viertel, H. Suter, Y.F. Wang, Valentin V. Khoze, J. Behrens, P. J. Li, J. Schütte, M. Guanziroli, G. A. Yang, M. Schneegans, Harvey B Newman, D. Lanske, Cheng Chen, J. P. Martin, B. Stöhr, C. G. Yang, Pierre Lecomte, K. Hilgers, A. van Laak, K. Lanius, G. Hu, P. Lebrun, L. Zehnder, Fridolin Dittus, Thomas Hebbeker, C. Zaccardelli, Paul Lecoq, E. Shumilov, A. Bujak, M. Schöntag, K. Freudenreich, P.G. Seiler, F. Diez-Hedo, W. Böhlen, V. Shoutko, S.J. Fan, K. S. Kumar, J.P. Burq, Carlos Willmott, Peter Denes, S. Schulte, J.B. Ye, Speranza Falciano, J.M. Qian, Paolo Bagnaia, F. J. Eppling, L. W. Jones, M. Napolitano, Guo-Ming Chen, S. Banerjee, S. Morganti, U. Uwer, M. Tonutti, J. Schwenke, H. T. Li, Marco Meschini, J. Wenninger, I. Clare, D. Kirkby, X.R. Shi, P. Göttlicher, J. Salicio, X. Y. Cui, H. R. Gustafson, W. Ruckstuhl, D. S. Yan, D. P. Stickland, L. Vuileumier, S. M. Ting, S. Beingessner, An.A. Vorobyov, T. Matsuda, Y. Mir, C. H. Ye, Sc Yeh, G. Fernandez, Tariq Aziz, O. Adriani, Y.J. Pei, Lucas Taylor, Wolfgang Lohmann, H. Vogt, B. Bertucci, D. Zhang, J. Ulbricht, J. Mnich, M. Bourquin, W. Friebel, Nicanor Colino, K. Strauch, T. Foreman, P. Duinker, D. Antreasyan, J. Bao, Zheng Wang, Federico Carminati, F. de Notaristefani, Andre Sopczak, K. N. Qureshi, Y. H. Chang, George Alverson, M.L. Chen, Crisostomo Sciacca, Vineet Kumar, M. Chemarin, Marco Pieri, Marcella Diemoz, S. Patricelli, Q. Ye, Wen-Gan Ma, G. Von Dardel, A. Degré, Konrad Deiters, M. Vollmar, T. Böhringer, P. Marchesini, Alberto Aloisio, Ming Zeng, M. Röhner, D. Wright, R. L. Summer, Th. Meinholz, L. Baksay, G. Gratta, X. W. Tang, I. Sheer, P. A. Piroué, Y.F. Mao, C.Y. Chien, R. T. Van de Walle, I. Scott, T.J. Wenaus, Manjit Kaur, H. Akbari, Daqiang Zhang, C. Dionisi, A. Chen, Pablo Garcia-Abia, Alain Hervé, A. Bay, Carlo Civinini, M. Maolinbay, X.G. Li, M. Aguilar-Benitez, I. Duran, Herwig Schopper, M. White, Petr Levchenko, S. Röhner, F. Wittgenstein, L. Ludovici, E. Drago, L. Niessen, Sau Lan Wu, M. Harris, E. Dénes, R. Sehgal, L. Z. Sun, X. L. Wang, M. Vivargent, Z. M. Wang, B. Spiess, V. Lalieu, F. Bruyant, R. Dolin, M. Fukushima, J. M. Le Goff, J. A. Rubio, V. Koutsenko, E. Jagel, G. Herten, W. Wallraff, Guofan Hu, G. Faber, J. G. Branson, A. Kuhn, J. A. Bakken, Z. W. Yin, S. N. Ganguli, V. Plyaskin, V. Pojidaev, Nikita Smirnov, B. P. Roe, B. L. Betev, G. Sartorelli, Oliver Kornadt, M. Pohl, G. Morand, M. Fabre, Georgi Sultanov, R. A. Khan, T. Driever, J. Busenitz, V. P. Andreev, G.J. Bobbink, R.J. Wu, J.M. Lubbers, O. Rind, Hafeez R. Hoorani, S. Rosier-Lees, P. Le Coultre, G. H. Wang, K. Hangarter, R. Starosta, D. Luckey, Gy L. Bencze, Reinhard W. Schulte, F. C. Erné, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), L3, and IHEF (IoP, FNWI)
Subjects: Physics, Coupling constant, Nuclear and High Energy Physics, Muon, 010308 nuclear & particles physics, Electron–positron annihilation, media_common.quotation_subject, Electroweak interaction, Weinberg angle, Electron, 01 natural sciences, 7. Clean energy, Asymmetry, Nuclear physics, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], 010306 general physics, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment, Lepton, media_common
Abstract: We have measured the partial widths for the three reactions e + e − → Z 0 → e + e − , μ + μ − , τ + τ − . The results are Γ ee = 84.3±1.3 MeV, √ Γ ee Γ μμ =83.9±1.4 MeV, and √ Γ ee Γ ττ =83.9±1.4 MeV, where the errors are statistical. The systematic errors are estimated to be 1.0 MeV, 0.9 MeV, and 1.4 MeV, respectively. We perform a simultaneous fit to the cross sections for the e + e − →e + e − , μ + μ − , and τ + τ − data, the differential cross section as a function of polar angle for the electron data, and the forward- backward asymmetry for the muon data. We obtain the leptonic partial with Γ ll =84.0±0.9 (stat.) MeV. The systematic error is estimated to be 0.8 MeV. Also, we obtain the axial-vector and vector weak coupling constants of charged leptons, g A =−0.500±0.003 and g ν =−0.064 −0.013 +0.017 .
Published: 1990

24. Los médicos de Atención Primaria ante la Salud Mental.

Author: García, C. Camps, Grisbert, C., Gutiérrez, R., and Montilla, J. F.
Published: 1995

25. Abordaje de los problemas de salud mental desde atención primaria. Relación con los servicios de apoyo especializados

Author: N. Salleras Marcó, P. Solanas Saura, M. Beltran Vilella, M. García-Oria, E. Igual Massalles, and C. Camps García
Subjects: Medicine(all), Salud mental, Organización y administración, Organisation and administration, Mental health, General Medicine, Family Practice, Atención primaria, Primary care
Abstract: ObjetivosConocer la relación entre asistencia primaria (AP) y salud mental (SM), valorando: a) percepción de los problemas de SM en AP: formación de los profesionales y relación médicopaciente, y b) relación entre AP y los servicios de soporte especializados: reuniones de coordinación y motivos de las derivaciones.DiseñoEstudio descriptivo.EmplazamientoSiete centros de AP que comparten el mismo centro de salud mental (CSM) de la Regió Sanitària Girona.ParticipantesTodos los médicos de AP de los 7 centros (n = 66).Mediciones y resultados principalesEncuesta específica, anónima y autoadministrada, que consta de 71 ítems tipo Likert, distribuidos en 14 campos; 51 respuestas (77,2%); un 60,4% valora positivamente su formación en SM; un 100% considera que una buena relación médico-paciente mejora la adhesión al tratamiento, y un 76,5% la ve dificultada por falta de tiempo.Los pacientes agresivos y manipuladores provocan un mayor grado de tensión (70,6 y 66,7%).Lo más valorado de la relación con el CSM es su apoyo en el seguimiento de los pacientes (69,6%) y el acuerdo en la división de responsabilidades en el tratamiento de los trastornos mentales (71,1%). Las formas de apoyo más valoradas son las reuniones de interconsulta (80,4%) y las interconsultas telefónicas (78,4%).Los factores que más condicionan la derivación al CSM son las ideas de suicidio (96,1%) y la gravedad de la sintomatología (94%).ConclusionesSería necesario ofrecer mayor formación al médico de AP sobre SM.Los médicos de AP consideran escaso el tiempo que pueden dedicar a sus enfermos psiquiátricos. La disponibilidad de un equipo de apoyo especializado es indispensable en AP.ObjectivesTo find the relationship between primary care (PC) and mental health (MH) by evaluating: 1) perception of MH problems in PC: training of professionals and doctor-patient relationship, and 2) relationship between PC and specialist support services: coordination meetings and reasons for referrals.DesignDescriptive study.SettingSeven PC centres that share the same mental health centre in the Girona Health Region.ParticipantsAll the PC doctors from the 7 centres (n = 66).Measurements and main resultsSpecific, anonymous and self-administered survey, with 71 Likert-type items, distributed in 14 fields. 51 replies (77.2%). 60.4% valued positively their MH training. 100% thought that a good doctor-patient relationship improves adherence to treatment, and 76.5% saw this hindered by lack of time. Aggressive and manipulative patients caused a higher level of tension (70.6% and 66.7%). The point most highly valued of their relationship with the MH centre was its support in patient follow-up (69.6%) and the agreement to share responsibilities for treatment of mental disorders (71.1%). The forms of support most valued were: inter-clinical meetings (80.4%) and inter-clinic telephone consultations (78.4%). The factors most conditioning referral to the MH centre were ideas of suicide (96.1%) and the seriousness of the symptoms (94%).ConclusionsGreater MH training should be offered to PC doctors. PC doctors think they have little time available to devote to their psychiatric patients. Availability of a specialist PC support team is essential.
Full Text: View/download PDF

26. Search for the neutral Higgs boson from $Z^{0}$ decay

Author: Yu. Galaktionov, Dimitri Bourilkov, J. Alcaraz, T. Kramer, Marco Meschini, J. J. Blaising, R. Rosmalen, B. N. Jin, M. MacDermott, G. Sauvage, R. L. Summer, H. Haan, Mariagrazia Alviggi, M. A. Niaz, L. Baksay, A. Arefiev, L. Zehnder, I. Vetlitsky, Cheng Chen, B. Stöhr, T. Foreman, Aa Vorobyov, S. Banerjee, Harvey B Newman, V.G. Shevchenko, P. Extermann, K. Hilgers, B. Borgia, A. van Laak, I. Leedom, C. Zaccardelli, J. Martin, Boleslaw Wyslouch, C.Y. Chien, H. Hofer, K. L. Tung, Y.J. Pei, B. Bertucci, D. Zhang, J. Ulbricht, X.R. Shi, I. Clare, J. Busenitz, L. Urbàn, D.N. Mao, C. Souyri, P. Göttlicher, Lamberto Luminari, M. Gailloud, J. M. Salicio, U. Micke, J.C. Sens, R. Raghavan, M. Möller, Nicanor Colino, J. Fehlmann, W. Lange, R. Weill, D. Linnhofer, Federico Carminati, Tariq Aziz, Y.P. Tong, Laurent Vuilleumier, E. Isiksal, H. F. Chen, Z.P. Zhang, Pierre Lecomte, G. Sartorelli, M. J. Glaubman, S. Rosier-Lees, A. Heavey, P. Le Coultre, Qiang Li, R. Dolin, K. N. Qureshi, P. McBride, Petr Levchenko, S. Röhner, R.C. Ball, Adrian Biland, J. Berdugo, G. H. Wang, Charles Timmermans, K. Hangarter, A. Malinin, Raffaello D'Alessandro, X.L. Wang, C. Grinnell, A. L. Anderson, S. Beingessner, P.G. Seiler, Ying Wu, J. F. Zhou, Crisostomo Sciacca, Yu. Kamyshkov, Marco Pieri, Mw Gruenewald, K.D. Shmakov, S. J. Fan, C.R. Wang, C. Rippich, J. Wenninger, V. Pojidaev, S. Patricelli, R. Starosta, D. Antreasyan, C. Zabounidis, U. Herten, D. Kaplan, Leonardo Merola, D. Luckey, Gy L. Bencze, Reinhard W. Schulte, F. Diez-Hedo, W. Walk, Valery Schegelsky, Antonino Zichichi, J. Mnich, F. Wittgenstein, J.M. Lubbers, H. Rykaczewski, P. Arce, L. Ludovici, Peter Denes, C. G. Yang, G. Mirabelli, G. Chiefari, S. Shevchenko, E. Drago, Nikita Smirnov, S. Schulte, A. Engler, Konrad Deiters, Q. Ye, L. Niessen, Egidio Longo, C. Spartiotis, B. Monteleoni, T. Riemann, T. Azemoon, Z.F. Gong, R.J. Wu, M. Fukushima, B.Z. Yang, D. Goujon, K. Lübelsmeyer, Piero Spillantini, E. G. Thomas, Paolo Bagnaia, Alberto Aloisio, P. Duinker, Jd Burger, M. Capell, W. Kittel, H. Vogt, A. Grimes, F. Marzano, W. Krenz, C. Li, K. S. Kumar, R. Malik, Speranza Falciano, D. Perret-Gallix, H. S. Fesefeldt, W. Ruckstuhl, Th. Meinholz, J.P. Burq, Vincenzo Innocente, R. Morand, Z. L. Xue, R. Bizzarri, S. Hancke, Marcos Cerrada, Sau Lan Wu, Ian Brock, F. DeNotaristefani, Y. Karyotakis, T. Driever, D. P. Stickland, G. J. Bobbink, M. M. Ilyas, J. Bao, H.J. Schreiber, Howard A. Stone, T.S. Dai, X. W. Tang, I. Sheer, J.M. Qian, R. Fabbretti, P. A. Piroué, Philip Kaaret, Axel König, L. Leistam, Y. Mi, U. Becker, F. Tonisch, Q. Fan, Y. Mir, C. H. Ye, Yanwen Liu, J. M. Le Goff, G. Schwering, M. Schneegans, D. Pandoulas, T. McMahon, T. Spickermann, S. Kwan, Bernard Ille, Sc Yeh, G. Fernandez, H. El Mamouni, L. Montanet, F. J. Eppling, M. Harris, J. Fay, Zhuoxiang Ren, A. Sopczak, M. Wadhwa, X. Leytens, R. Magahiz, J. M. You, D. S. Yan, S. X. Wu, P. Berges, Mingshui Chen, J. A. Rubio, M. Maire, J. D. Swain, N. Produit, L. Antonov, M. Bourquin, K. Strauch, Hafeez R. Hoorani, B. L. Betev, M. Fabre, S. M. Ting, W.D. Nowak, T.J. Wenaus, Manjit Kaur, D. DiBitonto, Ph. Rosselet, Thomas Ferguson, An.A. Vorobyov, T. Matsuda, W. Lohmann, J. Krizmanic, G. A. Yang, M. Steuer, M. Dhina, D. Boutigny, A. A. Syed, H. Anderhub, Georgi Sultanov, G. Morand, G. Forconi, J. Weber, A. Marchionni, C. Dionisi, R. W. Kraemer, V.R. Krastev, O. Adriani, A. Böhm, H. Nowak, E. Gonzalez, Suresh C Tonwar, B.C. Stringfellow, D. J. Schotanus, G. Coignet, R. A. Khan, F. Crijns, V. P. Andreev, G.B. Mills, Pablo Garcia-Abia, S. Lanzano, Bernardo Adeva, Alain Hervé, Kajari Mazumdar, S. Khokhar, Samuel C.C. Ting, J.M. Thenard, A.M. Cartacci, H. Akbari, H.R. Dimitrov, P.H. Fisher, C. Civinni, M. Sachwitz, G. Finocchiaro, A. Bay, L. Li, G. M. Chen, Steven Goldfarb, D. Duchesneau, Xd Cai, Marcel Merk, R.B. Sutton, F. Cesaroni, J. Y. Liao, G. Rahal-Callot, J. Perrier, D. Ren, J.F. Li, H. Suter, D.H. Zhang, Y.F. Wang, G. Landi, M. Maolinbay, J. Schütte, Richard Mount, X.G. Li, M. Aguilar-Benitez, I. Duran, Valentin V. Khoze, K. Schultze, E. Tarkovsky, F. Bruyant, V. Morgunov, Herwig Schopper, M. White, D. Lanske, Luciano Romero, Qian Wang, E. Dénes, U. Vikas, R. Sehgal, A. Contin, Alexander Savin, B. P. Roe, R. de Asmundis, P. Vikas, M. Vollmar, E. Nagy, M. Vivargent, Christine Buisson, M. Guanziroli, C. F. He, Z. M. Wang, D. Wright, Giorgio Gratta, A. Pevsner, E. Shumilov, J. Zoll, J. H. Field, M. Schöntag, J. Behrens, P. J. Li, K. Sudhakar, P. Lebrun, Fridolin Dittus, Barry Blumenfeld, S.Y. Zhang, W. Böhlen, V. Shoutko, Wesley James Metzger, J.H. Wang, P. K. Malhotra, U. Uwer, H. A. Rizvi, A. Kunin, H. van der Graaf, A. Chen, L.S. Hsu, J. Salicio, M. Tonutti, R. Leiste, Igor Vorobiev, Ren-Yuan Zhu, Luciano Barone, Jozsef Toth, J. Lettry, Claudio Luci, M. Hebert, Panos A Razis, P. Blömeke, Elisabetta Gallo, F.C. Erné, Q.Y. Yang, A. Gordeev, M. Micke, G.G.G. Massaro, G. Paternoster, D.W. Schmitz, F. Carbonara, A. Gurtu, S. Reucroft, Z.Q. Yang, Robert Clare, A. Leike, H. Fenker, L. Martinez, W.G. Ma, F. L. Linde, Thomas Hebbeker, Paul Lecoq, V. Commichau, M. Napolitano, H. S. Chen, M. Bocciolini, A. Hasan, X. Lue, U. K. Chaturvedi, Y. S. Lu, Jérôme Rose, R. Wilhelm, G. Trowitzsch, Lawrence W. Jones, B. Spiess, P. Marchesini, V. Lalieu, Ming Zeng, M. Röhner, V. Koutsenko, Z.M. Wang, Y.F. Mao, S. Nowak, E. Jagel, W. Wallraff, Guofan Hu, R. T. Van de Walle, Laszlo Gutay, J. G. Branson, Z. W. Yin, S. N. Ganguli, A. Degré, M.L. Chen, M. Gettner, C. Maña, Marcella Diemoz, G. Von Dardel, D. Kirkby, Z.Y. Lin, A. Bujak, Oliver Kornadt, M. Pohl, T. Böhringer, E. Valente, D. McNally, G. Viertel, Hans J. Vogel, S. Morganti, J. Schwenke, X. Y. Cui, M. Chemarin, G. Herten, Y. H. Chang, George Alverson, W. Friebel, G. Faber, Vineet Kumar, Corinne Goy, F. Ferroni, Y. Zeng, A. Kuhn, J. A. Bakken, V. Plyaskin, P. Schmitz, Alexei Klimentov, C. Camps, K. Freudenreich, T. Angelov, K. Lanius, G. Hu, Carlos Willmott, Z.Z. Xu, H. T. Li, R. Liu, S. S. Gau, P.V.K.S. Baba, Qi An, S. Lökös, K.S. Yang, Th. Rombach, Simonetta Gentile, Kenneth Francis Read, G. Conforto, Decamp, D, Deschizeaux, B, Lees, Jp, Minard, Mn, Crespo, Jm, Delfino, M, Fernandez, E, Martinez, M, Miquel, R, Mir, Lm, Orteu, S, Pacheco, A, Perlas, Ja, Tubau, E, Catanesi, Mg, Depalma, M, Farilla, A, Iaselli, G, Maggi, G, Mastrogiacomo, A, Natali, S, Nuzzo, S, Ranieri, A, Raso, G, Romano, F, Ruggieri, F, Selvaggi, G, Silvestris, L, Tempesta, P, Zito, G, Chen, Y, Hu, H, Huang, D, Lin, J, Ruan, T, Wang, T, Wu, W, Xie, Y, Xu, D, Xu, R, Zhang, J, Zhao, W, Albrecht, H, Bird, F, Blucher, E, Charity, T, Drevermann, H, Garrido, L, Grab, C, Hagelberg, R, Haywood, S, Jost, B, Kasemann, M, Kellner, G, Knobloch, J, Lacourt, A, Lehraus, I, Lohse, T, Luke, D, Marchioro, A, Mato, P, May, J, Mertens, V, Minten, A, Miotto, A, Palazzi, P, Pepealtarelli, M, Ranjard, F, Richstein, J, Roth, A, Rothberg, J, Rotscheidt, H, Vonruden, W, Stdenis, R, Schlatter, D, Takashima, M, Talby, M, Taureg, H, Tejessy, W, Wachsmuth, H, Wheeler, S, Wiedenmann, W, Witzeling, W, Wotschack, J, Ajaltouni, Z, Bardadinotwinowska, M, Falvard, A, Gay, P, Henrard, P, Jousset, J, Michel, B, Montret, Jc, Pallin, D, Perret, P, Prat, J, Proriol, J, Prulhiere, F, Bertelsen, H, Hansen, F, Hansen, Jd, Hansen, Jr, Hansen, Ph, Lindahl, A, Madsen, B, Mollerud, R, Nilsson, B, Petersen, G, Simopoulou, E, Vayaki, A, Badier, J, Bernard, D, Blondel, A, Bonneaud, G, Bourotte, J, Braems, F, Brient, Jc, Ciocci, Ma, Fouque, G, Guirlet, R, Mine, P, Rouge, A, Rumpf, M, Videau, H, Videau, I, Zwierski, D, Candlin, Dj, Conti, A, Parrini, G, Corden, M, Georgiopoulos, C, Goldman, Jh, Ikeda, M, Lannutti, J, Levinthal, D, Mermikides, M, Sawyer, L, Antonelli, A, Baldini, R, Bencivenni, G, Bologna, G, Bossi, F, Campana, P, Capon, G, Chiarella, V, Deninno, G, Dettorrepiazzoli, B, Felici, G, Laurelli, P, Mannocchi, G, Murtas, F, Murtas, Gp, Nicoletti, G, Picchi, P, Zografou, P, Altoon, B, Boyle, O, Flavell, Aj, Halley, Aw, Tenhave, I, Hearns, Jl, Hughes, I, Lynch, Jg, Martin, Dj, Oneill, R, Raine, C, Scarr, Jm, Smith, K, Thompson, A, Brandl, B, Braun, O, Geiges, R, Geweniger, C, Hanke, P, Hepp, V, Kluge, Ee, Maumary, Y, Panter, M, Putzer, A, Rensch, B, Stahl, A, Tittel, K, Wunsch, M, Belk, At, Beuselinck, R, Binnie, Dm, Cameron, W, Cattaneo, M, Dornan, Pj, Greene, Am, Dugeay, S, Forty, Rw, Hassard, Jf, Patton, S, Sedgbeer, Jk, Taylor, G, Tomalin, Ir, Wright, Ag, Kneringer, E, Kuhn, D, Rudolph, G, Bowdery, Ck, Brodbeck, Tj, Finch, Aj, Foster, F, Hughes, G, Keemer, Nr, Nuttall, M, Rowlingson, B, Sloan, T, Snow, Sw, Barczewski, T, Bauerdick, Lat, Kleinknecht, K, Renk, B, Roehn, S, Sander, Hg, Schmelling, M, Steeg, F, Albanese, Jp, Aubert, Jj, Benchouk, C, Bonissent, A, Etienne, F, Nacasch, R, Payre, P, Pietrzyk, B, Qian, Z, Blum, W, Cattaneo, P, Comin, M, Cowan, G, Dehning, B, Dietl, H, Fernandezbosman, M, Hauff, D, Jahn, A, Lange, E, Lutjens, G, Lutz, G, Manner, W, Moser, Hg, Pan, Y, Richter, R, Schwarz, A, Settles, R, Stiegler, U, Stierlin, U, Stimpfl, G, Thomas, J, Waltermann, G, Debouard, G, Boucrot, J, Callot, O, Chen, X, Cordier, A, Davier, M, Ganis, G, Grivaz, Jf, Heusse, P, Janot, P, Journe, V, Kim, Dw, Lefrancois, J, Lloydowen, D, Lutz, Am, Marotte, P, Veillet, Jj, Amendolia, Sr, Bagliesi, G, Batignani, G, Bosisio, L, Bottigli, U, Bradaschia, C, Ferrante, I, Fidecaro, F, Foa, L, Focardi, E, Forti, F, Giassi, A, Giorgi, Ma, Ligabue, Franco, Lusiani, Alberto, Mannelli, Eb, Marrocchesi, P, Messineo, A, Palla, F, Sanguinetti, G, Scapellato, S, Steinberger, J, Tenchini, R, Tonelli, G, Triggiani, G, Carter, Jm, Green, Bj, Green, Mg, Mckemey, Ak, March, Pv, Medcalf, T, Saich, Mr, Strong, Ja, Thomas, Rm, Wildish, T, Botterill, Dr, Clifft, Rw, Edgecock, Tr, Edwards, M, Fisher, Sm, Harvey, J, Hill, Dl, Jones, Tj, Morrissey, M, Norton, Pr, Salmon, Dp, Thompson, Jc, Blochdevaux, B, Colas, P, Klopfenstein, C, Lancon, E, Locci, E, Loucatos, S, Mirabito, L, Monnier, E, Perez, P, Perrier, F, Rander, J, Renardy, Jf, Roussarie, A, Schuller, Jp, Ashman, Jg, Booth, Cn, Combley, F, Dinsdale, M, Martin, J, Parker, D, Thompson, Lf, Brandt, S, Burkhardt, H, Grupen, C, Meinhard, H, Neugebauer, E, Schafer, U, Seywerd, H, Stupperich, K, Gobbo, B, Liello, F, Milotti, E, Ragusa, F, Rolandi, Luigi, Bellantoni, L, Boudreau, Jf, Cinabro, D, Conway, J, Cowen, Df, Feng, Z, Harton, Jl, Hilgart, J, Jared, Rc, Johnson, Rp, Leclaire, Bw, Pan, Yb, Parker, T, Pater, Jr, Ritz, S, Saadi, Y, Sharma, V, Wear, Ja, Weber, Fv, Wu, Sl, Xue, St, and Zobernig, G.
Subjects: Physics, Nuclear physics, Nuclear and High Energy Physics, Particle physics, Electron–positron annihilation, Hadron, Higgs boson, Context (language use), Particle Physics - Experiment, Standard Model
Abstract: A search for the neutral Higgs boson, using the processes Z 0 → H 0 e + e − , Z 0 → H 0 μ + μ − , Z 0 → H 0 τ + τ − , Z 0 → H 0 v v and Z 0 → H 0 q q , is performed on data collected by the ALEPH detector corresponding to about 11 550 events of Z0 → hadrons. Combining all these processes, the mass range excluded is 32 MeV−15 GeV at 95% CL and 40 MeV−12 GeV at 99% CL. The result from this experiment is unambiguous in the context of the standard model.
Published: 1989

27. PSY35 COST-EFFECTIVENESS ANALYSIS OF THE EPOETIN TREATMENT IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY, EPICOST STUDY PRELIMINARY RESULTS (ONVIDA GROUP)

Author: A Colmenarejo, JL Poveda, J Rifá, A Casas, C Rubio-Terrés, C Camps, C Jara, B Massuti, Francisco Lobo, and F Barón
Subjects: medicine.medical_specialty, Chemotherapy, business.industry, Anemia, Internal medicine, medicine.medical_treatment, Health Policy, Public Health, Environmental and Occupational Health, Medicine, In patient, Cost-effectiveness analysis, business, medicine.disease
Full Text: View/download PDF

28. A STUDY OF COSMIC RAY SECONDARIES INDUCED BY THE MIR SPACE STATION USING AMS-01

Author: Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, L. Aof, A. Arefievg, P. Azzarellod, E. Babuccic, L. Baldinih, i, M. Basileh, D. Barancourtj, F. Baraok, l, G. Barbierj, G. Barreirak, R. Battistonc, R. Beckeri, U. Beckeri, L. Bellagambah, P. Bénéd, J. Berdugoa, P. Bergesi, B. Bertuccic, A. Bilande, S. Bizzagliac, S. Blaskoc, Boschini, M, M. Bourquind, L. Broccoh, G. Brunih, M. Buénerdj, J. D. Burgeri, W. J. Burgerc, X. D. Caii, C. Campsn, P. Cannarsae, M. Capelli, G. Carosii, D. Casadeih, J. Casausa, G. Castellinio, h, C. Cecchic, Y. H. Changp, H. F. Chenq, H. S. Chenr, Z. G. Chenf, N. A. Chernoplekovs, T. H. Chiuehp, K. Chot, M. J. Choiu, Y. Y. Choiu, Y. L. Chuangv, F. Cindoloh, V. Commichaun, A. Continh, E. Cortina Gild, M. Cristinzianid, J. P. da Cunhaw, T. S. Daii, C. Delgadoa, B. Demirközi, J. D. Deusl, N. Dinuc, 1, L. Djambazove, I. D’Antoneh, Z. R. Dongx, P. Emonetd, J. Engelbergy, F. J. Epplingi, T. Eronenz, G. Espositoc, P. Extermannd, J. Favieraa, E. Fiandrinic, P. H. Fisheri, G. Flueggen, N. Fouqueaa, Y.u. Galaktionovg, P. Giustih, Grandi, D, O. Grimme, W. Q. Gux, K. Hangartern, A. Hasane, R. Henning, V. Hermelaa, H. Hofere, M. A. Huangv, W. Hungerforde, M. Ionicac, R. Ionicac, M. Jongmannse, K. Karlamaay, W. Karpinskiab, G. Kenneye, J. Kennyc, D. H. Kimt, G. N. Kimt, K. S. Kimu, M. Y. Kimu, A. Klimentovi, g, R. Kossakowskiaa, V. Koutsenkoi, M. Kraebere, G. Laboriej, T. Laitinenz, G. Lamannac, E. Lanciottia, G. Laurentih, A. Lebedevi, C. Lechanoine Lelucd, M. W. Leet, S. C. Leev, G. Levih, P. Levtchenkoc, 3, C. L. Liuac, H. T. Liur, I. Lopesw, G. Luf, Y. S. Lur, K. Lübelsmeyerab, D. Luckeyi, W. Lustermanne, C. Mañaa, A. Margottih, F. Mayetj, R. R. McNeilad, B. Meillonj, M. Menichellic, A. Mihulae, B. Monreali, A. Mouraol, A. Mujuneny, F. Palmonarih, A. Papic, H. B. Parkt, W. H. Parkt, M. Pauluzzic, F. Pausse, E. Perrind, A. Pescih, A. Pevsneraf, M. Pimentak, V. Plyasking, V. Pojidaevg, M. Pohld, V. Postolachec, N. Produitd, Rancoita, PG, D. Rapind, F. Raupachab, D. Rene, Z. Renv, M. Ribordyd, J. P. Richeuxd, E. Riihonenz, J. Ritakariy, S. Rot, U. Roesere, C. Rossinj, R. Sagdeevag, D. Santosj, G. Sartorellih, C. Sbarrah, S. Schaelab, A. Schultz von Dratzigab, G. Schweringab, G. Scolieric, E. S. Seoag, J. W. Shint, E. Shoumilovg, V. Shoutkoi, R. Siedlingab, D. Sont, T. Songx, M. Steueri, G. S. Sunx, H. Sutere, X. W. Tangr, Samuel C. C. Tingi, S. M. Tingi, M. Tornikoskiy, J. Torstiz, J. Trümperah, J. Ulbrichte, S. Urpoy, E. Valtonenz, J. Vandenhirtzab, F. Velceac, E. Velikhovs, B. Verlaate, 4, I. Vetlitskyg, F. Vezzuj, J. P. Vialleaa, G. Viertele, D. Vitéd, H. Von Guntene, S. Waldmeier Wickie, W. Wallraffab, B. C. Wangac, J. Z. Wangf, Y. H. Wangv, K. Wiiky, C. Williamsh, S. X. Wui, p, P. C. Xiax, J. L. Yanf, L. G. Yanx, C. G. Yangr, J. Yangu, M. Yangr, S. W. Yeq, 5, P. Yehv, Z. Z. Xuq, H. Y. Zhangai, Z. P. Zhangq, D. X. Zhaox, G. Y. Zhur, W. Z. Zhuf, H. L. Zhuangr, A. Zichichih, B. Zimmermann, P. Zuccon, BOELLA, GIULIANO FILIPPO, GERVASI, MASSIMO, M. AGUILAR, J. ALCARAZ, J. ALLABY, B. ALPAT, G. AMBROSI, H. ANDERHUB, L. AO, A. AREFIEV, P. AZZARELLO, E. BABUCCI, L. BALDINI, M. BASILE, D. BARANCOURT, F. BARAO, G. BARBIER, G. BARREIRA, R. BATTISTON, R. BECKER, U. BECKER, L. BELLAGAMBA, P. BENE, J. BERDUGO, P. BERGES, B. BERTUCCI, A. BILAND, S. BIZZAGLIA, S. BLASKO, G. BOELLA, M. BOSCHINI, M. BOURQUIN, L. BROCCO, G. BRUNI, M. BUENERD, J.D. BURGER, W.J. BURGER, X.D. CAI, C. CAMPS, P. CANNARSA, M. CAPELL, G. CAROSI, D. CASADEI, J. CASAUS, G. CASTELLINI, C. CECCHI, Y.H. CHANG, H.F. CHEN, H.S. CHEN, Z.G. CHEN, N.A. CHERNOPLEKOV, T.H. CHIUEH, K. CHO, M.J. CHOI, Y.Y. CHOI, Y.L. CHUANG, F. CINDOLO, V. COMMICHAU, A. CONTIN, E. CORTINA-GIL, M. CRISTINZIANI, J.P. DA CUNHA, T.S. DAI, C. DELGADO, B. DEMIRKOEZ, J.D. DEUS, N. DINU, L. DJAMBAZOV, I. D'ANTONE, Z.R. DONG, P. EMONET, J. ENGELBERG, F.J. EPPLING, T. ERONEN, G. ESPOSITO, P. EXTERMANN, J. FAVIER, E. FIANDRINI, P.H. FISHER, G. FLUEGGE, N. FOUQUE, YU. GALAKTIONOV, M. GERVASI, P. GIUSTI, D. GRANDI, O. GRIMM, W.Q. GU, K. HANGARTER, H. HASAN, R. HENNING, V. HERMEL, H. HOFER, M.A. HUANG, W. HUNGERFORD, M. IONICA, R. IONICA, M. JONGMANNS, K. KARLAMAA, W. KARPINSKI, G. KENNEY, J. KENNY, D.H. KIM, G.N. KIM, K.S. KIM, M.Y. KIM, A. KLIMENTOV, R. KOSSAKOWSKI, V. KOUTSENKO, M. KRAEBER, G. LABORIE, T. LAITINEN, G. LAMANNA, E. LANCIOTTI, G. LAURENTI, A. LEBEDEV, C. LECHANOINE-LELUC, M.W.LEE, S.C. LEE, G. LEVI, P. LEVTCHENKO, C.L. LIU, H.T. LIU, I. LOPES, G. LU, Y.S. LU, K. LUBELSMEYER, D. LUCKEY, W. LUSTERMANN, C. MANA, A. MARGOTTI, F. MAYET, R.R. MCNEIL, B. MEILLON, M. MENICHELLI, A. MIHUL, B. MONREAL, A. MOURAO, A. MUJUNEN, F. PALMONARI, A. PAPI, H.B. PARK, W.H. PARK, M. PAULUZZI, F. PAUSS, E. PERRIN, A. PESCI, A. PEVSNER, M. PIMENTA, V. PLYASKIN, V. POJIDAEV, M. POHL, V. POSTOLACHE, N. PRODUIT, P.G. RANCOITA, D. RAPIN, F. RAUPACH, D. REN, Z. REN, M. RIBORDY, J.P. RICHEAUX, E. RIIHONEN, J. RITAKARI, S. RO, U. ROESER, C. ROSSIN, R. SAGDEEV, D. SANTOS, G. SARTORELLI, C. SBARRA, S. SCHAEL, A. SCHULTZ VON DRATZIG, G. SCHWERING, G. SCOLIERI, E.S. SEO, J.W. SHIN, E. SHOUMILOV, V. SHOUTKO, R. SIEDLING, D. SON, T. SONG, M. STEUER, G. S. SUN, H. SUTER, X.W. TANG, SAMUEL C.C. TING, S.M. TING, M. TORNIKOSKI, J. TORSTI, J. TRUEMPER, J. ULBRICHT, S. URPO, E. VALTONEN, J. VANDENHIRTZ, F. VELCEA, E. VELIKHOV, B. VERLAAT, I. VETLITSKI, F. VEZZU, J.P. VIALLE, G. VIERTEL, D. VITE, H. VON GUNTEN, S. WALDMEIER WICKI, W. WALLRAFF, B.C. WANG, J.Z. WANG, Y.H. WANG, K. WIIK, C. WILLIAMS, S.X. WU, P.C. XIA, J.L. YAN, L.G. YAN, C.G. YANG, J. YANG, M. YANG, S.W. YE, P. YEH, Z.Z. XU, H.Y. ZHANG, Z.P. ZHANG, D.X. ZHAO, G.Y. ZHU, W.Z. ZHU, H.L. ZHUANG, A. ZICHICHI, B. ZIMMERMANN, P. ZUCCON, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, CIEMAT, E-28040 Madrid, Spain6, UCL - SST/IRMP - Institut de recherche en mathématique et physique, Ambrosi, Giovanni, Azzarello, Philipp, Bene, Pierre, Bourquin, Maurice, Cortina Gil, Eduardo, Cristinziani, Markus, Emonet, Pascal Philippe, Leluc, Catherine, Perrin, Eric, Pohl, Martin, Produit, Nicolas, Rapin, Divic Jean, Ribordy, Mathieu, Richeux, Jean-Pierre, Vite, Davide, Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, L., A, A., A, P., A, E., B, L., B, I, M., B, D., B, F., B, L, G., B, R., B, U., B, P., B, J., B, B., B, A., B, S., B, Boella, G, Boschini, M, J. D., B, W. J., B, X. D., C, C., C, P., C, M., C, G., C, D., C, J., C, H, Y. H., C, H. F., C, H. S., C, Z. G., C, N. A., C, T. H., C, K., C, M. J., C, Y. Y., C, Y. L., C, F., C, V., C, A., C, E., C, J. P., D, T. S., D, C., D, B., D, J. D., D, N., D, L., D, I., D, Z. R., D, P., E, J., E, F. J., E, T., E, G., E, J., F, E., F, P. H., F, G., F, N., F, Galaktionovg, Y, Gervasi, M, P., G, Grandi, D, O., G, W. Q., G, K., H, A., H, R., H, V., H, H., H, M. A., H, W., H, M., I, R., I, M., J, K., K, W., K, G., K, J., K, D. H., K, G. N., K, K. S., K, M. Y., K, A., K, G, R., K, V., K, M., K, G., L, T., L, E., L, A., L, C., L, M. W., L, S. C., L, P., L, C. L., L, H. T., L, I., L, Y. S., L, K., L, D., L, W., L, C., M, A., M, F., M, R. R., M, B., M, M., M, F., P, A., P, H. B., P, W. H., P, M., P, E., P, V., P, N., P, Rancoita, P, D., R, F., R, Z., R, M., R, J. P., R, E., R, J., R, S., R, U., R, C., R, R., S, D., S, G., S, C., S, S., S, A., S, E. S., S, J. W., S, E., S, V., S, T., S, M., S, G. S., S, H., S, X. W., T, Samuel C. C., T, S. M., T, M., T, J., T, J., U, S., U, E., V, J., V, F., V, B., V, I., V, J. P., V, G., V, D., V, H., V, S., W, W., W, B. C., W, J. Z., W, Y. H., W, K., W, C., W, S. X., W, P, P. C., X, J. L., Y, L. G., Y, C. G., Y, J., Y, M., Y, S. W., Y, P., Y, Z. Z., X, H. Y., Z, Z. P., Z, D. X., Z, G. Y., Z, W. Z., Z, H. L., Z, A., Z, B., Z, and P., Z
Subjects: Nuclear and High Energy Physics, FIS/06 - FISICA PER IL SISTEMA TERRA E PER IL MEZZO CIRCUMTERRESTRE, Physics::Instrumentation and Detectors, Astrophysics::High Energy Astrophysical Phenomena, satellite, interaction, Space Shuttle, Cosmic ray, Field of view, Astrophysics, ddc:500.2, 01 natural sciences, pi, High Energy Physics - Experiment, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], FIS/05 - ASTRONOMIA E ASTROFISICA, cosmic rays, primary, 0103 physical sciences, International Space Station, Alpha Magnetic Spectrometer, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], AMS, 010303 astronomy & astrophysics, Instrumentation, Cosmic rays, Physics, 010308 nuclear & particles physics, space shuttle, Space shuttle, Astronomy, Mir, magnetic spectrometer, Cosmic rays, Spallation, AMS, Mir, Space shuttle, spallation, flux, Energy particle, 13.85.Tp, 25.40.Sc, 29.30.Aj, 95.55.Vj, 95.85.Ry, cosmic radiation, muon, ams, 13. Climate action, Muon flux, Spallation, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE, Particle Physics - Experiment
Abstract: The Alpha Magnetic Spectrometer (AMS-02) is a high energy particle physics experiment that will study cosmic rays in the $\sim 100 \mathrm{MeV}$ to $1 \mathrm{TeV}$ range and will be installed on the International Space Station (ISS) for at least 3 years. A first version of AMS-02, AMS-01, flew aboard the space shuttle \emph{Discovery} from June 2 to June 12, 1998, and collected $10^8$ cosmic ray triggers. Part of the \emph{Mir} space station was within the AMS-01 field of view during the four day \emph{Mir} docking phase of this flight. We have reconstructed an image of this part of the \emph{Mir} space station using secondary $\pi^-$ and $\mu^-$ emissions from primary cosmic rays interacting with \emph{Mir}. This is the first time this reconstruction was performed in AMS-01, and it is important for understanding potential backgrounds during the 3 year AMS-02 mission., Comment: To be submitted to NIM B Added material requested by referee. Minor stylistic and grammer changes
Published: 2004

29. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk.

Author: Calvo V, Niazmand E, Carcereny E, Rodriguez-Abreu D, Cobo M, López-Castro R, Guirado M, Camps C, Laura Ortega A, Bernabé R, Massutí B, Garcia-Campelo R, Del Barco E, Luis González-Larriba J, Bosch-Barrera J, Martínez M, Torrente M, Vidal ME, and Provencio M
Subjects: Humans, Female, Male, Middle Aged, Aged, Risk Factors, Adult, Registries, Lung Neoplasms genetics, Lung Neoplasms epidemiology, Lung Neoplasms mortality, Artificial Intelligence, Genetic Predisposition to Disease, Big Data
Abstract: Objectives: Lung Cancer (LC) is a multifactorial disease for which the role of genetic susceptibility has become increasingly relevant. Our aim was to use artificial intelligence (AI) to analyze differences between patients with LC based on family history of cancer (FHC)., Materials and Methods: From August 2016 to June 2020 clinical information was obtained from Thoracic Tumors Registry (TTR), a nationwide database sponsored by the Spanish Lung Cancer Group. In addition to descriptive statistical analysis, an AI-assisted analysis was performed. The German Technical Information Library supported the merging of data from the electronic medical records and database of the TTR. The results of the AI-assisted analysis were reported using Knowledge Graph, Unified Schema and descriptive and predictive analyses., Results: Analyses were performed in two phases: first, conventional statistical analysis including 11,684 patients of those 5,806 had FHC. Median overall survival (OS) for the global population was 23 months (CI 95 %: 21.39-24.61) in patients with FHC versus 21 months (CI 95 %: 19.53-22.48) in patients without FHC (NFHC), p < 0.001. The second AI-assisted analysis included 5,788 patients of those 939 had FHC. 58.48 % of women with FHC had LC. 9.53 % of patients had an EGFR or HER2 mutation or ALK translocation and at least one relative with cancer. A family history of LC was associated with an increased risk of smoking-related LC. Non-smokers with a family history of LC were more likely to have an EGFR mutation in NSCLC. In Bayesian network analysis, 55 % of patients with a family history of LC and never-smokers had an EGFR mutation., Conclusion: In our population, the incidence of LC in patients with a FHC is higher in women and younger patients. FHC is a risk factor and predictor of LC development, especially in people ≤ 50 years. These results were confirmed by conventional statistics and AI-assisted analysis., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Calvo reported receiving personal fees from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Takeda, Pfizer, Sanofi and AMGEN outside the submitted work; being a consultant or advisor and speakerś bureau for Roche, Bristol Myers Squibb/Celgene, Merck Sharp & Dohme, AstraZeneca, Takeda Sanofi and AMGEN and receiving travel, accommodations, and expenses from Takeda, Roche, Bristol Myers Squibb and Merck Sharp & Dohme. Dr. Carcereny reported receiving consulting fees from AstraZeneca, Novartis, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Merck Sharp & Dohme; payment or honoraria from AstraZeneca, Roche, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer and receiving travel, accommodations, and expenses from Roche, Merck Sharp & Dohme, Takeda, Bristol Myers Squibb and Pfizer. Dr. Cobo reported receiving consulting fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Takeda, Pfizer, Kyowa, Sanofi, Jansen; payment or honoraria from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Takeda, Kyowa, Pierre-Fabre, Novocure, Sanofi, Jansen and receiving travel, accommodations, and expenses from AstraZeneca, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Pierre-Fabre and being advisor for Gilead. Dr. López-Castro reported receiving consulting fees from Takeda, Roche, Pfizer, Novartis, Pierre-Fabre, Bristol Myers Squibb; payment or honoraria from Pfizer, Pierre-Fabre, Takeda, Roche, Novartis Jansen and receiving travel, accommodations, and expenses from Roche, Takeda, Novartis and Merck Sharp & Dohme. Dr. Bernabé reported receiving grant from Roche; payment or honoraria from Roche, Merck Sharp & Dohme, Pfizer, AMGEN, Takeda, Astrazeneca and receiving travel, accommodations, and expenses from Roche, Bristol Myers Squibb and being advisor for Takeda, Roche, Bristol Myers Squibb and Astrazeneca. Dr. Garcia-Campelo reported receiving consulting fees from AMGEN, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Roche, Janssen, Lilly, Merck Sharp & Dohme, Pfizer, Sanofi, Takeda, Pfizer; payment or honoraria from AMGEN, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Roche, Janssen, Lilly, Merck Sharp & Dohme, Pfizer, Sanofi, Takeda and receiving travel, accommodations, and expenses from AstraZeneca, Roche, Pfizer and being advisor for AstraZeneca. Dr. del Barco reported receiving travel, accommodations and expenses from Merck Sharp & Dohme. Dr. Bosch-Barrera reported receiving grants from Pfizer and Roche outside the submitted work; payment or honoraria from Astrazeneca, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Sanofi and receiving travel, accommodations, and expenses from Merck Sharp & Dohme, Roche and Takeda. Dr. Provencio reported receiving grants from Bristol Myers Squibb, Takeda, Roche, Pfizer, and Merck Sharp & Dohme outside the submitted work; being a consultant or advisor for Bristol Myers Squibb, Roche, Merck Sharp & Dohme, AstraZeneca, and Takeda; being on the speakers’ bureau for Bristol Myers Squibb, Roche, AstraZeneca, and Merck Sharp & Dohme; receiving research funds from Pierre Fabre, Roche, Boehringer Ingelheim, and Bristol Myers Squibb; and receiving travel, accommodations, and expenses from Roche, Bristol Myers Squibb, and AstraZeneca. The remaining authors declare no conflict of interest., (Copyright © 2024. Published by Elsevier B.V.)
Published: 2024
Full Text: View/download PDF

30. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

Author: Provencio M, Robado de Lope L, Serna-Blasco R, Nadal E, Diz Tain P, Massuti B, González-Larriba JL, Insa A, Sánchez-Hernández A, Casal-Rubio J, García-Campelo R, Sequero López S, Rogado J, Martínez-Martí A, Bosch-Barrera J, Bernabé R, Vázquez Estévez S, Ponce S, de Castro J, Coves Sarto J, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Peña Cabia S, López Martín A, Sala González MÁ, Cobo M, Camps C, Barneto I, Calvo V, Collazo-Lorduy A, Cruz-Bermúdez A, and Romero A
Subjects: Humans, Female, Male, Middle Aged, Aged, Neoplasm Staging, Prognosis, Adult, Prospective Studies, Immunotherapy methods, Biomarkers, Tumor genetics, Aged, 80 and over, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung therapy, Proto-Oncogene Proteins B-raf genetics, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms mortality, Lung Neoplasms therapy, Mutation
Abstract: Background: Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown., Materials and Methods: Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing., Results: The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78-2.85; P < 0.001)., Conclusion: BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M. Provencio declares consulting fees, payment for lectures, presentations or speakers bureaus and support for attending meetings and/or travel from BRISTOL-MYERS SQUIBB, Astra Zeneca, MSD, Roche, Takeda. This author has also declared that he have a pending patent (n° EP 22 382 701.5). R. Serna-Blasco declares to be in possession of a pending patent (n° EP 22 382 701.5). E. Nadal declares Grants or contracts from Roche, Pfizer, Bristol-Myers Squibb and Merck Serono; consulting fees from Roche, Bristol Myers Squibb, Merck Sharp Dohme, Merck-Serono, Sanofi, Pfizer, Lilly, Janssen, AMGEN, Daiichi-Sankyo, Boehringer-Ingelheim, AstraZeneca, Takeda, Sanofi, Pierre Fabre, Qiagen, and Bayer; payment for lectures, presentations or speakers bureaus from Roche, Bristol Myers Squibb, Merck Sharp Dohme, Merck-Serono, Sanofi, Pfizer, Lilly, Janssen, Amgen, Boehringer-Ingelheim, AstraZeneca, Takeda, Sanofi, Pierre Fabre and Qiagen; support for attending meetings and/or travel from Roche, Takeda and Pfizer; and Participation on data safety Monitoring board or advisory board from Roche, Apollomics and MSD. M.P. Diz Taín declares Payment or honoraria for lectures, presentations or speakers bureaus from BRISTOL-MYERS SQUIBB, Astra-Zeneca, Roche, MSD, Takeda, Pfizer and Amgen; support for attending meetings and/or travel from BRISTOL-MYERS SQUIBB, Roche, MSD and Takeda; Participation on a Data Safety Monitoring Board or Advisory Board from BRISTOL-MYERS SQUIBB, Astra-Zeneca, and Boehringer Ingelheim; and other financial or non-financial interests from Astra-Zeneca, Roche, Mirati, and Pfizer. B. Massuti declares consulting fees and support for attending meetings and/or travel from Bristol-Myers Squibb, Takeda, Merck Sharpe and Dohme. J.L. González Larriba declares consulting fees from MSD, Janssen Cilag, Bristol Myers Squibb, Boehringer Ingelheim, and AMGEN; Payment or honoraria for lectures, presentations or speakers bureaus from MSD, Astra Zeneca, Roche, Pfizer, Janssen-Cilag, Novartis, Astella Pharma, and Bristol-Myers Squibb; Support for attending meetings and/or travel from MSD, Takeda, Bristol-Myers Squibb, Roche, Pfizer, and Janssen-Cilag. A. Insa declares Payment or honoraria for lectures, presentations or speakers bureaus from AMGEN, Bristol-Myers Squibb, Roche, and Takeda; Support for attending meetings and/or travel from Roche, Pfizer, and MSD; Participation on a Data Safety Monitoring Board or Advisory Board from Astra Zeneca, Sanofi, and Pfizer. A. Sánchez-Hernández declares Payment or honoraria for lectures, presentations or speakers bureaus from Roche, Lilly, MSD, Sanofi, Astra Zeneca, Janssen, Takeda, Merck, Novartis, Pfizer, and Bristol-Myers Squibb; Support for attending meetings and/or travel from Roche, Sanofi, MSD Takeda, Janssen, Pfizer, and Bristol-Myers Squibb. R. García-Campelo declares Grants or contracts from Bristol-Myers Squibb, Astra Zeneca, and MSC; consulting fees from Roche, Bristol-Myers Squibb, MSD, Sanofi, Takeda, Pfizer, Regeneron, AMGEN, and Astra Zeneca. J. Rogado declares Payment or honoraria for lectures, presentations or speakers bureaus from Roche, Astra Zeneca, MSD, MERCK, Ferrer, Persan Farma, Fresenius Kabi, and Sanofi; Support for attending meetings and/or travel from Roche, MSD, Bristol-Myers Squibb, Astra Zeneca, and Lilly; Participation on a Data Safety Monitoring Board or Advisory Board from Fresenius Kabi, MSD, Sanofi. A. Martínez-Martí declares consulting fees from AstraZeneca/MedImmune, Bristol-Myers Squibb, F. Hoffmann La Roche AG, MSD, and Pfizer; Payment or honoraria for lectures, presentations, speakers bureaus from AstraZeneca/MedImmune, Bristol-Myers Squibb, F. Hoffmann La Roche AG, MSD, MSD, and Pfizer; Payment for expert testimony from AstraZeneca/MedImmune; Support for attending meetings and/or travel from AstraZeneca/MedImmune, Bristol-Myers Squibb, F. Hoffmann La Roche AG, MSD, Pfizer, and Lilly; Participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca/MedImmune, MSD, F. Hoffmann La Roche, Bristol-Myers Squibb. J. Bosch-Barrera declares consulting fees from Sanofi and Roche; Payment or honoraria for lectures, presentations or speakers bureaus from Roche, Bristol-Myers Squibb, Astra Zeneca, and Pfizer; Support for attending meetings and/or travel from Takeda and MSD. R. Bernabé-Caro declares an investigational grant Roche; Payment or honoraria for lectures, presentations, speakers bureaus from Roche, Bristol-Myers Squibb, Pfizer, MSD, Amgen, Takeda, and Astra Zeneca; Participation on a Data Safety Monitoring Board or Advisory Board from Takeda, Roche, Bristol-Myers Squibb, and Astra Zeneca. J. de Castro Carpeño declares consulting from fees Astra Zeneca, Bristol Myers Squibb, Hoffmann- La Roche, MSD, Boehringer Ingelheim, Janssen, Lilly, Sanofi, Takeda, Pfizer, and Glaxo; Payment or honoraria for lectures, presentations, speakers bureaus from Astra Zeneca, Bristol Myers Squibb, Hoffmann- La Roche, MSD, Pfizer, Janssen, Takeda, and Sanofi; Support for attending meetings and/or travel from Astra Zaneca, MSD, and Hoffmann- La Roche; Participation on a Data Safety Monitoring Board or Advisory Board from Astra Zeneca, Bristol Myers Squibb, Hoffmann- La Roche, MSD, Glaxo, Janssen, Gilead, and Sanofi. N. Reguart declares Payment or honoraria for lectures, presentations or speakers bureaus from MSD, Bristol Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, Bayer, Merck, Pfizer, Takeda, Novartis, Astra-Zeneca, Janssen Oncology, Sanofi, Eli Lilly, and Amgen; Support for attending meetings and/or travel from Roche, Takeda, and MSD. M. Dómine declares consulting fees and Payment or honoraria for lectures, presentations or speakers bureaus from Astra Zeneca, Bristol-Myers Squibb, MSD, Pfizer, Roche, and Takeda; Support for attending meetings and/or travel from Astra Zeneca, MSD, Pfizer, and Takeda. M. Majem declares Grants or contracts from Roche and Astra Zeneca; Payment or honoraria for lectures, presentations or speakers bureaus from Roche, Astra Zeneca, MSD, Pfizer, Helsinn, Cassen, AMGEN, Janssen, Sanofi, Pierre Fabre, Bristol-Myers Squibb, and Takeda; Support for attending meetings and/or travel from Astra Zeneca, MSD, and Roche. A. Estival declares Payment or honoraria for lectures, presentations or speakers bureaus from MSD, Pharmamar, Astra Zeneca, Takeda, Roche, and GSK; Support for attending meetings and/or travel from MSD, Boehringer Ingelheim, and Pharmamar; Participation on a Data Safety Monitoring Board or Advisory Board from Roche and MSD. A. López Martín declares Payment or honoraria for lectures, presentations, speakers bureaus from GSK, Bristol-Myers Squibb, and Astra Zeneca; Support for attending meetings and/or travel from Pfizer and Takeda. M. A. Sala González declares Payment or honoraria for lectures, presentations or speakers bureaus from Takeda and Roche; Support for attending meetings and/or travel from Roche and PharmaMar. M. Cobo declares consulting fees from Novartis, Roche, Astra Zeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, MSD, Lilly, Takeda, Pfizer, Kyowa, Sanofi, and Jansen. Payment or honoraria for lectures, presentations or speakers bureaus from Novartis, Astra Zeneca Boehringer-Ingelheim, Bristol-Myers Squibb, Roche, Lilly, MSD, Takeda, Kyowa, Pierre-Fabre, Novocure, Sanofi, and Jansen. I. Barneto declares Payment or honoraria for lectures, presentations or speakers bureaus from Bristol-Myers Squibb, Astra Zeneca, MSD, Takeda, AMGEN, and Novartis; Support for attending meetings and/or travel from MSD and Astra Zeneca; Participation on a Data Safety Monitoring Board or Advisory Board from Sanofi. V. Calvo declares consulting fees from Roche, Astra Zeneca, MSD, Bristol-Myers Squibb, Takeda, Sanofi, and AMGEN; Payment or honoraria for lectures, presentations or speakers bureaus from Roche, Astra Zeneca, MSD, Bristol-Myers Squibb, Takeda, Pfizer, and Janssen; Support for attending meetings and/or travel from Astra Zeneca, Roche, and Takeda. A. Collazo declares Payment or honoraria for lectures, presentations or speakers bureaus from Astra Zeneca and Janssen; Support for attending meetings and/or travel from MSD and Takeda. A. Romero declares consulting fees from Takeda; Payment or honoraria for lectures, presentations or speakers bureaus from Illumina, Health in code, and Thermofisher. Support for attending meetings and/or travel from Thermofisher Scientific. Bristol Myers Squibb Foundation, and Takeda; the author also declares a pending patent (n° EP 22 382 701.5). The rest of the authors declare no potential conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

31. Improvement of non-adherence and reduction of BP values in patients with difficult-to-treat hypertension: the ATHAN clinical trial.

Author: Oliveras A, Vázquez S, Vega MV, Camps C, Illana FJ, Armario P, Crespo M, and de la Sierra A
Abstract: Hypertension treatment and blood pressure (BP) control reduce cardiovascular disease burden. However, prevalence of controlled BP is overall insufficient and lack of adherence to treatment is a suggested major contributor. This prospective, randomized clinical trial was designed to evaluate whether a specific 3-month (m) action plan to improve therapeutic adherence results in a decrease in BP. Patients with ambulatory 24 h-BP ≥ 130/80 mmHg despite receiving ≥2 antihypertensive drugs and with therapeutic non-compliance confirmed by antihypertensive drugs analyzed in urine were randomized (1:1) to receive a specific 3 m program to improve adherence (INT = intervention) or routine follow-up (C = control). Antihypertensive treatment was not modified and knowledge of non-adherence was only notified to patients randomized to the intervention group. Before randomization and at 3 m all patients underwent urinary screening for antihypertensive drugs and 24 h-ambulatory-BP monitoring. Forty-five patients (36% women, mean age: 58 ± 13 yr) were randomized. At 3 m, mean (95% CI) BP differences (INT vs. C) were 12.2 mmHg (4.3-20.8), adjusted-p = 0.032 and 8.7 mmHg (2.5-14.8), adjusted-p = 0.018 for 24 h-systolic and 24 h-diastolic BP, respectively. Differences (INT vs. C) for office SBP and DBP were 18.4 mmHg (6.8-30.1), adjusted-p = 0.005 and 15.7 mmHg (7.2-24.2), adjusted-p < 0.001. Non-detected antihypertensive drugs were median [IQR]: 40% [25-100] and 0% [0-20] at baseline and 3 m, respectively, in the INT group, and 33.3% [25-63.7] and 33.3% [23.8-57.9], in the C group (p < 0.001 for the 3-month between-group comparison). A combined action plan of notifying knowledge of non-adherence plus a 3-month specific nursing intervention to improve therapeutic adherence results in BP reduction in patients with inadequate therapeutic compliance., (© 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension.)
Published: 2024
Full Text: View/download PDF

32. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry.

Author: Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Cantero A, Rodríguez-Abreu D, Estival A, Carcereny E, Hernandez A, López Castro R, Medina A, García Campelo R, Fernández Bruno M, Barnabé R, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, and Provencio M
Abstract: Background: Early detection is crucial to improve lung cancer survival rates. Delays in diagnosis might negatively impact the prognosis of the disease. This study aims to analyze the diagnostic delay in lung cancer patients and describe if there is an association between delay and survival., Methods: The data source used was the Thoracic Tumor Registry of the Spanish Lung Cancer Group. This analysis was restricted to lung cancer cases with information on the first date of consultation by symptoms and date of diagnosis. The delay was calculated as the number of days between the two dates. A descriptive analysis was performed, and ordinal logistic regressions were fitted with delay as the dependent variable. Kaplan-Meier survival analysis and Cox regression were performed., Results: 22,755 lung cancer cases were included. Never smokers were 1.16 (95%CI: 1.06-1.27) times more likely to register longer delay than smokers. Stage 0-I-II cases had a 3.09 (95%CI: 2.88-3.32) higher risk of longer delay compared to III-IV stages. Overall, 5-year survival rate after diagnosis was 23.64% (95%CI: 22.88-24.41). In those categorized as having the shortest delay 5-year survival was 17.67% (95%CI: 16.31-19.07) and in the extreme delay it was 32.98% (95%CI: 31.28-34.69) (p<0.001). Adjusted mortality risk was higher in those with the shortest delay (HR 1.36, CI95%: 1.30-1.43) in comparison with the extreme delay., Conclusions: Diagnostic delay is short among Spanish lung cancer patients, indicating a relatively quick diagnostic process. Extreme delays appear to be associated with higher survival rates, possibly attributed to slow-growing tumors, earlier stage at diagnosis or basically the natural history of this disease., (Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.)
Published: 2024
Full Text: View/download PDF

33. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

Author: Rosell R, Jantus-Lewintre E, Cao P, Cai X, Xing B, Ito M, Gomez-Vazquez JL, Marco-Jordán M, Calabuig-Fariñas S, Cardona AF, Codony-Servat J, Gonzalez J, València-Clua K, Aguilar A, Pedraz-Valdunciel C, Dantes Z, Jain A, Chandan S, Molina-Vila MA, Arrieta O, Ferrero M, Camps C, and González-Cao M
Subjects: Humans, Cell Line, Tumor, Animals, Mice, Pyridines pharmacology, Pyridines therapeutic use, Pyrimidines pharmacology, Pyrimidines therapeutic use, Xenograft Model Antitumor Assays, Mice, Nude, Pyrimidinones pharmacology, Pyrimidinones therapeutic use, Female, Triazines pharmacology, Triazines therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, Piperazines, Piperidines, Pyridazines, Pyridones, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins c-met genetics, Proto-Oncogene Proteins c-met metabolism, Proto-Oncogene Proteins c-met antagonists & inhibitors, Mutation, Omeprazole pharmacology, Omeprazole therapeutic use
Abstract: Background: KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate receptor of hepatocyte growth factor (HGF), was reported to be overexpressed in KRAS-mutant lung cancer cells leading to tumor-growth in anchorage-independent conditions., Methods: Cell viability assay and synergy analysis were carried out in native, sotorasib and trametinib-resistant KRAS-mutant NSCLC cell lines. Colony formation assays and Western blot analysis were also performed. RNA isolation from tumors of KRAS-mutant NSCLC patients was performed and KRAS and MET mRNA expression was determined by real-time RT-qPCR. In vivo studies were conducted in NSCLC (NCI-H358) cell-derived tumor xenograft model., Results: Our research has shown promising activity of omeprazole, a V-ATPase-driven proton pump inhibitor with potential anti-cancer properties, in combination with the MET inhibitor tepotinib in KRAS-mutant G12C and non-G12C NSCLC cell lines, as well as in G12C inhibitor (AMG510, sotorasib) and MEK inhibitor (trametinib)-resistant cell lines. Moreover, in a xenograft mouse model, combination of omeprazole plus tepotinib caused tumor growth regression. We observed that the combination of these two drugs downregulates phosphorylation of the glycolytic enzyme enolase 1 (ENO1) and the low-density lipoprotein receptor-related protein (LRP) 5/6 in the H358 KRAS G12C cell line, but not in the H358 sotorasib resistant, indicating that the effect of the combination could be independent of ENO1. In addition, we examined the probability of recurrence-free survival and overall survival in 40 early lung adenocarcinoma patients with KRAS G12C mutation stratified by KRAS and MET mRNA levels. Significant differences were observed in recurrence-free survival according to high levels of KRAS mRNA expression. Hazard ratio (HR) of recurrence-free survival was 7.291 (p = 0.014) for high levels of KRAS mRNA expression and 3.742 (p = 0.052) for high MET mRNA expression., Conclusions: We posit that the combination of the V-ATPase inhibitor omeprazole plus tepotinib warrants further assessment in KRAS-mutant G12C and non G12C cell lines, including those resistant to the covalent KRAS G12C inhibitors., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

34. The impact of inversions across 33,924 families with rare disease from a national genome sequencing project.

Author: Pagnamenta AT, Yu J, Walker S, Noble AJ, Lord J, Dutta P, Hashim M, Camps C, Green H, Devaiah S, Nashef L, Parr J, Fratter C, Ibnouf Hussein R, Lindsay SJ, Lalloo F, Banos-Pinero B, Evans D, Mallin L, Waite A, Evans J, Newman A, Allen Z, Perez-Becerril C, Ryan G, Hart R, Taylor J, Bedenham T, Clement E, Blair E, Hay E, Forzano F, Higgs J, Canham N, Majumdar A, McEntagart M, Lahiri N, Stewart H, Smithson S, Calpena E, Jackson A, Banka S, Titheradge H, McGowan R, Rankin J, Shaw-Smith C, Evans DG, Burghel GJ, Smith MJ, Anderson E, Madhu R, Firth H, Ellard S, Brennan P, Anderson C, Taupin D, Rogers MT, Cook JA, Durkie M, East JE, Fowler D, Wilson L, Igbokwe R, Gardham A, Tomlinson I, Baralle D, Uhlig HH, and Taylor JC
Subjects: Humans, Male, Female, Pedigree, Genome, Human, Whole Genome Sequencing, Methyl-CpG-Binding Protein 2 genetics, Mutation, Homeodomain Proteins genetics, Middle Aged, Rare Diseases genetics, Chromosome Inversion genetics
Abstract: Detection of structural variants (SVs) is currently biased toward those that alter copy number. The relative contribution of inversions toward genetic disease is unclear. In this study, we analyzed genome sequencing data for 33,924 families with rare disease from the 100,000 Genomes Project. From a database hosting >500 million SVs, we focused on 351 genes where haploinsufficiency is a confirmed disease mechanism and identified 47 ultra-rare rearrangements that included an inversion (24 bp to 36.4 Mb, 20/47 de novo). Validation utilized a number of orthogonal approaches, including retrospective exome analysis. RNA-seq data supported the respective diagnoses for six participants. Phenotypic blending was apparent in four probands. Diagnostic odysseys were a common theme (>50 years for one individual), and targeted analysis for the specific gene had already been performed for 30% of these individuals but with no findings. We provide formal confirmation of a European founder origin for an intragenic MSH2 inversion. For two individuals with complex SVs involving the MECP2 mutational hotspot, ambiguous SV structures were resolved using long-read sequencing, influencing clinical interpretation. A de novo inversion of HOXD11-13 was uncovered in a family with Kantaputra-type mesomelic dysplasia. Lastly, a complex translocation disrupting APC and involving nine rearranged segments confirmed a clinical diagnosis for three family members and resolved a conundrum for a sibling with a single polyp. Overall, inversions play a small but notable role in rare disease, likely explaining the etiology in around 1/750 families across heterogeneous clinical cohorts., Competing Interests: Declaration of interests H.H.U. declares research support or consultancy fees from Janssen, UCB Pharma, GSK, Eli Lilly, Bristol Myers Squibb BMS, OMass and Mestag. J.Y. is now employed by Novo Nordisk., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

35. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma.

Author: Patiño-García A, Guruceaga E, Andueza MP, Ocón M, Fodop Sokoudjou JJ, de Villalonga Zornoza N, Alkorta-Aranburu G, Uria IT, Gurpide A, Camps C, Jantus-Lewintre E, Navamuel-Andueza M, Sanmamed MF, Melero I, Elgendy M, Fusco JP, Zulueta JJ, de-Torres JP, Bastarrika G, Seijo L, Pio R, Montuenga LM, Hernáez M, Ochoa I, and Perez-Gracia JL
Subjects: Humans, Middle Aged, Aged, Exome Sequencing, Genetic Predisposition to Disease, Phenotype, Germ Cells pathology, Adenocarcinoma of Lung genetics, Lung Neoplasms genetics, Lung Neoplasms pathology
Abstract: Background: Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in the individual susceptibility to the carcinogenic effects of tobacco. We characterized the germline profile of subjects presenting these extreme phenotypes with Whole Exome Sequencing (WES) and Machine Learning (ML)., Methods: We sequenced germline DNA from heavy smokers who either developed lung adenocarcinoma at an early age (extreme cases) or who did not develop lung cancer at an advanced age (extreme controls), selected from databases including over 6600 subjects. We selected individual coding genetic variants and variant-rich genes showing a significantly different distribution between extreme cases and controls. We validated the results from our discovery cohort, in which we analysed by WES extreme cases and controls presenting similar phenotypes. We developed ML models using both cohorts., Findings: Mean age for extreme cases and controls was 50.7 and 79.1 years respectively, and mean tobacco consumption was 34.6 and 62.3 pack-years. We validated 16 individual variants and 33 variant-rich genes. The gene harbouring the most validated variants was HLA-A in extreme controls (4 variants in the discovery cohort, p = 3.46E-07; and 4 in the validation cohort, p = 1.67E-06). We trained ML models using as input the 16 individual variants in the discovery cohort and tested them on the validation cohort, obtaining an accuracy of 76.5% and an AUC-ROC of 83.6%. Functions of validated genes included candidate oncogenes, tumour-suppressors, DNA repair, HLA-mediated antigen presentation and regulation of proliferation, apoptosis, inflammation and immune response., Interpretation: Individuals presenting extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma show different germline profiles. Our strategy may allow the identification of high-risk subjects and the development of new therapeutic approaches., Funding: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript., Competing Interests: Declaration of interests MFS reports grants from Bristol Myers Squibb and Roche, as well as honoraria from lectures and advisory from MSD, BMS and Numab; and travel support from Roche, Astra-Zeneca and BMS. IM reports receiving commercial research grants from AstraZeneca, BMS, Highlight Therapeutics, Alligator, Pfizer Genmab and Roche; has received speakers bureau honoraria from MSD; and is a consultant or advisory board member for BMS, Roche, AstraZeneca, Genmab, Pharmamar, F-Star, Bioncotech, Bayer, Numab, Pieris, Gossamer, Alligator and Merck Serono. JJZ declares consultancy and advisory Board from American Heart Technologies and Median Technologies. GB declares honoraria from lectures and advisory from General Electric, Siemens Healthineers; educational activities for General Electric, Siemens Healthineers, Bayer; and institutional research grants from Siemens Healthineers, Guerbet. LMS reports a role as scientific advisor for Sabartech, Serum, Astra Zeneca, Roche, MSD, and Median technologies, and has received honoraria as a speaker from Astra Zeneca, GSK, Roche, Menarini, and Chiesi. LMM declares research grants from Astra-Zeneca, BMS, Serum Detect Inc. and Pharmamar; speaker fee from Astra Zeneca; participation in advisory boards from Serum Detect Inc; and has a Licenced patent co-holder from AMADIX. JLPG declares research grants and support from Astellas, Amgen, BMS, MSD, Novartis, Roche, Seattle Genetics; participates in advisory boards for Astellas, BMS, Ipsen, MSD, Roche, Seattle Genetics; and travel support from BMS, MSD, Roche., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

36. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.

Author: Provencio M, Cobo M, Rodriguez-Abreu D, Carcereny E, Cantero A, Calvo V, López Castro R, Bernabé R, Bosch-Barrera J, Massutí B, García Campelo R, Sánchez-Hernández A, Laura Ortega A, Guirado M, Del Barco E, Camps C, Casal-Rubio J, Dómine M, Angeles Sala M, Padilla A, Luís González Larriba J, and de Asís Aparisi F
Subjects: Aged, Humans, Male, Female, Aged, 80 and over, Prospective Studies, Registries, Biomarkers, Data Analysis, Lung Neoplasms epidemiology, Lung Neoplasms therapy, Thoracic Neoplasms epidemiology
Abstract: Objectives: Cancer is a disease of old age; however, most studies usually included minority of patients fit elderly. The purpose is to investigate the clinical characteristics and genetic information of patients with thoracic tumors who are 80 years old or older compared to those under 80 years old., Study Design and Methods: The Thoracic Tumor Registry (TTR) is a Spanish observational, prospective cohort study that included patients diagnosed with thoracic tumors. Data were collected from medical records related to sociodemographic, epidemiological, clinical, molecular/genetic, and treatment outcome variables., Results: The total number of patients, recruited from August 2016 to April 2023, was 26.193 (93,1 % were younger than 80 years and 6,9 % were 80 years or older). In the group of older patients: the male ratio increased (72,9 % vs. 80 %); the number of elderly people who had never smoked or were ex-smokers increased (9,9 % vs. 21,1 % and 44,8 % vs. 61,3 %, respectively) and the number of current smokers decreased (43,3 % vs. 17,5 %); had higher ECOG performance status at diagnosis (for ECOG ≥ 2, 15 % vs. 32,9 %), and there were more patients with previous cancer (17,3 % vs. 28 %). The proportion of men is higher than that of women (73 % vs. 27 % in <80 years and 80 % vs. 20 % in ≥80 years). For all biomarkers, the proportion of patients who had a molecular determination was lower in older patients. There were no differences in terms of alterations in the biomarkers tested; except for EGFR, for which the positivity rate was higher in patients aged 80 years and older (25 % vs. 15,3 %)., Conclusion: The proportion of older patients with targeted mutations is higher. So, at least at diagnosis, it should be proceeded in a standard way. Then, when it comes to treatment, comorbidities and patient's baseline situation should be considered., Clinical Trial Registration: NCT02941458., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

37. Difficulties on the access to innovative targeted therapies for lung cancer in Spain.

Author: Calvo V, Camps C, Carcereny E, Cobo M, Dómine M, García Campelo MR, González Larriba JL, Guirado M, Hernando-Trancho F, Massutí B, Nadal E, Rodríguez-Abreu D, Sánchez A, Sullivan IG, and Provencio M
Subjects: Humans, Protein-Tyrosine Kinases genetics, Spain, Proto-Oncogene Proteins genetics, Mutation, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics
Abstract: Purpose: Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain., Methods: Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments., Results: More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System., Conclusion: SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries., (© 2023. The Author(s).)
Published: 2024
Full Text: View/download PDF

38. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.

Author: Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, Estival A, Carcereny E, Cucurull M, López Castro R, Medina A, García Campelo R, Cordeiro González P, Sánchez-Gastaldo A, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, Sánchez-Hernández A, Guirado Risueño M, Del Barco Morillo E, Garrido Fernández A, and Provencio M
Subjects: Humans, Female, Middle Aged, Male, Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases genetics, Anaplastic Lymphoma Kinase genetics, ErbB Receptors genetics, Proto-Oncogene Proteins genetics, Mutation, Lung Neoplasms epidemiology, Lung Neoplasms genetics, Lung Neoplasms diagnosis
Abstract: Introduction: The aim of this study was to analyze the clinical and genetic characteristics of young lung cancer cases, and to compare them with those of older cases., Methods: We used the Thoracic Tumors Registry (TTR) as a data source representative of lung cancer cases diagnosed in Spain, and included all cases registered until 9/01/2023 which had information on age at diagnosis or the data needed to calculate it. We performed a descriptive statistical analysis and fitted logistic regressions to analyze how different characteristics influenced being a younger lung cancer patient., Results: A total of 26,336 subjects were included. Lung cancer cases <50 years old had a higher probability of being women (OR: 1.38; 95% CI: 1.21-1.57), being in stage III or IV (OR: 1.32; 95% CI: 1.08-1.62), not having comorbidities (OR: 5.21; 95% CI: 4.59-5.91), presenting with symptoms at diagnosis (OR: 1.53; 95% CI: 1.29-1.81), and having ALK translocation (OR: 7.61; 95% CI: 1.25-46.32) and HER2 mutation (OR: 5.71; 95% CI: 1.34-24.33), compared with subjects ≥50 years. Among subjects <35 years old (n=61), our study observed a higher proportion of women (59.0% vs. 26.6%; p<0.001), never smokers (45.8% vs. 10.3%; p<0.001), no comorbidities (21.3% vs. 74.0%; p<0.001); ALK translocation (33.3% vs. 4.4%; p<0.001) and ROS1 mutation (14.3% vs. 2.3%; p=0.01), compared with subjects ≥35 years., Conclusions: Lung cancer displays differences by age at diagnosis which may have important implications for its clinical management., (Copyright © 2023 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.)
Published: 2024
Full Text: View/download PDF

39. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.

Author: Postel-Vinay S, Coves J, Texier M, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, and Rosell R
Subjects: Humans, Double-Blind Method, Maintenance Chemotherapy, Phthalazines adverse effects, Piperazines adverse effects, Poly(ADP-ribose) Polymerase Inhibitors adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms pathology
Abstract: Background: Platinum-sensitivity is a phenotypic biomarker of Poly (ADP-ribose) polymerase inhibitors (PARPi) sensitivity in histotypes where PARPi are approved. Approximately one-third of non-small cell lung cancers (NSCLC) are platinum-sensitive. The double-blind, randomized phase II PIPSeN (NCT02679963) study evaluated olaparib, a PARPi, as maintenance therapy for patients with platinum-sensitive advanced NSCLC., Methods: Chemonaïve patients with ECOG performance status of 0-1, platinum-sensitive, EGFR- and ALK-wild-type, stage IIIB-IV NSCLC were randomized (R) to receive either olaparib (O) maintenance or a placebo (P). The primary objective was progression-free survival (PFS) from R. Secondary objectives included overall survival (OS) and safety. With an anticipated hazard ratio of 0.65, 144 patients were required to be randomized, and approximately 500 patients enrolled., Results: The trial was prematurely terminated because anti-PD(L)1 therapy was approved during the trial recruitment. A total of 182 patients were enrolled, with 60 patients randomized: 33 and 27 in the O and P arms, respectively. Patient and tumor characteristics were well-balanced between arms, except for alcohol intake (33% vs 11% in the O and P arms, respectively, p = 0.043). The median PFS was 2.9 and 2.0 months in the O and P arms, respectively (logrank p = 0.99). The median OS was 9.4 and 9.5 months in the O and P arms, respectively (p = 0.28). Grade ≥3 toxicities occurred in 15 and 8 patients in O and P arms, with no new safety concerns., Conclusion: PIPSeN was terminated early after enrollment of only 50% of the pre-planned population, thus being statistically underpowered. Olaparib maintenance did neither improve median PFS nor OS in this patient population., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Published: 2024
Full Text: View/download PDF

40. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma.

Author: Torres-Martínez S, Calabuig-Fariñas S, Moreno-Manuel A, Bertolini G, Herreros-Pomares A, Escorihuela E, Duréndez-Saéz E, Guijarro R, Blasco A, Roz L, Camps C, and Jantus-Lewintre E
Subjects: Humans, Galectin 3, Prognosis, Biomarkers, Tumor Microenvironment, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms metabolism, Adenocarcinoma of Lung pathology, Carcinoma, Squamous Cell pathology
Abstract: Despite the success of therapies in lung cancer, more studies of new biomarkers for patient selection are urgently needed. The present study aims to analyze the role of galectin-3 (GAL-3) in the lung tumor microenvironment (TME) using tumorspheres as a model and explore its potential role as a predictive and prognostic biomarker in non-small cell lung cancer patients. For in vitro studies, lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) primary cultures from early-stage patients and commercial cell lines were cultured, using tumorsphere-forming assays and adherent conditions for the control counterparts. We analyzed the pattern of secretion and expression of GAL-3 using reverse transcription-quantitative real-time PCR (RTqPCR), immunoblot, immunofluorescence, flow cytometry, and immunoassay analysis. Our results using three-dimensional (3D) models of lung tumor cells revealed that soluble GAL-3 (sGAL-3) is highly expressed and secreted. To more accurately mimic the TME, a co-culture of tumorspheres and fibroblasts was used, revealing that GAL-3 could be important as an immunomodulatory molecule expressed and secreted in the TME, modulating immunosuppression through regulatory T cells (T REGS ). In the translational phase, we confirmed that patients with high expression levels of GAL-3 had more T REGS , which suggests that tumors may be recruiting this population through GAL-3. Next, we evaluated levels of sGAL-3 before surgery in LUAD and LUSC patients, hypothesizing that sGAL-3 could be used as an independent prognostic biomarker for overall survival and relapse-free survival in early-stage LUAD patients. Additionally, levels of sGAL-3 at pretreatment and first response assessment from plasma to predict clinical outcomes in advanced LUAD and LUSC patients treated with first-line pembrolizumab were evaluated, further supporting that sGAL-3 has a high efficiency in predicting durable clinical response to pembrolizumab with an area under curve of 0.801 (P = 0.011). Moreover, high levels might predict decreased progression-free survival and OS to anti-PD-1 therapy, with sGAL-3 being a prognosis-independent biomarker for advanced LUAD., (© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Published: 2024
Full Text: View/download PDF

41. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer.

Author: Torres-Martínez S, Calabuig-Fariñas S, Gallach S, Mosqueda M, Munera-Maravilla E, Sirera R, Navarro L, Blasco A, Camps C, and Jantus-Lewintre E
Subjects: Humans, Immunotherapy, Biopsy, Biomarkers, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms diagnosis, Lung Neoplasms drug therapy
Abstract: Immunotherapy has been proven a viable treatment option for non-small cell lung cancer (NSCLC) treatment in patients. However, some patients still do not benefit. Finding new predictive biomarkers for immunocheckpoint inhibitor (ICI) response will improve treatment management in the clinical routine. In this regard, liquid biopsy is a useful and noninvasive alternative to surgical biopsies. In the present study, we evaluated the potential diagnostic, prognostic, and predictive value of seven different soluble mediators involved in immunoregulation. Fifty-two plasma samples from advanced NSCLC treated in first-line with pembrolizumab at baseline (PRE) and at first response assessment (FR) were analyzed. In terms of diagnostic value, our results revealed that sFGL1, sGAL-3, and sGAL-1 allowed for optimal diagnostic efficacy for cancer patients. Additionally, the combination of sFGL1 and sGAL-3 significantly improved diagnostic accuracy. Regarding the predictive value to assess patients' immune response, sCD276 levels at PRE were significantly higher in patients without tumor response ( p = 0.035). Moreover, we observed that high levels of sMICB at PRE were associated with absence of clinical benefit (pembrolizumab treatment less than 6 months) ( p = 0.049), and high levels of sMICB and sGAL-3 at FR are also related to a lack of clinical benefit ( p = 0.027 and p = 0.03, respectively). Finally, in relation to prognosis significance, at PRE and FR, sMICB levels above the 75th percentile are related to poor progression-free survival (PFS) ( p = 0.013 and p = 0.023, respectively) and overall survival (OS) ( p = 0.001 and p = 0.011, respectively). An increase in sGAL3 levels at FR was associated with worse PFS ( p = 0.037). Interestingly, high sGAL-3 at PRE was independently associated with PFS and OS with a hazard ratio (HR) of 2.45 (95% CI 1.14-5.25; p = 0.021) and 4.915 (95% CI 1.89-12.73; p = 0.001). In conclusion, plasma levels of sFGL1, sGAL-3, and sGAL-1 could serve as diagnostic indicators and sMICB, sCD276, and sGAL3 were linked to outcomes, suggesting their potential in assessing NSCLC under pembrolizumab treatment. Our results highlight the value of employing soluble immune biomarkers in advanced lung cancer patients treated with pembrolizumab at first-line.
Published: 2023
Full Text: View/download PDF

42. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study.

Author: Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Carcereny E, Cucurull M, López Castro R, Solís García E, Sánchez-Gastaldo A, Massutí B, Rodríguez-Abreu D, Estival A, Guirado Risueño M, Pamiés Ramón M, García Campelo R, Alonso-Jáudenes G, Camps C, Del Barco Morillo E, González Ojea C, Dómine M, Sanchez-Hernandez A, Bosch-Barrera J, Sala González MÁ, and Provencio M
Abstract: Objectives: The aim of the study was to ascertain the percentage of Spanish lung cancer cases that would fulfil the lung cancer screening inclusion criteria recommended by the United States Preventive Service Task Force (USPSTF) in 2013 and 2021., Methods: A cross-sectional study was carried out. All lung cancer cases registered in the Thoracic Tumor Registry with data on date of birth, date of diagnosis, smoking habit, number of pack-years and time elapsed since smoking cessation were included., Results: The study included 15 006 patients diagnosed with lung cancer in Spain between 2016 and 2022. Eligibility to participate in screening increased from 53.7% to 63.5% (an increase of 9.8%) according to the 2013 and 2021 recommendations, respectively. The percentage of eligible men rose by 9.2 percentage points with the 2021 versus 2013 recommendations, whereas this rise was 11.5 percentage points in women. Under the 2021 recommendations, 36.6% of women and 5.3% of men would not have fulfilled the screening inclusion criteria due to being never-smokers; 14.9% of women and 11.0% of men would not have fulfilled the age criterion; and 27.0% of ex-smokers among women compared to 35.6% among men would not have been eligible due to >15 years having elapsed since smoking cessation., Conclusions: In Spain, over one-third of lung cancer cases could not be detected through screening, by virtue of not meeting the most recent inclusion criteria stated by the USPSTF. The degree of fulfilment in a potential nationwide screening programme should be analysed, with the aim of establishing inclusion criteria in line with each country's context., Competing Interests: Conflict of interest: A. Ruano-Ravina is an associate editor of this journal. The remaining authors declare no conflicts of interest regarding the publication of this article., (Copyright ©The authors 2023.)
Published: 2023
Full Text: View/download PDF

43. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.

Author: Aparicio I, Iranzo P, Reyes R, Bote H, Saigi M, Bringas M, Bosch-Barrera J, Corral J, Aparisi F, Ruffinelli JC, Jiménez B, Lage Y, López-Castro R, Majem M, Vázquez S, Artal Á, Rodríguez-Pérez Á, Lázaro-Quintela M, Torres JMS, Reguart N, Cucurull M, Gil-Bazo I, Camps C, Nadal E, Del Barrio A, Garrido P, Dómine M, Álvarez R, Muñoz AJ, and Calles A
Subjects: Humans, Antineoplastic Combined Chemotherapy Protocols adverse effects, Incidence, Mutation, Proto-Oncogene Proteins B-raf genetics, Retrospective Studies, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms epidemiology, Lung Neoplasms genetics, Lung Neoplasms drug therapy, Thromboembolism etiology, Thromboembolism genetics
Abstract: Introduction: We aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected., Methods: Between 2008 and 2021, 182 patients with BRAF-mutant advanced NSCLC (BRAF V600E, n = 70; BRAF non-V600E, n = 112) were retrospectively identified from 18 centers in Spain. Patients received chemotherapy (n = 147), immunotherapy (n = 69), targeted therapy (n = 42), and immunotherapy + chemotherapy (n = 26)., Results: Incidence rate of TEE was 26.4 % (95%CI: 19.9 %-32.9 %). A total of 72 TEE were documented among 48 patients, as 18 patients (37.5 %) developed more than one event. Median time to TEE onset was 2 months, 69 % of TEE occurred in the peridiagnostic period (+/- 90 days from cancer diagnosis), and in 16 pts. (33 %) TEE was the form of lung cancer presentation. Although most TEE were only venous (82 %; PE, n = 33; DVT, n = 16), arterial events were reported in 31 % and occurred earlier, or TEE presented in atypical locations (13.9 %). TEE were related to high hospitalization rate (59 %), recurrence (23 %), and mortality (10.4 %) despite appropriate anticoagulant/antiaggregant treatment. Median OS in patients without-TEE was 19.4 months (95%CI: 4.6-34.1), and significantly shorter in patients with arterial-TEE vs venous-TEE vs both of them: 9.9 months (95%CI: 0-23.5) vs 41.7 months (95%CI: 11.3-72.2 m) vs 2.7 months (95%CI: 2.1-3.3), p = 0.001. Neither clinical or molecular features (BRAF V600E/non-V600E), nor cancer treatment was associated to TEE occurrence. Khorana score underperformed to predict thrombosis at cancer diagnosis, as only 19.2 % of patients were classified as high-risk., Conclusions: Thrombotic events represent a new clinical feature of BRAF-mutant lung cancer. Patients with almost a 30 % incidence of TEE should be offered systematic anticoagulation., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:, (Copyright © 2023. Published by Elsevier Ltd.)
Published: 2023
Full Text: View/download PDF

44. Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.

Author: Pagnamenta AT, Camps C, Giacopuzzi E, Taylor JM, Hashim M, Calpena E, Kaisaki PJ, Hashimoto A, Yu J, Sanders E, Schwessinger R, Hughes JR, Lunter G, Dreau H, Ferla M, Lange L, Kesim Y, Ragoussis V, Vavoulis DV, Allroggen H, Ansorge O, Babbs C, Banka S, Baños-Piñero B, Beeson D, Ben-Ami T, Bennett DL, Bento C, Blair E, Brasch-Andersen C, Bull KR, Cario H, Cilliers D, Conti V, Davies EG, Dhalla F, Dacal BD, Dong Y, Dunford JE, Guerrini R, Harris AL, Hartley J, Hollander G, Javaid K, Kane M, Kelly D, Kelly D, Knight SJL, Kreins AY, Kvikstad EM, Langman CB, Lester T, Lines KE, Lord SR, Lu X, Mansour S, Manzur A, Maroofian R, Marsden B, Mason J, McGowan SJ, Mei D, Mlcochova H, Murakami Y, Németh AH, Okoli S, Ormondroyd E, Ousager LB, Palace J, Patel SY, Pentony MM, Pugh C, Rad A, Ramesh A, Riva SG, Roberts I, Roy N, Salminen O, Schilling KD, Scott C, Sen A, Smith C, Stevenson M, Thakker RV, Twigg SRF, Uhlig HH, van Wijk R, Vona B, Wall S, Wang J, Watkins H, Zak J, Schuh AH, Kini U, Wilkie AOM, Popitsch N, and Taylor JC
Subjects: Humans, Whole Genome Sequencing, Genetic Testing, Mutation, Cell Cycle Proteins, Genetic Variation, Rare Diseases diagnosis, Rare Diseases genetics
Abstract: Background: Whole genome sequencing is increasingly being used for the diagnosis of patients with rare diseases. However, the diagnostic yields of many studies, particularly those conducted in a healthcare setting, are often disappointingly low, at 25-30%. This is in part because although entire genomes are sequenced, analysis is often confined to in silico gene panels or coding regions of the genome., Methods: We undertook WGS on a cohort of 122 unrelated rare disease patients and their relatives (300 genomes) who had been pre-screened by gene panels or arrays. Patients were recruited from a broad spectrum of clinical specialties. We applied a bioinformatics pipeline that would allow comprehensive analysis of all variant types. We combined established bioinformatics tools for phenotypic and genomic analysis with our novel algorithms (SVRare, ALTSPLICE and GREEN-DB) to detect and annotate structural, splice site and non-coding variants., Results: Our diagnostic yield was 43/122 cases (35%), although 47/122 cases (39%) were considered solved when considering novel candidate genes with supporting functional data into account. Structural, splice site and deep intronic variants contributed to 20/47 (43%) of our solved cases. Five genes that are novel, or were novel at the time of discovery, were identified, whilst a further three genes are putative novel disease genes with evidence of causality. We identified variants of uncertain significance in a further fourteen candidate genes. The phenotypic spectrum associated with RMND1 was expanded to include polymicrogyria. Two patients with secondary findings in FBN1 and KCNQ1 were confirmed to have previously unidentified Marfan and long QT syndromes, respectively, and were referred for further clinical interventions. Clinical diagnoses were changed in six patients and treatment adjustments made for eight individuals, which for five patients was considered life-saving., Conclusions: Genome sequencing is increasingly being considered as a first-line genetic test in routine clinical settings and can make a substantial contribution to rapidly identifying a causal aetiology for many patients, shortening their diagnostic odyssey. We have demonstrated that structural, splice site and intronic variants make a significant contribution to diagnostic yield and that comprehensive analysis of the entire genome is essential to maximise the value of clinical genome sequencing., (© 2023. Crown.)
Published: 2023
Full Text: View/download PDF

45. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.

Author: Provencio M, Carcereny E, López Castro R, Calvo V, Rodríguez Abreu D, Cobo M, Ortega AL, Bernabé R, Guirado M, Massutí B, Del Barco-Morillo E, Bosch-Barrera J, Camps C, Carroll R, Rault C, Chaib C, Penrod J, Vo L, Ralphs E, and Daumont MJ
Abstract: Background: The burden of non-small cell lung cancer (NSCLC) remains high in Spain, with lung cancer accounting for 20% of cancer-related deaths annually. Programs such as the Spanish Thoracic Tumour Registry (TTR) and the global I-O Optimise initiative have been developed to observe patients in clinical practice with the aim of improving outcomes. This analysis examined treatment patterns and survival in patients with stage III NSCLC from the TTR. These patients represent a heterogenous group with complex treatment pathways., Methods: The TTR is an ongoing, observational, prospective, and retrospective cohort multicentre study (NCT02941458) that follows patients with thoracic cancer in Spain. Adults aged ≥18 years with stage IIIA/IIIB NSCLC enrolled in the TTR between 01 Jan 2010 and 31 Oct 2019 were included in this analysis. Initial treatment received was described by cancer stage and histology (squamous and non-squamous NSCLC). Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were calculated over a 5-year period., Results: A total of 1,838 patients were included in the cohort, including 1,082 with stage IIIA (58.9%) and 756 with stage IIIB (41.1%). Median follow-up was 18.3 months. The median age of patients was 66 years, and most had non-squamous NSCLC (54.0%), were male (81.2%), and were active or former smokers (93.4%). Overall, 26.3% of patients received surgical resection (37.0% for stage IIIA and 11.1% for stage IIIB). The most frequent initial treatment received was concurrent chemoradiotherapy for stage IIIA (30.2%) and stage IIIB (37.0%) patients. Median OS was lower in patients with stage IIIB than stage IIIA (28 vs. 37 months) disease and was lower for patients with squamous than non-squamous histology (19 vs. 26 months). Median PFS and OS varied when patients were stratified by initial treatment., Conclusions: This TTR analysis describes the clinical reality surrounding the initial management and survival outcomes for stage III NSCLC in Spain and presents survival outcomes comparable with other real-world evidence. It provides insights into the diverse approaches used before the availability of immunotherapies and targeted treatments in the non-metastatic NSCLC setting., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-176/coif). MP served as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. All authors report that this work was supported by Bristol Myers Squibb. MP reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events and support for attending meetings and/or travel from AstraZeneca, Bristol Myers Squibb, Janssen, MSD, Pfizer, Roche and Takeda. RLC reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Aristo, AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Pierre-Fabre, Roche and Takeda; and support for attending meetings and/or travel from Novartis, Roche and Takeda. VC reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Pfizer, Roche and Takeda. DRA reports consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Novartis and Roche. DRA also reports support for attending meetings and/or travel from MSD, Novartis and Roche. BM reports consulting fees from AstraZeneca, Roche and Sanofi. BM also reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, MSD, Roche and Takeda; and support for attending meetings and/or travel from AstraZeneca and MSD. JBB reports institutionally awarded grants and personal fees from Pfizer and Roche. JBB also reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Roche and Sanofi; and support for attending meetings and/or travel from MSD, Roche and Takeda. ER is an employee of IQVIA. RC, Carlos Chaib, JP, LV and MJD are employees of Bristol Myers Squibb, the study sponsor. Carlos Chaib, JP and LV also report stock ownership in Bristol Myers Squibb. The authors have no other conflicts of interest to declare., (2023 Translational Lung Cancer Research. All rights reserved.)
Published: 2023
Full Text: View/download PDF

46. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Author: Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, and Romero A
Subjects: Humans, Neoplasm Recurrence, Local drug therapy, Neoplasm Staging, Survival Analysis, Combined Modality Therapy, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms drug therapy, Lung Neoplasms surgery, Nivolumab administration & dosage, Nivolumab adverse effects, Nivolumab therapeutic use, Platinum Compounds administration & dosage, Platinum Compounds adverse effects, Platinum Compounds therapeutic use
Abstract: Background: Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients., Methods: In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety., Results: A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan-Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan-Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%)., Conclusions: In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone. (Funded by Bristol Myers Squibb and others; NADIM II ClinicalTrials.gov number, NCT03838159; EudraCT number, 2018-004515-45.)., (Copyright © 2023 Massachusetts Medical Society.)
Published: 2023
Full Text: View/download PDF

47. Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.

Author: Janik A, Torrente M, Costabello L, Calvo V, Walsh B, Camps C, Mohamed SK, Ortega AL, Nováček V, Massutí B, Minervini P, Campelo MRG, Del Barco E, Bosch-Barrera J, Menasalvas E, Timilsina M, and Provencio M
Subjects: Humans, Male, Female, Aged, Neoplasm Recurrence, Local diagnosis, Machine Learning, Prognosis, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms diagnosis, Lung Neoplasms therapy
Abstract: Purpose: Stratifying patients with cancer according to risk of relapse can personalize their care. In this work, we provide an answer to the following research question: How to use machine learning to estimate probability of relapse in patients with early-stage non-small-cell lung cancer (NSCLC)?, Materials and Methods: For predicting relapse in 1,387 patients with early-stage (I-II) NSCLC from the Spanish Lung Cancer Group data (average age 65.7 years, female 24.8%, male 75.2%), we train tabular and graph machine learning models. We generate automatic explanations for the predictions of such models. For models trained on tabular data, we adopt SHapley Additive exPlanations local explanations to gauge how each patient feature contributes to the predicted outcome. We explain graph machine learning predictions with an example-based method that highlights influential past patients., Results: Machine learning models trained on tabular data exhibit a 76% accuracy for the random forest model at predicting relapse evaluated with a 10-fold cross-validation (the model was trained 10 times with different independent sets of patients in test, train, and validation sets, and the reported metrics are averaged over these 10 test sets). Graph machine learning reaches 68% accuracy over a held-out test set of 200 patients, calibrated on a held-out set of 100 patients., Conclusion: Our results show that machine learning models trained on tabular and graph data can enable objective, personalized, and reproducible prediction of relapse and, therefore, disease outcome in patients with early-stage NSCLC. With further prospective and multisite validation, and additional radiological and molecular data, this prognostic model could potentially serve as a predictive decision support tool for deciding the use of adjuvant treatments in early-stage lung cancer.
Published: 2023
Full Text: View/download PDF

48. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients.

Author: Herreros-Pomares A, Doria P, Gallach S, Meri-Abad M, Guijarro R, Calabuig-Fariñas S, Camps C, and Jantus-Lewintre E
Subjects: Humans, Hedgehog Proteins genetics, Hedgehog Proteins metabolism, Neoplasm Recurrence, Local pathology, Signal Transduction, Zinc Finger Protein GLI1 genetics, Zinc Finger Protein GLI1 metabolism, Adenocarcinoma genetics, Adenocarcinoma surgery, Adenocarcinoma metabolism, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms genetics, Lung Neoplasms surgery, Lung Neoplasms metabolism
Abstract: Background: Mutations and deregulations in components of the Hedgehog (Hh) pathway have been associated with cancer onset and tumor growth in different malignancies, but their role in non-small cell lung cancer (NSCLC) remains unclear. This study aims to investigate the expression pattern of the main components of the Hh pathway in tumor and adjacent normal tissue biopsies of resected NSCLC patients., Methods: The relative expression of GLI1, PTCH1, SHH, and SMO was analyzed by quantitative polymerase chain reaction (PCR) in a cohort of 245 NSCLC patients. Results were validated in an independent cohort of NSCLC patients from The Cancer Genome Atlas (TCGA)., Results: We found that SMO and GLI1 were overexpressed in the tumor compared with normal-paired tissue, whereas PTCH1 and SHH were underexpressed. In addition, patients with higher expression levels of PTCH1 presented better outcomes. A gene expression score, called the Hedgehog Score, was calculated using a multivariable model including analyzed components of the Hh signaling pathway. NSCLC patients with a high Hedgehog Score had significantly shorter relapse-free survival (RFS) and overall survival (OS) than patients with a low score, especially at stage I of the disease. Similarly, patients in the adenocarcinoma (ADC) subcohort had shorter RFS and OS. Multivariate Cox analysis exhibited that the Hedgehog Score is an independent prognostic biomarker for OS in both the entire training cohort and the ADC subcohort. The Hedgehog Score was validated in an independent cohort of NSCLC patients from TCGA, which confirmed its prognostic value., Conclusions: Our results provide relevant prognostic data for NSCLC patients and support further studies on the Hh pathway., (© 2022. Society of Surgical Oncology.)
Published: 2023
Full Text: View/download PDF

49. Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.

Author: Shoemark A, Griffin H, Wheway G, Hogg C, Lucas JS, Camps C, Taylor J, Carroll M, Loebinger MR, Chalmers JD, Morris-Rosendahl D, Mitchison HM, De Soyza A, Brown D, Ambrose JC, Arumugam P, Bevers R, Bleda M, Boardman-Pretty F, Boustred CR, Brittain H, Caulfield MJ, Chan GC, Fowler T, Giess A, Hamblin A, Henderson S, Hubbard TJP, Jackson R, Jones LJ, Kasperaviciute D, Kayikci M, Kousathanas A, Lahnstein L, Leigh SEA, Leong IUS, Lopez FJ, Maleady-Crowe F, McEntagart M, Minneci F, Moutsianas L, Mueller M, Murugaesu N, Need AC, O'Donovan P, Odhams CA, Patch C, Perez-Gil D, Pereira MB, Pullinger J, Rahim T, Rendon A, Rogers T, Savage K, Sawant K, Scott RH, Siddiq A, Sieghart A, Smith SC, Sosinsky A, Stuckey A, Tanguy M, Taylor Tavares AL, Thomas ERA, Thompson SR, Tucci A, Welland MJ, Williams E, Witkowska K, and Wood SM
Subjects: Humans, Mutation, Cilia, Bronchiectasis diagnosis, Bronchiectasis genetics, Ciliary Motility Disorders diagnosis, Ciliary Motility Disorders genetics, Ciliopathies complications, Kartagener Syndrome diagnosis, Kartagener Syndrome genetics
Abstract: Background: Bronchiectasis can result from infectious, genetic, immunological and allergic causes. 60-80% of cases are idiopathic, but a well-recognised genetic cause is the motile ciliopathy, primary ciliary dyskinesia (PCD). Diagnosis of PCD has management implications including addressing comorbidities, implementing genetic and fertility counselling and future access to PCD-specific treatments. Diagnostic testing can be complex; however, PCD genetic testing is moving rapidly from research into clinical diagnostics and would confirm the cause of bronchiectasis., Methods: This observational study used genetic data from severe bronchiectasis patients recruited to the UK 100,000 Genomes Project and patients referred for gene panel testing within a tertiary respiratory hospital. Patients referred for genetic testing due to clinical suspicion of PCD were excluded from both analyses. Data were accessed from the British Thoracic Society audit, to investigate whether motile ciliopathies are underdiagnosed in people with bronchiectasis in the UK., Results: Pathogenic or likely pathogenic variants were identified in motile ciliopathy genes in 17 (12%) out of 142 individuals by whole-genome sequencing. Similarly, in a single centre with access to pathological diagnostic facilities, 5-10% of patients received a PCD diagnosis by gene panel, often linked to normal/inconclusive nasal nitric oxide and cilia functional test results. In 4898 audited patients with bronchiectasis, <2% were tested for PCD and <1% received genetic testing., Conclusions: PCD is underdiagnosed as a cause of bronchiectasis. Increased uptake of genetic testing may help to identify bronchiectasis due to motile ciliopathies and ensure appropriate management., Competing Interests: Conflict of interest: A. Shoemark has received grants from AstraZeneca. G. Wheway is currently employed by Illumina Inc. M.R. Loebinger has received consultancy or speaker fees from Insmed, AstraZeneca, Parion, Grifols and Armata. J.D. Chalmers has received grants or contracts from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Novartis and Insmed; and received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis and Zambon. J.S. Lucas reports grants from NHS England, NIHR and AIR Charity. H.M. Mitchison is a Trustee of Ciliopathy Alliance. A. De Soyza reports grants from AstraZeneca, GlaxoSmithKline and Pfizer; consulting fees and lecture honoraria from Gilead, GlaxoSmithKline, AstraZeneca, LifeArc and 30T; participation on advisory board at Bayer; receipt of equipment from GlaxoSmithKline. All other authors have nothing to disclose., (Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.)
Published: 2022
Full Text: View/download PDF

50. The control of carpel determinacy pathway leads to sex determination in cucurbits.

Author: Zhang S, Tan FQ, Chung CH, Slavkovic F, Devani RS, Troadec C, Marcel F, Morin H, Camps C, Gomez Roldan MV, Benhamed M, Dogimont C, Boualem A, and Bendahmane A
Subjects: Flowers genetics, Flowers growth & development, Meristem metabolism, Plant Breeding, Gene Expression Regulation, Plant, Plant Proteins genetics, Plant Proteins metabolism, Cucurbitaceae genetics, Cucurbitaceae growth & development, Sex Determination Processes
Abstract: Male and female unisexual flowers evolved from hermaphroditic ancestors, and control of flower sex is useful for plant breeding. We isolated a female-to-male sex transition mutant in melon and identified the causal gene as the carpel identity gene CRABS CLAW (CRC). We show that the master regulator of sex determination in cucurbits, the transcription factor WIP1 whose expression orchestrates male flower development, recruits the corepressor TOPLESS to the CRC promoter to suppress its expression through histone deacetylation. Impairing TOPLESS-WIP1 physical interaction leads to CRC expression, carpel determination, and consequently the expression of the stamina inhibitor, the aminocyclopropane-1-carboxylic acid synthase 7 (CmACS7), leading to female flower development. Our findings suggest that sex genes evolved to interfere with flower meristematic function, leading to unisexual flower development.
Published: 2022
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

286 results on '"C. Camps"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources